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Abstract 
The introduction of Fel-O-Vax FIV in 2002 was the first commercially available lentiviral 
vaccine.  Consisting of whole inactivated virus (WIV) and inactivated infected cells, 
vaccination lead to the production of a strong humoral and T-cell immune response. As FIV 
is a lentivirus, the viral genome must be integrated into the host genome and therefore 
leads to lifelong infection. For this reason, the detection of FIV specific antibodies has been 
used as a proxy for FIV infection and led to the development of several commercially 
available serology diagnosis kits. As vaccination leads to the development of FIV antibodies 
it is not possible to differentiate infected from vaccinated animals (DIVA) using 
conventional serology diagnosis assays.  Several attempts have been made to DIVA FIV 
vaccinated cats, however no test can differentiate FIV vaccinated from infected animals 
and FIV uninfected and unvaccinated animals.  
The data presented in this thesis demonstrates that it is possible to DIVA cats when 
vaccinated with a mutated chimeric virus representative of isolates circulating in the field.  
The identification and characterisation of a novel envelope glycoprotein, isolated from a 
client owned cat with broad neutralising antibodies to FIV, a unique potential N-linked 
glycosylation mutation at the apex of variable loop 2 revealed a neutralisation sensitive 
epitope. By swapping the env gene of a molecular clone of FIV-Glasgow8 with that of the 
novel field isolate, it was hypothesised that vaccinated with the chimaeric virus (FIV ΔV2) 
could elicit a broadly neutralising antibody response capable of protection against low does 
challenge with virulent UK primary isolate, FIV-Glasgow8.  Additionally, by mutating the 
principal immunodominant (PID) of the transmembrane region of FIV ΔV2 from that of FIV 
to lion lentivirus subtype-E (LLV-E), it was proposed that the humoral immune response 
towards the wildtype sequence would be abolished, and recognise only LLV-E PID when 
plasma/sera were screened for reactivity to either PID sequence in a peptide ELISA format.  
The pathogenesis of FIV ΔV2 revealed the rapid production of homologous neutralising 
antibodies that corresponded with a marked reduction in the proviral load. Although no 
heterologous neutralising antibodies were detected, it was thought that If the PID of the 
FIV ΔV2 virus were mutated to that of LLV-E (DIVA virus) and used as a whole inactivated 
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virus candidate vaccine in a prime boost regime, cats may elicit both homologous and 
heterologous neutralising antibodies whilst at the same time demonstrate sufficient 
reactivities to the two different PID sequences that it would be possible to DIVA cats solely 
by conventional serology techniques.  
The DIVA virus did not afford protection against low dose challenge with FIV-Glasgow8 and 
appeared to enhance infection as all vaccinates became infected before controls. 
Additionally, no homologous or heterologous neutralising were produced, although the 
antibody response towards the PID sequences differed substantially so that DIVA could be 
performed on cats by conventional serology. Such was the utility of the PID peptide ELISA 
it was possible to differentiate infected from vaccinate cats and unvaccinated from 
uninfected cats, an observation that has never previously been reported. 
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Chapter 1 Introduction. 
 
1.1 Discovery and origins 
Feline immunodeficiency virus (FIV) was first isolated in 1986 from a group of sick cats 
housed in a cattery in Petaluma, California and was initially named feline T-lymphotropic 
lentivirus (Pedersen et al, 1987). Its classification as a lentivirus was based primarily on the 
viral tropism for primary and permanent T-lymphoblastoid cell lines, the Mg2+- dependent 
reverse transcriptase as well as the protein structure and morphology (Yamamoto et al, 
1988. Stephens et al, 1989). 
1.2 Virus genome and structure. 
Sequencing of the prototypic FIV isolate, FIV-Petaluma (FIV-PET) revealed that the genome 
comprised approximately 9400 base pairs (Talbot et al, 1989). Within the genome, three 
distinct open reading frames (ORF) encoding the major structural proteins (gag), 
polymerase (pol) and envelope (env) were identified. The genome is flanked at the 5’ and 
3’ prime ends by long terminal repeats (LTRs) that have roles in promotor and enhancer 
activity (Figure 1-1).  
 
Figure 1-1. Genomic organisation of the FIV genome. The 3 major ORF are shown, 
indicating the proteins encoded. The transcriptional and enhancing binding sites are shown 
at the 5’ LTR. Figure adapted from Kenyon and Lever, 2011. 
 
The FIV virion is 105-125nm in diameter, with a spherical or ellipsoid shape (Pedersen et al, 
1989). Characterisation of the protein content of mature virions revealed gag-derived 
proteins with estimated molecular weights of p24 (capsid, CA), p17 (matrix, MA), p10 
(nucleocapsid, NC), and p55 (unprocessed Gag). A glycosylated protein with a molecular 
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weight of 130 kDa was shown to be processed into the envelope glycoprotein (Env) that 
comprises the surface unit (SU) protein (gp95) and the transmembrane domain (TM) 
(Steinman et al, 1990. Stephens et al, 1991. Verschoor et al, 1993).  The structural 
morphology of FIV is represented in Figure 1-2. The pol gene encodes the reverse 
transcriptase (RT) enzyme as well as the protease (PR) and integrase (IN) proteins that are 
essential for virus replication and integration. Accessory proteins include OrfA, for which 
the exact role is unknown, the Vif protein that counteracts cellular restriction factors and 
Rev that facilitates nuclear export of spliced and unspliced viral RNA transcripts (Kenyon 
and Lever, 2011). 
 
 
Figure 1-2. Structural morphology the FIV virion. The FIV virion contains 2 copies of the 
negative sense RNA genome. The SU and TM proteins facilitate virus entry in target cells 
where replication, integration, assembly and egress complete the virus life cycle (see 
below). 
 
1.3 Virus Life cycle and replication.  
FIV targets activated CD4+ T lymphocytes as it utilises the T-cell activation marker CD134 as 
its primary receptor molecule (Shimojima et al, 2004). Upon binding of FIV Env, 
conformational changes occur within the Env protein that expose a cryptic epitope in the 
third hypervariable loop (V3) that facilitates binding with the co-receptor molecule CXCR4 
(de Parseval et al, 2006). Fusion of the cellular and viral membranes allows the viral core 
to enter the cell where the initiation of reverse transcription begins. The reverse 
transcription is Mg2+ dependant and transcribes a positive DNA copy of the RNA genome 
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while it is still contained within the virion. The cDNA is then shuttled into the nucleus where 
it forms the pre-integration complex and becomes integrated into the host genome, a 
process facilitated by the pol-encoded IN protein. The integrated viral genome then acts as 
a template for the synthesis of the viral structural proteins. The Gag polyprotein, containing 
the MA, CA and NC proteins captures the viral genome through the signal sequence (Ψ) 
located in the NC (Lever, 2007) and is transported to the cellular membrane where MA 
facilitates the incorporation of Env into virions (Freed, 1998). Budding of the virus is 
facilitated by the unique FIV protein p2 (Luttge and Freed, 2010), after which maturation 
of the virion occurs. The virally encoded PR cleaves 9 separate proteins to give rise to a fully 
mature and infectious virus (Elder et al, 1993, Kohl et al, 1998). 
 
Figure 1-3. The lifecycle of FIV. A unique property of retroviruses is the integration of the 
viral genome in the host DNA resulting in latent, lifelong infection. These cells are virus DNA 
positive but viral RNA negative and so are invisible to immune surveillance (Murphy et al, 
2012). Figure adapted from Beczkowski, 2012. 
1.4 Epidemiology.  
Based on the phylogeny of the env gene, FIV isolates can be classified into 5 distinct clades, 
A to E (Sodora et al, 1994. Kakinuma et al, 1995. Pecorara et al, 1996), with a sixth subtype 
F being isolated in New Zealand (Haywood et al, 2004). A distinct phylogenetic cluster has 
also been identified in Texas, which branches off from the clade B isolates (Weaver et al, 
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2004), however this appears to be restricted to Texas. Sero-epidemiological studies have 
revealed a wide range in the FIV prevalence around the world, from 2.5% in the US (Levy 
et al, 2006), 5.5% in Canada (Ravi et al, 2010), 23.3% in Japan (Nakamura et al, 2010), 8% 
in Australia (Norris et al, 2007), 12.7% in the UK (Hosie et al, 1989) and 3.2% in Germany 
(Gleich et al, 2009). Sick adult cats, male cats and cats with outdoor access are more likely 
to be infected, (Yamamoto et al, 1989, Ishida et al, 1989, Levy et al, 2006, Hosie et al, 1989), 
however free-roaming cats (especially stray or feral cats) are significantly more likely to be 
infected with FIV (Levy et al, 2006). In these studies a proportion of FIV infected cats 
displayed no clinical signs and appeared healthy.  FIV has been isolated in every continent, 
with the exception of Antarctica, and the major clade distribution is shown in Figure 1-4. 
 
Figure 1-4. Distribution of the major FIV clades. Figure reproduced from Hosie et al, 2009. 
Clade A isolates are the most common circulating isolates of FIV and include, FIV-GL8, FIV-
Pet, FIV-Dixon, FIV -AM19 and FIV-19k1 which make up a significant proportion of isolates 
used in pathogenesis and vaccine trials. Of note is the absence of FIV from large parts of 
Asia, however this is due to the lack of available data and not the absence of virus. 
 
1.5 Pathogenesis. 
Early studies indicated that the clinical signs associated with FIV infection included 
gingivitis/stomatitis, respiratory complications, emaciation and wasting as well as general 
lymphadenopathy, neurological signs and skin complaints (Hosie et al, 1989, Pedersen et 
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al, 1988 and 1989, Sparger et al, 1989, Ravi et al, 2010, Yamamoto et al, 1989, Muirden 
2002, Ishida et al, 1989). Many of the clinical signs reported in FIV infection arise from 
secondary opportunistic infections, as infection with FIV alone does not induce severe 
clinical signs, with the rare exception of neurological disorders (Hosie et al, 2009. 
Hartmann, 2012). The primary or acute stage of infection with FIV typically results in sero- 
conversion within 4-6 weeks (Figure 1-5) and a peak in viraemia approximately 5 – 10 weeks 
post infection (Hosie et al, 2002 & 2005, Dunham et al, 2006). Infection leads to a gradual 
depletion of CD4+ T cells (Hofmann-Lehman et al, 1996) as the virus targets cells expressing 
the T cell activation marker CD134 (Shimojima et al, 2004). This gradually erodes the 
foundation of the adaptive arm of the immune system and, as the numbers of CD4+ T cells 
decrease, infected cats enter the silent or asymptomatic stage of infection (Figure 1-5).  
Cats may appear healthy during the asymptomatic stage, with the only indicators of 
infection being the persistence of FIV antibodies and the continuing gradual decline in CD4+ 
T cell numbers. During the asymptomatic stage of infection, the CD8+ T cell compartment 
expands, resulting in an inversion of the CD4+:CD8+ T cell ratio (Willett et al, 1996). Cats can 
remain in the asymptomatic stage of infection for weeks or years, depending on the 
virulence of the infecting strain of FIV (Diehl et al, 1995, Addie et al, 2000). 
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Figure 1-5. Pathogenesis of FIV. The initial peak viral load declines to the set point, 
coinciding with an increase in the cellular immune response. The development of a 
neutralising antibody (nAb) response is shown, however the time course for the 
development of nAb varies between different isolates. Most cats will develop nAb, 
although it has been demonstrated experimentally that some cats do not produce a 
significant nAb response. Figure from Ferrantelli and Ruprecht 2002. 
 
The secondary phase of infection is characterised by pronounced immune dysfunction, 
including a significant reduction in the level of T cell proliferative responses to stimulation 
(Torten et al, 1991) and polyclonal B-cell activation leading to hypergammaglobulinemia 
(Flynn et al, 1994). The pronounced immunodeficiency induced by FIV predisposes cats to 
secondary opportunistic infections that can be fatal (de Rozieres et al, 2004.  Diehl et al, 
1995. Pedersen et al, 1987).  Although one would expect infection with FIV to substantially 
decrease the life expectancy of a cat, longitudinal studies have demonstrated that FIV 
infection does not significantly shorten a cats’ survival time (Addie et al, (2000). Ravi et al, 
(2010). Beczkowski et al, (2015).   
 
The pathogenesis and tropism of FIV is also regulated by the interaction of the viral spike 
(gp120) with the primary receptor of FIV, CD134. As infection progresses, FIV is able to 
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infect diverse cell types including B-cells and CD8+ T cells (English et al, 1993. Dean et al, 
1996). As the primary receptor for FIV is CD134, this change in tropism must be facilitated 
by altered usage of the primary receptor by the viral spike. Willett et al, (2006) was able to 
demonstrate that at least two different domains within the CD134 receptor facilitate CDR-
2 independent or CDR-2 dependant entry into the cell (Cysteine rich domain) (Figure 1-6). 
 
 
Figure 1-6. Differential utilisation of CD134 as FIV infection progresses. Oval shapes 
represent cysteine rich domain 1 to 3 (red feline, blue human) used in the studies 
performed by Willett et al (2006) and Beczkowski et al (2014) to decipher the receptor 
utilisation of various FIV strains. Dependence on CDR-2 was determined by comparing the 
infectivity of FIV isolates on 2 different cell lines, expressing either feline CD134 (Orange, 
left) or chimaeric (human/feline CD134, right). The x axis represents the infectivity ratios 
of the 2 cell lines where CDR-2 independent isolates (CPG41, GL8) cannot infect cells 
expressing chimaeric CD134, resulting in a higher ratio (red arrows). Isolates that are CDR-
2 independent are able to infect both cell lines equally well, resulting in a lower infectious 
ratio. The green and orange triangles represent the theoretical quantities of CDR-2 
dependant and independent variants throughout the clinical course of FIV infection.  Figure 
from Hosie et al (2017). 
During the early stages of infection, the predominant circulating virus requires a strict 
interaction with both CDR-1 and CDR2 domains of CD134 for entry into the cell (CDR-2 
dependant), whereas the predominant circulating viruses present during the late stages of 
infection require only CDR-1 for cell entry (CDR-2 independent). The pathogenesis of such 
relaxed receptor utilisation was further characterised by the discovery that CDR-2 
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independent strains of virus were predominantly associated with cats that had deceased 
since the last time of sampling or were defined as clinically healthy or sick based on a CD4+ 
T-cell of <350 cells/µl respectively. CDR-2 independent strains of virus were almost 
exclusively isolated from cats that had deceased or were classed as clinically sick since the 
last time of sampling (Beczkowski et al, 2014). Statistical analysis showed that the 
emergence of CDR-2 independent strains correlated with a CD4+ T-cell count >350 cells/µl 
and demonstrates a correlation between the emergence of CDR-2 variants and declining 
clinical status.  Whether the emergence of CDR-2 independent isolates of FIV is a cause or 
consequence of disease progression or immune system pressure remains to be established. 
 
1.6 Diagnosis. 
 
Since FIV integrates into the host genome, infection with FIV is persistent. Infection with 
FIV elicits strong cellular and humoral immune responses and the detection of FIV specific 
antibodies are used to diagnose FIV infection. Except for the research setting, detection of 
virus is rarely used, because virus isolation requires extensive expertise/materials, is time 
consuming and is not suited to large-scale screening of cat samples (Hosie et al, 2009. 
Crawford et al, 2007). Other problems that can arise when utilising virus isolation as a 
primary screening assay include the quality and type of sample and the requirement for a 
second confirmatory assay to be conducted. However, anti-FIV antibodies can be detected 
in plasma throughout infection. A complete description of the serological and molecular 
methods used for the diagnosis of FIV infection follows. 
 
1.6.1 Measurements of diagnostic accuracy 
 
1.6.1.1 Sensitivity and specificity 
A common measure of the accuracy of a diagnostic assay is the sensitivity (proportion of 
true positive samples correctly identified) and specificity (proportion of true negative 
samples correctly identified). These values are calculated by the formula detailed below 
and the figures expressed as either a percentage or a proportion ranging from zero to 1.  
Sensitivity: Number of positive samples detected/ total number of true positive samples 
Specificity: Number of negative samples detected/ total number of true negative samples 
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When candidate diagnostic assays are evaluated it is important to generate a parallel data 
set using an accepted reference assay or ‘reference standard’; for FIV diagnosis either 
immunostaining or virus isolation have been used as reference standard tests should 
identify all true positive and negative samples within a population (Hosie et al, 2009, 
Hartmann et al, 2007, Levy et al, 2004, Crawford et al, 2005). Since no method is 100% 
accurate, an accepted method is utilised that detects a high percentage of both negative 
and positive samples. Therefore, if a diagnostic assay has a sensitivity of 99% (or 0.99), it 
would be expected that 1 out of every 100 samples tested would result in a false negative 
result. If the same assay has a specificity of 99%, then 1 out of every 100 samples tested 
would result in a false positive result. The interpretation of such analyses should take into 
consideration the prevalence of FIV in the population/local area since this impacts the 
positive predictive value. In areas where the prevalence is low, for example 1%, then 1/100 
samples would test positive (true positive). If the test specificity is 99%, then another 1/100 
samples will test positive (false positive), so that the positive predictive value of a positive 
result is only 50%.  Hence positive results from areas of low prevalence or from cats not at 
risk of FIV infection should always be confirmed using a confirmatory assay (Hosie et al, 
2009). As different research groups utilise different reference standards, methodologies 
and cut-off values for diagnostic assays, it is often difficult to compare values for sensitivity 
and specificity from different data sets (Reitsma et al, 2005). 
1.6.1.2 Receiver operator curve (ROC) analysis. 
 
ROC analysis is used to compare the sensitivity and specificity data derived from studies 
where different reference standards or methodologies have been employed. ROC analysis 
converts each pair of sensitivity and specificity figures into a single measure of accuracy, 
the odds ratio (Reitsma et al, 2005. Lalkhen and McCluskey, 2008). The odds ratio calculates 
the odds of a sample testing positive if it had been exposed compared to the odds of the 
same result occurring if the sample had not been exposed (Lalkhen and McCluskey, 2008). 
A disadvantage of using ROC analysis to determine the odds ratio is that estimates of 
specificity and sensitivity are not directly available (Reitsma et al, 2005). 
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1.7 Serological diagnosis.  
 
1.7.1 Immunofluorescence antibody assay (IFA) 
 
The IFA assay utilises fixed virus infected cells as the source of antigen recognised by anti-
FIV antibodies, visualised using a fluorescently labelled anti-cat Ig secondary antibody.  
Variations in the assay include the cell line used to propagate the virus, the isolate of virus 
used to infect the cells, the ratio of virus infected cells to uninfected virus cells, the 
fluorophore conjugated to the secondary antibody and the dilution of plasma sample 
tested. Although the sensitivities of IFA primary screening assays are typically high (94.7-
100%), the observed rate of false positive results has led to lower specificities (90-100% 
(Levy et al, 2004. Reid et al, 1992). As the assay utilises fixed, infected cells, it is 
hypothesised that non-specific, cross-reactive antibodies could bind cellular antigens either 
on the cell membrane or incorporated into the viral envelope. Although IFA is routinely 
used as a screening test, few studies have compared the performance of IFA as a diagnostic 
tool against a reference standard test, such as virus isolation or immunostain analysis. 
However, it was possible to examine the performance of IFA from studies in which samples 
had undergone preliminary screened by IFA (Verschoor et al, 1993. Furuya et al, 1992). It 
appears that IFA is a useful screening test to identify samples that are clearly seropositive 
or seronegative, with the caveat that samples from cats in either the acute or terminal 
stages of FIV infection might be mis-diagnosed.  Cats in the terminal stages of infection 
might test seronegative as a result of either B-cell exhaustion or a lack of available antibody 
following antigen-antibody complex formation in cats with high virus loads.  In the early, 
acute stage of infection, delayed sero-conversion might also result in false negative results. 
Indeed, 14/206 samples (6.8%) tested inconclusive using IFA (Verschoor et al, 1993) and a 
similar percentage of inconclusive samples was reported in a study that compared IFA and 
immunostain analysis for the diagnosis of HIV-1 in people (73/999 samples (7.3%), Carlson 
et al, 1987). This demonstrates that non-specific, cross-reactive antibodies are not 
restricted to feline plasma or the isolates and cell lines used in FIV IFA.  
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1.7.2 Immunostain analysis. 
 
Although immunostain analysis has been reported to have 98% sensitivity and specificity 
(Levy et al, 2004), problems can arise when using immunostain analysis for sero-diagnosis.  
The lack of a visible SU protein band on immunostain, despite the presence of anti-SU 
antibodies has been reported (Hosie and Jarrett, 1990, Verschoor et al, 1993). It was 
concluded that the FIV Env might be mechanically torn from the virion during the 
ultracentrifugation step of virus purification. This problem was circumvented by using 
infected cell lysates (Hosie and Jarrett, 1990), although this resulted in non-specific staining 
by antibodies cross-reacting with cellular proteins, requiring samples to be screened also 
against a lysate of uninfected cells (O’Connor et al, 1989). Nevertheless, immunostain 
analysis is often utilised as a confirmatory test and as a “reference standard” reference test 
(together with virus isolation) for assessing the sensitivity and specificity of serological 
diagnostic assays (Hosie et al, 2009. Crawford et al, 2005. Levy et al, 2004. Andersen and 
Tyrrell, 2004). 
 
1.7.3 Enzyme linked immunoabsorbent assay (ELISA) 
 
The first commercially available FIV ELISA was the PetCheck Feline T-Lymphotropic 
Lentivirus Antibody Test Kit (IDEXX Corporation, Portland, Maine, USA). This ELISA was 
developed by O’Connor et al (1989) and utilised disrupted virus, grown in Crandell feline 
kidney cells (Crfk cells) as the capture antigen. The ELISA assay identified all 141 sero-
positive samples tested and the results were confirmed by immunostain analysis 
(antibodies recognising both p24 and p17 required for confirmation) and 
radioimmunoprecipitation (RIPA) assays to detect antibodies recognising gp120. Only 
3/141 discrepant results were identified, with samples testing ELISA positive but 
inconclusive on immunostain analysis; these samples were defined as positive, based on 
the precipitation of anti-gp120 antibodies in a RIPA assay. However, when FIV sero-positive 
plasma samples were tested by both immunostain analysis and PetCheck ELISA, false 
positive rates of 26.5% (Hosie and Jarrett, 1990) and 10% (Reid et al, 1991) were reported. 
It was hypothesised that these false positive results might have been associated with the 
detection of antibodies that cross-reacted with cellular antigens derived from the Crfk cell 
line used to propagate the virus. Furthermore, the use of whole virus as the capture antigen 
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might have led to a reduction in the assay sensitivity, compared to the use of highly purified 
viral proteins in immunostain analysis (Rimmelzwaan et al, 1994).  
 
The use of viral proteins purified from bacterial or insect expression systems consistently 
outperformed disrupted whole virus as a source of capture antigen in ELISA tests, reducing 
the numbers of false positive samples compared to the PetCheck ELISA (Verschoor et al, 
1993. Furuya et al, 1992. Rimmelzwaan et al, 1994. Reid et al, 1991). However, it was 
recognised that the selection and processing of the viral proteins must be carefully 
considered. Expression of FIV r-Gag in Sf9 Spodoptera frugiperda cells produced a protein 
of approximately 50kDa, analogous to the native unprocessed Gag protein. When used as 
the source of capture antigen in an ELISA, only 2/93 samples reacted to the protein, 
although all samples had tested positive by immunostain analysis and contained antibodies 
recognising the core structural proteins (Verschoor et al, 1993). Conversely, FIV Gag protein 
expressed in Escherichia coli cells could be used to detect antibodies in 14/17 
(Rimmelzwaan et al, 1994), 61/65 (Furuya et al, 1992) or 78/78 (Reid et al, 1991) FIV sero-
positive samples. The highly sensitive ELISA reported by Reid et al utilised the pGEX-FIV p24 
expression vector containing the ORF of p24 encoded by the gag gene. However, anti-p24 
antibodies might not be detectable from samples collected during the early or terminal 
stages of FIV infection (Furuya et al, 1991) and the positive FIV sero-status of samples could 
be confirmed by the detection of anti-Env (gp120) antibodies by radioimmunoprecipitation 
with [35S] L-methionine and [35S] L-cysteine labelled antigen in the absence of p24 
antibodies, a finding confirmed by Rimmelzwaan et al (1994). It was concluded that anti-
Env antibodies appeared early in infection, and the delayed production of anti-p24 
antibodies could lead to false negative results (Verschoor et al, 1993. Rimmelzwaan et al, 
1994. Furuya et al, 1991). Reports by Reid et al (1991) and Verschoor et al (1993) 
demonstrated that the incorporation of two different viral antigens as the source of 
capture antigen increased both the sensitivity and specificity. However, the high variable 
Env amino acid sequence between FIV clades suggested that it might be difficult to identify 
a conserved Env epitope for inclusion (Bachmann et al, 1997).  
 
Since anti-Env antibodies could be detected before anti-p24 antibodies, attempts were 
made to include a conserved, antigenic Env epitope in serological diagnostic assays. By 
screening fragmented Env libraries with FIV sero-positive samples, an immunodominant 
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domain within the transmembrane (TM) region of Env was identified (Pancino et al, 1992). 
FIV sero-positive plasma samples raised against 5 different isolates of FIV contained 
antibodies that recognised the immunodominant epitope, comprising 5 amino acids 
flanked by 2 cysteine residues. This epitope was structurally constrained and an unlikely 
site of non-synonymous substitution (Pancino et al, 1992), findings that were 
independently reproduced, in part, by de Ronde et al (1993). Two independent studies 
assessed the suitability of the immunodominant domain as a candidate capture antigen for 
the sero-diagnosis of FIV. The first study demonstrated that FIV sero-positive plasma 
samples contained high titres of antibodies recognising the immunodominant epitope that 
developed as early as 2 weeks post infection, with titres reaching a peak at 6-8 weeks post 
infection and being maintained for at least 97 weeks (Fontenot et al, 1992). This study also 
demonstrated a lack of non-specific antibody binding in samples from transiently viraemic 
and persistently viraemic FeLV infected cats, demonstrating the virus-specific nature of the 
epitope (Fontenot et al, 1992). In a follow-up study, the synthetic peptide CNQNQFFCK, 
representing the immunodominant epitope, was used in ELISA tests to examine FIV sero-
positive plasma samples raised against at least 11 different FIV isolates from 4 
geographically distinct regions of Europe. In this study, 100% of plasma samples collected 
from cats naturally and experimentally infected with FIV recognised the synthetic TM 
peptide, with higher titres than had been observed against any other individual or 
combined Env antigen(s) (Avrameas et al, 1993). This TM peptide ELISA accurately 
determined the true FIV sero-status of 47 inconclusive samples and outperformed the 
commercially available PetCheck ELISA when testing inconclusive samples. Use of the 
immunodominant TM epitope peptide allowed the detection of FIV antibodies, on average, 
7 days sooner than the PetCheck ELISA (Avrameas et al, 1993). The sensitivity of the ELISA 
was further increased by extending the sequence of the immunodominant peptide from 9 
to 17 amino acids in length (CNQNQFFCK vs QELGCNQNQFFCKVPSA). These changes 
increased the assay sensitivity to 99.5% and the specificity to 100% (Sibille et al, 1995). 
 
Therefore, the characterisation of the major antigenic determinants of FIV greatly reduced 
the number of false positive results.  This is important because, although the identification 
of FIV infection does not justify euthanasia (Hosie et al, 2009), in situations where resources 
are limited, such decisions could potentially be based solely on initial screening profiles 
(Crawford et al, 2005. Ravi et al, 2010).   Where specificities of 57-100% (O’Connor et al, 
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1989, Levy et al, 2004, Reid et al, 1992, Hosie and Jarrett, 1990) were observed in early 
screening studies utilising whole virus as the source of capture antigen for ELISAs, the lower 
limit of specificity was greatly increased to values >95% by incorporating FIV recombinant 
proteins and the immunodominant TM peptide into ELISA tests (Sibille et al, 1995. 
Verschoor et al, 1993). This increased the sensitivity and specificity of diagnostic tests and 
also provided the tools necessary to study the development of the serological response 
against specific viral proteins in future vaccine and pathogenesis studies.   
 
1.8 Molecular diagnosis of FIV. 
 
The use of molecular techniques to diagnose FIV infection is recommended in cases where 
sero-diagnosis has been unsuccessful, or the use of serological assays is confounded, as in 
samples from vaccinated cats (Uhl et al, 2002). Molecular diagnostic tests for FIV infection 
were developed to aid the interpretation of serological tests and to overcome the 
limitations of the detection of antibodies in kittens (Crawford and Levy, 2007. Crawford et 
al, 2005. Nichols et al, 2016). 
  
1.8.1 PCR and RT-PCR 
 
The strict requirement for the proviral genome to integrate into the host genome leads to 
lifelong infection with FIV. Therefore, using the correct combination of primers/primers 
and probe, PCR and RT-PCR are useful and reliable diagnostic tools, having a high degree 
of specificity from complementary primers and probes and a relatively high assay 
throughput (Leutenegger et al, 1999). Several studies have evaluated PCR for use as a 
diagnostic assay in comparison to ELISAs and point of care (POC) kits. Initial results 
displayed considerable disparity between PCR results and those achieved with ELISAs/POC 
kits. Bienzle et al (2004) reported the outcomes of PCR testing when DNA from 10 mutually 
exclusive FIV sero-positive cats, as determined by ELISA and POC kits, was sent to 3 
different laboratories. One laboratory (a research laboratory) detected FIV provirus in 
10/10 samples, whereas two commercial laboratories detected FIV provirus in only 50% 
and 80% of the samples. A similar result was obtained when DNA samples from 10 
concordant FIV sero-negative samples were tested by the same three laboratories (10/10 
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samples were classified as FIV negative by the research laboratory but only 70% and 90% 
of the samples were classified as FIV negative by the 2 commercial laboratories). The lack 
of sensitivity and specificity was further highlighted in this study by the detection of FIV 
provirus is three DNA samples obtained from healthy dogs, living in cat-free houses. 
 
The commercially available PCR, FIV RealPCR™ Test (IDEXX Laboratories Inc), performed 
better; of 168 samples testing positive by POC ELISA (SNAP® FIV/FeLV Combo Test, IDEXX 
laboratories Inc) a 93% concordancy (156/168 results) was observed, with a calculated 
Kappa value of 0.87 (Nichols et al, 2016). Comparing the PCR results to virus isolation as 
the reference standard, the FIV RealPCR™ test gave 4 false positive results and one false 
negative result (Nichols et al, 2016). 
 
RT-PCR has been reported to be more sensitive and specific than PCR for proviral DNA. The 
measurement of the fluorescence signal generated by the displacement of the hybridised 
probe essentially removes the inclusion of non-specific PCR product in data analysis. 
However, the use of 3 complementary hybridising sequences raises the possibility of 
generating false negative results if the target sequence is not complementary to the primer 
and probe (Nichols et al, 2016). In two studies that assessed the performance of RT-PCR, 
sensitivity estimates of 92.3% and 79.3% were reported, with specificity estimates of 99% 
or 100% respectively (Pinches et al, 2007. Ammersbach et al, 2013). However, the 
reference standard assays used in these studies were not those generally accepted as 
reference standards (virus isolation or immunostaining) (Hosie et al, 2009, Hartmann et al, 
2007, Levy et al, 2004, Crawford et al, 2005) and so the results should be interpreted with 
caution. In a study comparing conventional PCR with RT-PCR, with all results confirmed by 
virus isolation (Crawford and Slater 2005), samples from 124 cats were tested (102 SPF and 
22 naturally infected cats, infected with a range of isolates from FIV clades A, B and C) to 
evaluate the performance of three laboratories offering PCR as a commercial diagnostic 
test. The agreement between the PCR results and virus isolation ranged from 58-90%, with 
the PCR assay performing better in regards to specificity than sensitivity.  
 
Theoretically, PCR testing should offer the ideal balance of sensitivity and specificity. The 
requirement for primer/template complementarity required for hybridisation and 
subsequent rounds of template amplification should eliminate false positive results. The 
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ability to optimise PCR assays and the inclusion of degenerate primers capable of 
hybridising with FIV isolates from all clades (Wang et al, 2010) should increase the test 
sensitivity.  However, the FIV genome displays high levels of plasticity and the divergence 
within and between clades has been reported to be as high as 26% when based on env and 
gag phylogeny (Steinrigl et al, 2003, Bachmann et al, 1997). Good primer and probe design 
should counteract, to some degree, the divergence reported in the FIV gag genome when 
screening samples using RT-PCR. However, without confirmatory sequencing when 
screening samples by conventional PCR, there is a risk of false positive results occurring by 
non-specific hybridisation and amplification, with results susceptible to operator error and 
bias when FIV status is determined by visually sizing the amplified PCR product (Crawford 
and Slater, 2005). Additionally, RT-PCR/PCR assays have not achieved the levels of 
sensitivity demonstrated with serological diagnostic assays (Sibille et al, 1995. Hartmann et 
al, 2007), with the sole licensed diagnostic PCR assay for FIV (FIV RealPCR™, IDEXX) having 
a sensitivity of 80.5% and specificity of 99.9% 
(http://www.idexx.com.au/pdf/en_au/smallanimal/education/realpcr-test-for-fiv.pdf). 
Recently it was reported that samples that tested negative for FIV provirus using this 
licensed PCR assay tested positive for FIV antibody using three commercially available POC 
kits (Westman et al, 2015). Although re-sampling and re-testing of the animals resulted in 
positive PCR results, these data demonstrates the reliability of current serological assays. 
 
1.9 Point of care test kits. 
 
Point of care (POC) test kits combine ELISA and lateral flow technology (Koivunen and 
Krogsrud, 2006). Generally referred to as lateral flow immunoassays, the detection and 
recognition of the analyte is exclusively facilitated by antibody, whether monoclonal or 
polyclonal (Koczula and Gallotta, 2016). Many POC kits have been developed for the 
serological diagnosis of FIV infection over recent years (Hartmann et al, 2007). Although 
the POC test kits have been individually evaluated, few independent studies have 
compared the performance of several POC test kits using the same sample set, and utilising 
a robust confirmatory reference standard assay. Hartmann et al (2007) evaluated the 
performance of seven POC kits that utilise a combination of FIV antigens and 
methodologies. Sensitivity values ranged from 92.6-100% and specificity values ranged 
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from 99-100% (Table 1-1), indicating that the POC test kits are suitable for in-house 
diagnosis of FIV. Both of the lateral flow ELISAs (SNAP® Combo Plus and PetChek® Plus anti-
FIV) performed better than other POC kits that utilised immunochromatography 
(Griessmayr et al, 2007). 
 
 
Table 1-1. Comparison of performance of POC kits. * LFIC = Lateral flow 
immunochromatography, LF ELISA= Lateral flow enzyme linked immunosorbent assay. † TM 
peptide= Immunodominant domain of TM. Most will have additional residues added 5’ or 
3’ to the nano-peptide CNQNQFFCK, r-p17 = recombinant p17, r-p24 =recombinant p24, 
p24 peptide = propriety peptide carrying an immunodominant epitope located with the 
p24 protein. ‡ = SNAP Combo plus is sold only in Europe whilst the SNAP Combo is sold in 
Australia, New Zealand and America. The SNAP Combo contains only TM peptide and r-
p24. Squares in red highlight the lowest performance figures whilst green squares highlight 
the highest performance figures. Figure adapted from Griessmayr et al/Hartmann et al, 
2007. 
 
POC kits have been shown to be reliable and reproducible, with tests using lateral flow 
technology having sensitivity values ranging from 91.2-100%, and specificity values ranging 
from 99.2-100%. It is theoretically possible to achieve highly accurate FIV sero-diagnosis by 
testing samples using two different kits (eg SNAP Combo Plus and PetChek Plus anti-FIV). 
Given the low cost of development, ease of use and production and the high reproducibility 
of the results of such tests (Koczula and Gallotta, 2016), POC kits are used widely for the in-
house diagnosis of FIV infection.  
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1.10 Vaccination 
 
A number of vaccine trials have been conducted to evaluate efficacy to protect cats against 
FIV infection. Different vaccine strategies, including recombinant vaccines, DNA 
vaccination, immune stimulating complexes (ISCOMS), subunit vaccines, whole inactivated 
virus (WIV) and infected inactivated cell vaccines (ICV) have shown variable results, from 
enhancement of infection to complete protection against both homologous and 
heterologous challenge (table 1-2 to table 1-8). Little success has been achieved with 
conventional vaccine strategies, although limited success has been achieved against 
homologous challenge using DNA vaccination, albeit inferior to WIV (Hosie et al, 1998 & 
2000). Protection against homologous challenge, that is challenge with the same virus 
isolate as the vaccine strain, has consistently been shown to be easier to achieve than 
challenge with heterologous isolates that differ from the vaccine strain (Yamaoto et al, 
1991. Hosie et al, 1995. Pu et al, 2001. Matteucci et al, 1996. Bishop et al, 1996). One of 
the main obstacles in eliciting heterologous protection against FIV infection is the divergent 
nature of the FIV envelope glycoprotein. Based on phylogeny of the env gene, FIV can be 
classified into 5 distinct clades (Figure 1-7), displaying considerable envelope amino acid 
sequence divergence (Sodora et al, 1994. Kakinuma et al, 1995. Pecorara et al, 1996). FIV 
therefore displays isolate specific neutralisation epitopes explaining, in part, the difficulty 
in achieving heterologous protection.   
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Figure 1-7. V3-V5 env phylogeny of 80 FIV isolates including vaccine and challenge strains. 
The FIV isolates that constitute the FIV vaccine (Fel-O-Vax FIV) are shown in blue, whilst 
challenge viruses are depicted in red and lavender. Any isolate depicted in italics has been 
utilised as a challenge virus during clinical trials. Isolates highlighted in lavender were used 
as challenge virus in trials funded by the NIH whilst isolates highlighted in red were used as 
challenge virus in trials funded by commercial companies.  FIV isolates can be classified in 
to one of 5 clades (A-E) and thus display significant genetic diversity. Taking into account 
the global distribution of FIV isolates (figure 1-4), the identification of a single isolate that 
can protect against all circulating strains and recombinants is challenging. Figure from 
Yamamoto et al, 2010. 
The most successful strategy utilised WIV derived from long term progressor cats as the 
candidate immunogens (Yamamoto et al, 2010). The prototype of the commercially 
available Fel-O-Vax FIV (Pu et al, 2001) demonstrated protection against low dose 
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homologous challenge, low dose intraclade heterologous challenge as well as protection 
against a low dose challenge with a distinct, heterologous isolate (Pu et al, 2001 & 2004. 
Yamamoto et al, 1993. Kusuhara et al, 2005). Similar results have been obtained using ICV, 
although protection against heterologous challenge was only shown following vaccination 
with a dual subtype vaccine containing immunogens derived from two diverse strains of 
FIV (Matteucci et al, 1996 & 1997, Bishop et al, 1996, Hohdatsu et al, 1997). After the use 
of 5000 laboratory cats over 14 years of vaccine testing, a commercial FIV vaccine (Fel-O-
Vax FIV) was released in the US in 2002, based on two, yearlong efficacy studies using a 
clade A challenge virus that differed to the two vaccine strains by 9 and 20 % at the Env 
amino acid sequence level (Pu et al, 2004). Consisting of 50µg FIV-Petaluma and FIV-
Shizuoka WIV and 1.5 – 2.5 x 107 inactivated infected Fet-J cells, supplemented with 5µg of 
human recombinant IL-12, (Omori et al, 2004. Coleman et al, 2014), the vaccine has 
demonstrated 84% efficacy against heterologous challenge and 71% efficacy against 
heterologous challenge one year after the last vaccination. Over 1.8 million doses were sold 
in the US within the first 4 years of licencing of the vaccine (Huang et al, 2004. Huang et al, 
2010. Yamamoto et al, 2007), however a recent study published by Westman and 
colleagues (2016) suggested that the vaccine showed a protective rate of only 56% under 
field conditions.  
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Table 1-2. Tabulation of FIV vaccine trials that have enhanced. 
 
 
 
 
 
 
Author. Year. Vaccine type. Inoculum/dose/clade.
Immunisation 
schudual 
(Weeks)/route.
Challenge 
strain/dose/clade
Challenge 
week/route/source
Protection 
rate.
Control 
Protection.
FIV ISCOMS 1/ FIVGL8 ISCOMS/ 10µg/A 0,5,18/S.C. 20/I.P./TCF 0/4 1/4
 r-p24 ISCOMS 2/ r-p24 ISCOMS/ 50µg/A 0,3,5,7/S.C. 9/I.P./TCF 0/4
  inactivated, infected cell vaccine 2x106 FIVGL8 infected cells/A 0,3,6,9,12,15/S.C. 21/I.P./TCF 0/5
Recombinant vaccinia virus with vGR657 
(Native Env)
vGR657 FIVAM19 Env ISCOMS/10µg 
protein/
0/6 
Recombinant vaccinia virus with vGR657 x 15 
(lacking SU/TM cleavage site)
vGR657 x 15 FIVAM19 Env 
ISCOMS/10µg protein/
0/6
vGR657x15 
vGR657 x 15 FIVAM19 Env 
ISCOMS/10µg protein/
2/6
β-Gal-FIV Env fusion protein. FIVAM19 Env ISCOMS/10µg protein/  0/6
SIV Env ISCOMS SIVmac32H 10µg/dose  0/6
Phosphate buffered saline Controls 0/6
1/5
12/i.m./TCFSiebelink et al 1995
Hosie et al 1992 FIV-GL8/20 CID50/A/
0,4,10/S.C. FIV-AM19/20 CID50/A
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Table 1-3. Tabulation of FIV vaccine trials that have enhanced. 
 
Author. Year. Vaccine type. Inoculum/dose/clade.
Immunisation 
schudual 
(Weeks)/route.
Challenge 
strain/dose/clade
Challenge 
week/route/source
Protection 
rate.
Control 
Protection.
200µg peptide 0/7
Adjuvant (controls) 0/3
FIV ISCOMs FIV AM6c/10µg Gag protein dose  0/6
FIV ISCOMs + vGR657x15 ISCOMs
FIV AM19 10µg Env/dose - FIV AM6c 
10µg Gag/dose
 0/6
vGR657x15 ISCOMS + FIV Gag ISCOMs
FIV AM19 10µg Env/dose - FIV 19k1 
10µg Gag/dose
0/5
Crfk ISCOMS 10µg Crfk protein/dose 0/6
SIV Env ISCOMS SIVmac32H 10µg/dose 0/6
PBS 0/6
FIV 34TF10 w/t env/400µg/A 0/7
FIV 34TF10 n14 env/400µg/A 0/7
FIV 34TF10 n92 env/400µg/A 0/7
pUC DNA/400µg/NA 0/7
FIV-19K1/5 X 106 cells/ A
5 X 106 uninfected cells (controls)
0/3 0/2FIV-19K1/ 10 CID50/A 18/I.M/TCFKarlas et al 1999 ICV 0,2,4,6,8,16/I.V.
Richardson et al 1997 DNA 0,2,4/I.M.
12/i.m./TCF
35/I.P./TCF
FIV-Pet/10 CID50/A 6/I.P/TCF
FIV-AM19/20 CID50/AHuisman et al 1998 0,4,10/S.C.
FIV-Pet/25 CID50/AFlynn et al 1997 V3- PID-p24 linear peptide. Subunit vaccine 0,3,6,15,19/S.C
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Table 1-4. Tabulation of predominantly whole inactivated virus FIV vaccine trials. 
 
 
Author. Year. Vaccine type. Inoculum/dose/clade.
Immunisation schudual 
(Weeks)/route.
Challenge strain/dose/clade
Challenge 
week/route/source
Protection 
rate.
Control 
Protection.
FIVPet/200µg/A 3/3
FIVPet/200µg/A + 1X107 inactivated 
FET1 cells
2/3
Adjuvant (controls) 0/3
Inactivated FL4 cells/1 x107 cells/A 2/4
Inactivated FET1 cells(FIVpet)/1 x107 
cells/A
4/5
inactivated FET1 cells/1X107 cells 
(controls)
0/5
Adjuvant (controls) 0/5
WIV FIVPet/250µg/A 13/15 
ICV FIVPet/2.5 x 107 cells/A 15/15 
WIV FIVPet/250µg/A 13/13
ICV FIVPet/250µg/A 14/15 
FIV-Pet/ 10 CID50/A (FeT-1) 5/6 0/6
FIV-GL8/ 5 CID50/A (Q201) 0/5 0/5
FIV-Pet/ 10 CID50/A (FeT-1) 4/5 0/5
FIV-GL8/ 10 CID50/A (Q201) 1/5 0/5
Pu et al study 1 WIV FIVPet+FIVshi/250µg +250µg/A+D 0,3,6/? FIV-Bang/ 10 CID50/B 9/I.V./in vivo 4/5 0/4
Pu et a study 2 WIV FIVPet+FIVshi/250µg +250µg/A+D 0,3,6/? FIV-Bang/100 CID50/B 9/I.V./in vivo 2/5 0/5
Pu et al study 3 WIV
FIVPet+FIVshi/250µg +250µg/A+D. 
Boosted FIVBang
0,3,6,29 FIV-Pet/ 50 CID50/A 31/i.v/in vivo 4/4 0/5
Pu et al study 4 WIV FIVShi/500µg/D 0,3,6 FIV-shi/50 CID50/D 9/i.v/in vivo 1/3 0/3
Pu et al study 5 WIV FIVPet+FIVshi/250µg +250µg/A+D 3 or 6 immunosations FIV-Pet/ 20-25 CID50/A
3 weeks after last 
boost/i.v/in vivo
6/6 0/9
FIV-Pet/ 10 ID50/A 10/I.P./TCF
Yamaoto et al study 2 ICV 0,2,4,6,8,10,18/S.C. FIV-Pet/ 10 ID50/A 10/I.P./TCF
Yamaoto et al study 1
1991
WIV 0,2,4,6,8/S.C.
Yamamoto et al. Study 1 1993
9/I.P./TCF
0,2,5/S.C. FIV-Pet/ 10 ID50/A 8/I.P./TFC
0/10
Yamamoto et al. Study 1 1993 0,2,5,38/S.C. FIV-Dixon/10 ID50/A/ 45/I.P./TCF
2001
Hosie et al study 1
1995 WIV
FIVPet/250µg/A 0,2,4,7,10,17/I.P. 20/I.P./TCF
Hosie et al study 1 FIVPet/250µg/A 0,3,6/I.P.
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Table 1-5. Tabulation of Fel-O-Vax FIV vaccine trials. 
 
 
 
Author. Year. Vaccine type. Inoculum/dose/clade.
Immunisation schudual 
(Weeks)/route.
Challenge strain/dose/clade
Challenge 
week/route/source
Protection 
rate.
Control 
Protection.
FIVPet + FIVShi (Fel-O-Vax). 3 doses 
as per manfacturers instructions/ 
A+D
4/4 
inactivated FeT-j/?/NA (controls) 0/2
PBS/NA/NA (controls) 0/4
FIVPet + FIVShi (Fel-O-Vax). 3 doses 
as per manfacturers instructions/ 
A+D
4/4
PBS/NA/NA (controls) 0/3
Huang et al 2004 WIV/ICV
FIVPet + FIVShi (Fel-O-Vax). 3 doses 
as per manfacturers instructions, 
boosted after 1 year/ A+D
0,3,6/S.C.
Undescribed challenge virus. 11% 
amino acid divergencey at the 
Envelope level/ 11 
ID50/undescribed clade. 
52/I.M/TCF 19/25 2/19
WIV/ICV
FIVPet + FIVShi (Fel-O-Vax). 3 doses 
as per manfacturers instructions, 
boosted after 1 year/ A+D
0,3,6,58 /S.C
FIV-Aomori-2/contact 
challenge/B
6/6
Unvaccinated Untreated Untreated 5/8
Challenge group FIV-Aomori-2/10000 TCID50/B Untreated 0/10
FIVGL8YI/250µg/A 0/4
0.5mls PBS/0.5mls adjuvant 0/4
Kusuhara et al.
9/I.V./in vivoPu et al study 1
2005
WIV/ICV 0,3,6/S.C FIV-FC1/15 CID50/B
Pu et al study 2 WIV/ICV 0,3,6/S.C FIV-FC1/15 CID50/B 9/I.V./in vivo
2005
Hosie et al 2005 WIV 0,3,7/S.C. FIV-GL8/10 CID50/A 10/I.P./TCF
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Table 1-6. Tabulation of predominantly whole inactivated virus FIV vaccine trials that have protected. 
 
 
 
 
 
Author. Year. Vaccine type. Inoculum/dose/clade.
Immunisation schudual 
(Weeks)/route.
Challenge strain/dose/clade
Challenge 
week/route/source
Protection 
rate.
Control 
Protection.
FIVPet + FIVShi (Fel-O-Vax). 3 doses 
as per manfacturers instructions/ 
A+D
0,3,6/S.C. 0/6
1ml PBS (controls) 0,3,6/S.C. 0/5
Huang et al 2010 WIV/ICV
FIVPet + FIVShi (Fel-O-Vax). 3 doses 
as per manfacturers instructions, 
boosted after 1 year/ A+D
0,3,6/S.C FIV-FC1/1000 infected PBMCs/B 54/I.V./in vivo 10/14 0/5
FIVBangstrom/?/A/B 10/I.V/in vivo 1/4
FIVFC1/?/B 10/I.V/infected PBMC 8/8
FIVNZ1/?/F/C 10/I.V/infected PBMC 2/5 
Coleman et al 2014 WIV/ICV 0,3,6/S.C.
FIVPet + FIVShi (Fel-O-Vax). 3 doses 
as per manfacturers instructions, 
boosted after 1 year/ A+D
Dunham et al. 2006 WIV/ICV FIVGL8/ 10 CID50/A 10/I.M/TCF
45 
 
 
Table 1-7. Tabulation of inactivated cell FIV vaccine trials. 
 
Author. Year. Vaccine type. Inoculum/dose/clade.
Immunisation schudual 
(Weeks)/route.
Challenge strain/dose/clade
Challenge 
week/route/source
Protection 
rate.
Control 
Protection.
Inactivated FIVM2 infected MBM 
cells/ 3X107 cells/B
5/6 
Inactivated MBM cells/ 3X107 cells 
(controls)
0/9
Inactivated FL4 cells/2.5X107 cells/A FIV-Pet/ 10 CID50/A 4/4
Inactivated FL4 cells/2.5X107 cells/A FIV-GL8/ 10 CID50/A 3/4
Q201 cells/2.5 x 107/NA FIV-GL8/ 10 CID50/A 1/3
Adjuvant (controls) FIV-GL8/ 10 CID50/A
Adjuvant (controls) FIV-Pet/ 10 CID50/A
Inactivated FL4 cells/2.5X107 cells/A FIV-Pet/ 10 CID50/A 1/8
Inactivated FL4 cells/2.5X107 cells/A FIV-GL8/ 10 CID50/A 1/6
FeTJ cells/2.5 x 107/NA FIV-Pet/ 10 CID50/A 0/6
Adjuvant (controls) FIV-Pet/ 10 CID50/A
Adjuvant (controls) FIV-GL8/ 10 CID50/A
0/7
0/8
0,3,6,9,21/S.C. FIV-M2/ 10 CID50/BICV
Bishop et al study2 ICV 0,2,5,10/S.C. 13/I.P./TCF
37/i.v./plasma
Bishop et al study 1
1996
ICV 0,2,4,7,10,22/S.C. 24/I.P./TCF
Matteucci et al . 1996
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Table 1-8. Tabulation of inactivated cell FIV vaccine trials. 
 
 
 
Author. Year. Vaccine type. Inoculum/dose/clade.
Immunisation schudual 
(Weeks)/route.
Challenge strain/dose/clade
Challenge 
week/route/source
Protection 
rate.
Control 
Protection.
FIVPet + FIVShi/2.5 x 107 cells/ A+D 4/4
FIVPet/2.5 x 107 cells/A 4/4
Adjuvant (controls) 0/8
FIVPet + FIVShi/2.5 x 107 cells/ A+D 4/4
FIVPet/2.5 x 107 cells/A 1/4
Adjuvant (controls) 0/4
PBMC FIVM2 infected/ 3X107 
fixed, infected MBM cells/B
2/3
FIVM2/ 10 CID50/B 0/3
PBMC FIVM2 infected/ 3X107 
fixed, infected MBM cells/B
0/3
FIVM2/ 10 CID50/B 0/3
Matteucci et al . 1997 ICV
1997
ICV 0,4,8/S.C.  FIV-Pet /10 CID50/A
Fixed FIVM2 infected MBM cells/ 
3X107 cells/B
0,3,6,9,21/S.C.
73/i.v./Plasma
Inactivated MBM cells/ 3X107 
cells/controls
0,3,6,9,21/S.C.
10/I.P./TCF
Hohdatsu et al study 2 ICV 0,4,8/S.C.  FIV-shi/10 CID50/D
Hohdatsu et al study 1
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1.11 Correlates of immunity 
 
Initial trials where protection had been elicited correlated the titre of virus neutralising 
antibody (VNA) with protection (Yamamoto et al, 1993. Hosie et al, 1995), however some 
cats displayed low VNA titres and yet were still protected. However, the protection 
afforded by vaccination with IWV or ICV could be passively transferred and cats were 
protected against low dose homologous challenge (Hohdatsu et al, 1993). The protection 
could be attributed to the nAb by challenge of kittens, derived from vaccinated queens, 
with low dose homologous virus. The protection observed could only be afforded by 
maternally derived antibodies obtained from colostrum (Pu et al, 1995). Passive transfer of 
antibody mediated immunity could not be demonstrated against heterologous challenge, 
using highly purified antibody preparations derived from the blood of Fel-O-Vax FIV 
vaccinated cats (Coleman et al, 2014), although protection against homologous challenge 
could be demonstrated. Many vaccination studies using WIV or ICV (FIV-Petaluma) could 
detect high titres of nAb against FIV-Petaluma but low titres or no heterologous nAb (Pu et 
al, 2001. Hosie et al, 1995. Coleman et al, 2014). The importance of nAb may have been 
over stated by the methodology used to originally quantitate the nAb titres induced by 
vaccination. Originally the presence of nAb was determined using a focus reduction assay 
that utilised culture adapted FIV-Petaluma and the CD134 negative cell line Cfrk. Culture 
adapted strains of FIV can infect cells independently of CD134 by directly binding the FIV 
co-receptor CXCR4 via the V3 region of Env (Seibelink et al, 1995). The V3 is known to be 
an immunodominant epitope (Avrameas et al, 1992) and a neutralisation epitope 
(Lombardi et al, 1993). It was demonstrated by Verschoor and colleagues (1995) that Crfk 
adaptation was the result of a glutamic acid to lysine mutation at amino acid position 407 
(E407K). The E407K mutation led to an increased net charge of the V3 loop and enhanced 
the neutralisation of culture adapted strains of FIV by antibodies targeting V3 (Baldinotti et 
al, 1994). 
Initial vaccine trials failed to assess the immunity afforded by cellular immunity. Cytotoxic 
T-lymphocytes (CTL) were demonstrated in lymphoid tissues 50 weeks after vaccination 
with FIV-Petaluma WIV that were Env-specific (Flynn et al, 1996). Importantly, it was shown 
that vaccinated protected cats developed Env-specific CTL responses whereas unprotected 
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(naturally infected) cats developed Gag-specific CTL responses. The levels of CTL activity 
were comparable to those observed during the initial stages of infection (Tellier et al, 1997) 
and adoptive transfer of T-cells to matched MHC recipients could protect 80% of cats 
against low dose homologous (FIV-Petaluma) challenge and 50% of cats against 
heterologous (FIV-FC1) challenge (Aranyos et al, 2014). Although limited protection was 
demonstrated by adoptive transfer of only CD4+ or CD8+ T-cells, optimal protection was 
observed when mixed T-lymphocytes were infused. No protection was observed when T-
cell depleted lymphocytes (i.e. B-cells alone) were infused. A defined Th1 immune response 
was observed in protected vaccines with increased levels of IFNγ, IL-2, and CTL associated 
cytotoxins and cytolysin (Aranyos et al, 2014).  
 
1.12 Broadly neutralising antibodies (BnAb). 
 
The importance of virus neutralising antibodies (VNA) has been demonstrated for both HIV 
and FIV through the use of passive transfer studies of sera derived from vaccinated animals. 
Passive transfer of immunity was first demonstrated by Hohdatsu et al, (1993) where by 
cats passively immunised with sera from cats that were experimentally vaccinated with 
either an inactivated infected cell vaccine or a whole inactivated virus vaccine where 
protected. This finding was further examined by the low dose challenge of kittens with 
FIVpet born to queens that were either experimentally infected or vaccinated with FIVpet. 
The authors were able to demonstrate protection to kittens born to queens that were not 
vaccinated or infected but received milk from infected or vaccinated queens demonstrating 
that the immunity transferred was mediated solely by maternally derived antibody. This 
study also revealed a relationship between the titre of passively transferred antibody and 
the level of protection observed. Kittens that received a high titre of antibody remained 
completely protected, whilst kittens receiving a medium titre where not completely 
protected (Pu et al, 1995). Similar observations have been reported for HIV, where 
humanised mice passively transferred with a cocktail of broadly neutralising antibodies 
were able to control and suppress viremia to undetectable levels (Klein et al, 2012). 
Sterilising immunity has been achieved using the humanised mouse model, where mice 
received a single intramuscular injection of self-complementary Adeno-associated virus 
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vectors that express the full length BnAb, 4E10 (Balazs et al, 2011). Mice were completely 
protected against HIV challenge, even when intravenously challenged with high dose HIV.  
Antibodies to infection with FIV has been well characterised, and passive immunity has 
been demonstrated, the development of nAb or BnAb is less well understood. The 
development of homologous nAb was studied by Beczkowski et al, (2015), comparing the 
levels of neutralisation (both homologous and heterologous) in cats with different degrees 
of disease progression and survival outcomes. Cats that developed strong homologous nAb 
showed no difference in the CD4+ T-cell decline compared to cats that did not mount a nAb 
response. This study also revealed that there was no correlation between the development 
of BnAb and time infected, or survival time. In this study, only 13% of the cats developed 
BnAb, as assessed by the ability to neutralise HIV(FIV) pseudotypes bearing Envs from the 
reference strains FIV-Glasgow8 (clade A) and FIV-B2452 (clade B). In a separate study by 
Hosie et al, (2011) the development of homologous nAb was examined in cats challenged 
with an infectious molecular clone of the virulent UK field isolate FIV-Glasgow8. Over the 
observation period (4 years), only 1/3 cats developed homologous nAb that strongly (>80% 
neutralisation) neutralised FIV-Glasgow8, whilst the remaining two cats only moderately 
neutralised FIV-Glasgow8 (50-60% neutralisation).  The frequency of cats developing BnAb 
following natural infection has been reported to be as low as 0.9% (2/345). Although nAb 
could be detected in 8.7% of the plasma samples tested for neutralisation against FIV-
Glasgow8, only two displayed broad neutralisation against a panel of FIV pseudotypes 
bearing Envs derived from clades A, B and C (Samman, 2010, Hosie et al, 2011). The 
development of BnAb is believed to correlate with the time spent infected and might reflect 
the poor antigenicity of FIV Env. As BnAb require extensive somatic hypermutation, the 
antigenicity of the Env is crucial and the majority of B-cell epitopes have been shown to be 
immunologically silent for FIV (Liao et al, 2013. McLellan et al, 2011. Haynes et al, 2012. 
Massi et al, 1997). Adding to this problem is the fact that BnAb have been shown to be 
poly/auto-reactive (Flynn et al, 1994) and thus many potential B-cells that may produce 
BnAb are deleted at the fist self-tolerance check point. Taken together, the literature 
demonstrates the importance of BnAb and thus they are believed to form a crucial 
component of any further efficacious lentiviral vaccine.  The difficulty in eliciting BnAb 
remains a challenge of vaccinology in general.  
 
50 
 
1.13 Differentiation of infected from vaccinated animals  
 
In 2002, the release of the Fel-O-Vax FIV vaccine led to concerns regarding the sero-
diagnosis of FIV. The dual subtype vaccine is composed of whole inactivated virus (WIV) 
and inactivated infected cells (Pu et al, 2001) and elicits strong cellular and humoral 
immune responses (Pu et al, 2001. Hohdatsu et al, 1997, Huang et al, 2010). As the 
antibodies elicited by vaccination are indistinguishable from those produced following 
natural infection, it is not possible to differentiate infected from vaccinated animals (DIVA) 
using serology assays (Uhl et al, 2002). In an independent study, samples from FIV infected, 
FIV uninfected and FIV vaccinated and uninfected cats were screened for FIV antibodies 
using a range of serological assays (Levy et al, 2004) as shown in Table 1-9. 
 
Table 1-9. The sensitivities and specificities of 4 serological assays used to screen samples 
from FIV infected, FIV negative and FIV vaccinated cats. All assays demonstrated 
sensitivities ranging from 98-100% and specificities ranging from 90-100% when used to 
screen plasma samples from FIV infected and uninfected cats. However, when screening 
samples from vaccinated cats, the specificity rate ranged from 0-54% demonstrating that 
these assays detecting FIV antibody could not differentiate infected from vaccinated 
animals. 1SNAP FIV/FeLV Combo, 2PetChek FIV antibody test. Figure adapted from Levy et 
al, 2004.  
 
As conventional serological assays could not DIVA, alternative diagnostic tests were 
required. Virus isolation is not routinely used outside of FIV research as it is costly, highly 
specialised, time consuming and not suitable for large-scale screening. If samples have 
been in transit for several days, the viability of the infected PBMCs may be significantly 
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reduced, leading to false negative results. Heparinised whole blood is required for virus 
isolation as the anti-coagulant EDTA is toxic to the cells used in co-cultivations with PBMCs 
to propagate FIV. Furthermore, some primary strains of FIV do not induce large syncytia 
and so a confirmatory assay must be performed to detect virus in culture fluids, such as an 
ELISA for FIV p24 or an assay for RT.  
 
The first attempts to develop a serological DIVA assay to DIVA were made by Kusuhara et 
al (2007), testing a range of FIV antigens. By comparing the antibody binding of samples 
screened against different FIV antigens and employing discriminant analysis, it was possible 
to differentiate infected from vaccinated animals using a combination of formalin 
inactivated whole virus and a peptide corresponding to an immunodominant epitope on 
TM. Using this method, 134/138 samples were correctly identified as FIV infected or 
uninfected, producing a discriminating variable of 97.1%. As samples from 
vaccinated/uninfected cats did not exceed the linear discriminant function, such samples 
tested FIV antibody negative. However, in this study no samples from FIV uninfected and 
unvaccinated cats were tested and therefore there was no evidence that the ELISA could 
be used to differentiate samples from FIV negative cats from samples collected from FIV 
vaccinated cats. Using the same antigens, Levy et al (2008) extended this study and 
demonstrated a sensitivity of 97.1% and specificity of 100%; however, the ELISA did not 
differentiate samples from either FIV negative cats or FIV vaccinated cats, presumably 
because of non- specific antibody reactivity with the formalin treated whole virus antigen. 
 
More recent studies have utilised existing assays/technologies as DIVA tests. The use of 
several POC kits has been examined as a potentially cost-effective method of differentiating 
infected from vaccinated animals. The use of the Witness FeLV/FIV test (which contains TM 
as the capture antigen) in conjunction with the Anigen Rapid FeLV/FIV test (which contains 
p24 as well as TM as capture antigens) allows FIV negative cats (both uninfected and 
unvaccinated) to be differentiated from FIV positive cats.  (Westman et al, 2015). However, 
it was not possible to differentiate FIV negative cats from those that were vaccinated. The 
testing regime and definition of a positive FIV test, together with the   small numbers of FIV 
infected cats included in the study, raises questions about evaluating the serological status 
of cats on the basis of the results of testing using these two-lateral flow 
immunochromatography POC kits. The results obtained in this study must be viewed in 
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light of the technology employed in the selected POC kits. Of the 358 samples screened in 
this study, 119 samples were from fully vaccinated cats, 21 samples were from FIV infected 
cats and 218 FIV from uninfected, unvaccinated cats. The Witness FeLV/FIV and Antigen 
Rapid FeLV/FIV kits correctly identified 351/358 samples; all of the vaccinated cats tested 
negative, all of the FIV infected cats tested positive and all FIV negative cats tested negative. 
In contrast, using the SNAP FIV/FeLV Combo test all vaccinated cats tested positive. It is not 
yet clear if these results reflected the different capture antigens or the technology coupled 
to each test. The use of fluorescence-activated cell sorting (FACS) analysis was recently 
evaluated as a DIVA assay. The identification of weak florescence from the β chain of the 
CD8αβ glycoprotein is more commonly observed in FIV infected cats, leading to increased 
levels of CD8low expression (Shimojima et al, 1998). By examining PBMCs for expression of 
the T-lymphocyte receptors CD4 and CD8low, Litster et al (2014) differentiated infected 
from vaccinated cats with a sensitivity of 98% and a specificity of 84%.  Comparing the 
CD4:CD8low ratios, the majority of vaccinated cats tested negative for FIV infection, 
however there were no statistically significant differences observed between any of the FIV 
uninfected groups. To date, none of these assays are licensed as FIV DIVA tests and only 
PCR testing is not confounded by vaccination.  
 
Studies evaluating the performance of RT-PCR/PCR as a potential DIVA assay have shown 
variable results (Westman et al, 2015, Crawford and Slater, 2005). As none of the available 
PCR based assays were licenced at the time of publication, assays were not standardised 
and used various proprietary formulations of primers, probe and reagents. Crawford and 
Slater, 2005 (table 1-10), reported sensitivity values of 41-93% and specificity values for 
uninfected, unvaccinated animals of 81-100%, although it was not possible to identify a 
single laboratory that achieved performance figures that would justify the use of a 
commercial PCR test to screen cats for FIV infection. Specificity values for uninfected, 
vaccinated animals ranged from 44-95% with the results of one laboratory achieving 
acceptable specificity figures for uninfected cats and vaccinated, uninfected cats. Tests 
performed in this laboratory did, however, have a poor sensitivity value of 76%, so that 24 
of every 100 positive samples tested would be reported falsely as negative.   
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Table 1-10. Tabulation of comparative PCR sensitivities and specificities for three 
diagnostic laboratories. Two types of PCR were available from 3 different diagnostic 
laboratories where one offers PCR based on whole blood a dried blood smear. * = 
Laboratory 1, uses RT-PCR, † = Laboratory 2, uses a nested conventional PCR. Θ= Laboratory 
3, uses a conventional PCR. ‡ =Laboratory 3, uses a conventional PCR on template derived 
from a dried blood smear. Squares in red highlight the lowest performance figures whilst 
green squares highlight the highest performance figures. Figure adapted from Crawford 
and Slater, 2005. 
 
A subsequent study evaluating the usefulness of a commercially available PCR (FIV 
RealPCR™, IDEXX) to differentiate infected from vaccinated animals demonstrated 
improved test sensitivity and specificity (table 1-11). These figures were obtained following 
the testing of 358 independently obtained samples from Australia. The sensitivity of the 
PCR assay was reported to be higher than stated by the manufacturer, although this may 
be related to there being fewer FIV infected cats included in the sample population, or that 
samples used in the Westman et al (2015) study had previously been screened for FIV 
antibodies using three POC kits, biasing the PCR results. Specificities for both uninfected 
and vaccinated animals closely matched the values quoted by the manufacturer, making 
the FIV PCR a reliable molecular diagnostic tool for detecting FIV infection and a potentially 
useful DIVA assay. Four false positive samples (1 originating from an FIV vaccinate and three 
from FIV negative, unvaccinated cats) and two false negative samples (both originating 
from FIV vaccinates) were identified. 
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Table 1-11. Independent validation of FIV RealPCR, utilising FIV infected, FIV uninfected 
and FIV vaccinated samples. † = 21 samples that were initially thought to be FIV negative 
were found to be FIV provirus positive and FIV antibody positive by three different POC 
kits. A further 5 samples that were derived from FIV vaccinated cats were shown to be FIV 
provirus and virus isolation positive (likely vaccine breakthrough cases). 
*(http://www.idexx.com.au/pdf/en_au/smallanimal/education/realpcr-test-for-fiv.pdf 
 
 
None of the DIVA assays described in this chapter are commercially licensed for the sero-
diagnosis of FIV. The IDEXX FIV RealPCR™, is licensed, has good specificity but lacks 
sensitivity as the primers used in the PCR reaction might not be optimal to detect the 
circulating clades of FIV in the region. The data demonstrated that all the assays could be 
used to differentiate infected from uninfected cats (all samples from vaccinated cats tested 
FIV negative) but it was not possible to differentiate vaccinated from uninfected, 
unvaccinated cats. The ideal DIVA assay should allow the identification of samples from (a). 
vaccinated, uninfected, (b). vaccinated infected, (c). unvaccinated, uninfected and (d). 
unvaccinated, infected cats. When utilising assays that specifically titrate sensitivity against 
specificity so as to avoid the detection of antibodies elicited by vaccination, there is a 
significant risk of false negative results. Cats in the initial stages of FIV infection with low 
titres of FIV antibody would test antibody negative, as would cats in the terminal stages of 
FIV infection with B-cell exhaustion or high viral loads that form complexes with any 
antibody so that no unbound antibody remains available for detection. The POC kit 
comparisons using different capture antigens indicate that kits containing the epitope from 
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TM display the highest specificities, with values of 99-100% (Sibille et al, 1995, Hartmann 
et al, 2007). This raises the question: can a DIVA test be developed based solely on the 
immunodominant epitope within TM?  
 
One hypothesis is that mutation of a conserved yet highly antigenic B-cell epitope within 
the virus could potentially differentiate infected from vaccinated cats. The principal 
immunodominant domain (PID) of TM has been shown to be highly conserved and 
antigenic; indeed, the epitope is a major constituent in many POC kits including the 
Witness®, SNAP® Combo Plus, FASTest® and DUO speed®. Therefore, if this epitope was 
able to withstand mutation, whilst maintaining virological function, and included in a WIV 
vaccine candidate, the humoral immune response towards the wildtype PID sequence 
would be abolished. If a peptide ELISA were to be developed utilising peptides that 
corresponded to the wildtype and mutated PID sequences as capture antigen, it would be 
possible to screen cat plasma for reactivity to wild type sequence (indicative of infection) 
or the mutated PID sequence (indicative of vaccination). Samples responding to neither 
peptide would be considered uninfected and unvaccinated, whilst samples responding to 
both peptides would be classed a vaccinated and infected. All retroviruses contain their 
own unique PID sequence, and have been shown to be able to withstand significant 
mutation.  Therefore, the PID of FIV is an attractive DIVA epitope and could be mutated to 
that of another retrovirus (Pancino et al, 1995. Pancino and Songio, 1997. Broche-Pierre et 
al, 2005). A prime candidate for this is the PID sequence of FIV derived from lions (FIVple). 
More specifically subtype E FIVple (termed lion lentivirus subtype E [LLV-E]), shares 
sequence homology with that of FIV derived from the domestic cat (FIVfca), however the 
5’ end of the PID sequence (Figure 1-8) displays sufficient divergency so that reactivity 
against the wildtype PID sequence should be abolished. Therefore, the rational of mutating 
the PID of FIV to that of LLV-E may allow for the differentiation of infected from vaccinated 
animals. 
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Figure 1-8. The difference in PID amino acid sequence between FIVfca and LLV-E (A) and 
the orientation of the PID with TM (B). A, amino acids shown in red highlight the difference 
between the FIVfca and LLV-E PID sequences. B, a cartoon representation of the 
transmembrane domain of the envelope glycoprotein with the location of the PID 
highlighted in orange. The PID forms a loop at the apex of variable loop 7 by the formation 
of disulphide bonds between the two terminal cysteines. The PID sequence of LLV-E differs 
by only 3 amino acids when compared to FIVfca (A), but it is hoped that this is enough 
sequence heterogeneity from the wild type sequence to abolish plasma reactivity if the 
wildtype PID sequence was mutated to that of LLV-E (B) and included in a candidate WIV 
vaccine.   
1.14 Aims. 
 
1. Determine the pathogenesis of a chimaeric FIV isolate containing the gag and pol 
proteins of FIV-Glasgow8 contained within a novel field isolate envelope 
(designated FIV ΔV2). 
2. The development of a DIVA peptide ELISA that is capable of differentiating infected 
from vaccinated animals. 
3. Mutation of the PID sequence of FIV ΔV2 to that of LLV-E (DIVA virus). 
4. Perform a DIVA WIV vaccine trial utilising the DIVA virus to determine of protection 
can be afforded whilst simultaneously performing DIVA. 
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Chapter 2 General materials and methods 
2.1 Molecular biology techniques. 
2.1.1 Primers and probes 
 
Primers and probes were designed using DNADynamo blue tractor software and ordered 
from the IDT website (Integrated DNA technologies, Interleuvenlaan, Belgium). Lyophilized 
primers were reconstituted with TE buffer (10mM Tris-HCl pH 8.0, 0.1mM EDTA) to prepare 
stocks at the final concentration of 100pmol/µl. Secondary primer stocks at 10pmol/µl 
were subsequently prepared in TE buffer for use in PCR assays. All primer stocks were 
stored at -20oC until needed.  
 
Probes were ordered using the custom probe design tool and labelled at the 5’ end with 
the reporter dye Fluorescein (FAM) and at the 3’ end with the quencher TAMRA. 
Lyophilized probes were reconstituted to 100pmol/µl with probe dilution buffer supplied 
by the manufacturer, aliquoted into 10µl amounts and stored at -20oC until required.  Prior 
to use, probes were thawed at room temperature in the dark and diluted to the final 
concentration (5pmol/µl) using deionised water.  
2.1.2 Polymerase chain reaction (PCR)  
 
Proviral DNA encoding the FIV envelope gene (env) was amplified using a nested PCR 
method. First, gDNA from ex vivo derived PBMCs or cells cultured in vitro was extracted 
using the QIAmp DNA mini extraction kit (Qiagen, Manchester, UK), as described in section 
2.1.8.  First round PCR products were amplified using the degenerate primers IF4 and XR2 
(Appendix 2) with the Phusion® high fidelity DNA polymerase kit (Hitchin, Hertfordshire, 
UK) using the volumes shown in Table 2-1. 
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Table 2-1.  Phusion PCR reactants and volumes. 
Selected templates were amplified on the GeneAmp 9700 PCR systems thermo cycler 
(Applied Biosystems) using the cycling conditions detailed in Table 2-2. 
 
 
 
 
 
 
 
 
 
 
Table 2-2. Phusion PCR cycling conditions 
PCR products were separated by agarose gel electrophoresis, extracted and purified as 
described in 2.1.4. Second round PCR were again performed with the Phusion® high fidelity 
DNA polymerase kit using GL8 Sal and GL8 Not1 specific primers (Appendix 1). GL8 Sal and 
GL8 Not1 primers anneal at 69oC. All other cycling conditions remained the same.  
 
Reagent 
Volume 
(µl) 
Phusion high fidelity DNA polymerase 
(2000u/ml) 
0.5 
GC buffer 10 
dNTPs (8µM) 1 
Forward primer (10pmol/µl) 1 
Reverse primer (10pmol/µl) 1 
DMSO 2 
Template 2 
H20 32.5 
Temperature 
(oC) 
Time 
(mm:ss) 
Number 
of cycles 
Stage of reaction 
98 03:00  1 
Initial 
denaturation 
98 00:10  
35 
Denaturation 
62.5 00:30  Annealing 
72 01:15  Elongation 
72 10:00  1 Final Elongation 
4 ∞ ∞   
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2.1.3 Agarose gel electrophoresis and PCR product purification. 
 
Amplified PCR products were separated using a 0.7 - 0.8% agarose gel and visualised under 
ultra violet (UV) light. PCR products were mixed with X10 loading dye before 
electrophoresis using an agarose gel containing ethidium bromide at 250ng/ml (Sigma 
Aldrich, Dorest, UK) for 1.5 hours at 100V in TBE buffer. Bands were visualised under UV 
light and excised using a sterile scalpel.  
Amplified DNA was extracted from the agarose gel using the QIAquick gel extraction kit 
(Qiagen, Manchester, UK), as per the manufacturer’s protocol.  Briefly, the DNA and 
agarose were incubated with QG buffer at 52oC until the agarose had completely dissolved. 
The mixture was then centrifuged through a QIAquick spin column in which the low pH 
(≤7.5pH) and high chaotropic salt concentration allowed binding of DNA to the silica 
membrane. Residual agarose, ethidium bromide and other impurities were washed 
through the membrane using PE wash buffer. The addition of a small volume of EB buffer 
(≥7.5pH) eluted the purified DNA. 
2.1.4 Quantitative polymerase chain reaction (qPCR) 
 
QPCR was performed to amplify and quantify the FIV proviral genome sequences from 
tissues. The relative proviral load was estimated by normalising the sample data against a 
housekeeping gene and extrapolating this value to a standard curve.  
The proviral FIV gag gene was detected by PCR amplification using the reagents listed in 
Table 2-3. Reactions of 20µl were added to a MicroAmp fast optical 96 well reaction plate. 
Each plate contained a set of standards containing 100-107 copies of the GL8-414 molecular 
clone of FIV in the plasmid pBR328. The gag gene was amplified using the cycling conditions 
listed in Table 2-4. Fluorescence was measured using the 7500 fast system sequence 
detection software v1.4 on the ABI 7500 fast PCR machine (Leicestershire, UK) 
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Table 2-3. FIV gag qPCR reactants and volumes. 
 
Table 2-4. QPCR cycling conditions. 
 
Sample values were normalised against the ribosomal DNA housekeeping gene. PCR 
reactions were set up using the reagents listed in Table 2-5 in total reaction volumes of 
20µl in the wells of MicroAmp fast optical 96 well reaction plates. Each normalisation plate 
contained a set of rDNA standards derived from the genomic DNA of the feline 
lymphoblastoid cell line, Mya-1. Five-fold serial dilutions of genomic DNA were prepared, 
from 800ng/µl to 1.02ng/µl. Amplifications were performed using the cycling conditions 
shown in Table 2-4 and fluorescence was detected using the 7500 fast system sequence 
detection software v1.4 on the ABI 7500 fast PCR machine (Leicestershire, UK). 
 
 
Reagent 
Volume 
(µl) 
Supplier 
x2 Taqman universal master mix 10 Applied Biosystems 
Forward primer (FIV-1360F) 1 IDT 
Reverse primer (FIV-1437R) 1 IDT 
FIV Gag probe 1 IDT 
template 1 N/A 
Denionised water 6 
Gibco, Life 
Technologies 
Temperature (oC) Time (mm:ss) Number of cycles 
50 02:00 1 
95 10:00 1 
95 00:15 
40 
60 01:00 
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Table 2-5. rDNA qPCR reactants and volumes 
 
Sequence detection data was expressed as ct values and the mean values for three 
replicates were calculated. Proviral loads were calculated by dividing the number of copies 
of FIV gag by the corresponding amount of DNA present in the normalisation wells. This 
value was then multiplied by 5000 to estimate the number of copies of FIV genome per 106 
cells (Leutenegger et al, 1999). 
2.1.5 FIV TM peptide ELISA 
 
A peptide ELISA was used to detect antibodies recognising an immunodominant TM 
epitope of FIV (Avrameas et al, 1993).  The wells of 96-well microtitre plate (Immulon 2 HB) 
were coated with 250ng/well of FIV TM peptide (AltaBioscience, Birmingham, UK) in 
sodium carbonate bicarbonate binding buffer (0.2M anhydrous sodium carbonate, 0.2M 
sodium carbonate and deionised water at a ratio of 1:11.5:4 respectively). The plate was 
incubated at 4oC overnight whilst being agitated at 30rpm. The next day, the wells were 
aspirated and washed 5 times with 200µl of phosphate buffered saline supplemented with 
0.1% Tween (PBST). Unabsorbed sites were blocked following incubation with 200µl of 2% 
low fat milk powder PBST (block) for 1 hour at room temperature. The wells were then 
aspirated and washed 5 times with 200µl of PBST and 100µl of plasma/sera were added to 
wells at a dilution of 1/200 in block. One hundred microliters of positive and negative 
Reagent Volume (µl) Supplier 
x2 Taqman universal 
master mix 
10 Applied Biosystems 
Forward primer          
(rDNA 343F) 
1 IDT 
Reverse primer                             
(rDNA 409R) 
1 IDT 
rDNA 370 probe 1 IDT 
gDNA template 1 N/A 
Denionised water 6 
Gibco, Life 
Technologies 
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controls were also added to the plate at a dilution of 1/200 in block. The positive control 
consisted of plasma derived from an experimentally infected SPF cat, whilst the negative 
control consisted of an SPF plasma from a control cat that was not experimentally infected. 
Both samples had previously undergone virus isolation to confirm their FIV status. The 
plates were sealed and incubated at room temperature for 1 hour before being washed 5 
times with 200µl of PBST, after which 100µl of biotinylated goat anti-cat secondary 
antibody (Vector laboratories, Peterborough, UK) were added to each well at a dilution of 
1/1000 (1-1.5µg/µl) in block. The plates were sealed and incubated at room temperature 
for 1 hour. Wells were then aspirated and washed 5 times with 200µl of PBST and 100µl of 
horseradish peroxidise conjugated to streptavidin [Vector laboratories, Peterbouough, UK 
(1-1.5µg/µl)] were added per well at a dilution of 1/1000 in block. The plates were sealed 
and incubated at room temperature for 20 minutes, aspirated and washed 5 times with 
200µl of PBST and then 100ul of 3',3',5'5'-Tetramethylbenzidine liquid (TMB super slow, 
Sigma Aldrich) were added to each well. Plates were again sealed and incubated at room 
temperature for 30 minutes before being read at 650nm on the MultiSkan ascent 
spectrophometer (MTX labsystems, Virginia, USA). 
 
To determine the sero-status of a give sample, the optical density of the plasma sample 
was divided by 2X the optimal density of the negative control. If this value, termed negative 
fold, was less than 2, the sample was considered a true negative. If the negative fold was 
between 2 and 3.9, the sample was considered inconclusive. If the negative fold was equal 
to or greater than 4, the sample was considered a true positive. 
2.1.6 DIVA ELISA. 
 
The DIVA ELISA was performed exactly as described for the FIV TM ELISA apart from the 
capture antigen used. As well as using a peptide that corresponds to the principal 
immunodominant domain of FIV, the plate was also coated with a peptide corresponding 
the principal immunodominant domain of LLV-E. More specifically one half of the plate (4 
X 12 wells) were coated with the FIV TM peptide whilst the other half were coated with 
LLV-E TM peptide in Sodium carbonate bicarbonate binding buffer as described in 2.1.6. All 
other reagents, concentrations, dilutions and suppliers are the same as those listed in 2.1.6. 
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The FIV positive control consisted of plasma derived from an experimentally infected SPF 
cat, whilst the negative control consisted of an SPF plasma from a control cat that was not 
experimentally infected. Both samples had previously undergone virus isolation to confirm 
their FIV status. The LLV-E positive control was derived from an 8-year-old male African lion 
from the Moremi game reserve in the Okavango delta (McEwan et al, 2008). Again, virus 
isolation confirmed the true status of this sample. As there was no difference in the optical 
density between an FIV or LLV sero-negative sample, and considering that African lion 
plasma is an expensive and limiting resource, it was deemed unnecessary to include an LLV 
negative control.  
 
To determine the vaccination status of a given sample, first the optical density of the 
plasma sample was divided by 2X the optimal density of the negative control. The negative 
fold of the optical density against the LLV-E peptide was divided by the negative fold of the 
optical density against the FIV TM peptide. If this value, termed absorbance ratio, was equal 
to or less than 3, the sample was considered unvaccinated. If the absorbance ratio was 
greater than 3, the sample was considered vaccinated. The absorbance ratio was calculated 
using plasma from cats that had been experimentally vaccinated with a genetically altered 
chimeric FIV virus that carried the PID amino acid sequence of LLV-E instead of FIV.  
In summary, the negative fold is used to determine the FIV sero-status of a given sample 
and the absorbance ratio is used to differentiate infected from vaccinated animals.  
2.1.7 Genomic DNA (gDNA) extraction. 
 
The QIAamp DNA mini kit (Qiagen, Manchester, UK) was used to extract gDNA from 
cultured cells, Ficoll purified peripheral blood mononuclear cells (PBMCs) and whole blood 
according to the manufacturer’s instructions. Briefly, up to 5x106 cells were resuspended 
in 200µl of PBS containing 20µl of proteinase K.  Next, 200µl of AL lysis buffer was added 
and the mixture incubated at 56oC for 10mins to ensure complete lysis of the cells. Two-
hundred microlitres of 96-100% ethanol was added and the lysate mixed thoroughly to 
precipitate the DNA after which it was passed through a QIAamp mini spin column by 
centrifugation at 8609g for 1 minute. Centrifugation steps were performed using the 
eppendorf 5418 centrifuge (Eppendorf UK Limited, Stevenage, UK). The bound DNA was 
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then washed in 500µl of AW1 buffer by centrifugation at 8609g for 1 minute. Another wash 
step was performed using 500µl of AW2 buffer by centrifugation at 16873g for 3 minutes.  
A dry spin was performed at 16873g for 1 minute to remove residual contaminants after 
which the DNA was eluted in 200µl of buffer AE. 
2.2 Tissue culture 
2.2.1 Recovery of cells frozen in liquid nitrogen. 
 
Cells were recovered from liquid nitrogen storage and rapidly thawed in a humidified 
incubator at 37oC. The cells were then resuspended in 10mls of PBS and centrifuged at 159g 
for 5 minutes in order to pellet the cells and remove the DMSO in the freezing medium. All 
cells were centrifuged using the eppendorf 5810 centrifuge (Eppendorf UK Limited, 
Stevenage, UK). Pelleted cells were then resuspended in 5mls of culture medium and 
cultures were set up in T25 flasks (Corning, Warrington, UK). Cultures were inspected daily 
and the medium was replaced, and/or the cells subcultured as required. 
2.2.2 Suspension cells 
 
Suspension cells were maintained in RPMI 1640 media (Gibco, Life Technologies, Paisley, 
UK) supplemented with 10% heat inactivated fetal bovine serum (Hyclone, Thermo 
Scientific), 100u/ml of penicillin, 100mg/ml of streptomycin, 2mM L-glutamine, 0.11mg/ml 
sodium pyruvate and 50µM 2-β-mercaptoethanol ("complete RPMI"). Cells were initially 
cultured in T25 culture flasks, examined daily and subcultured to maintain the cell 
concentration between 5 x 105 per ml and 5 x 106 per ml. Culture media were changed 
every 4 or 5 days by centrifugation at 159g for 5 minutes and the cells were subcultured in 
fresh complete RPMI.  Genetically modified cells were selected by the supplementing 
medium with 400µg/ml G418 (G418 sulphate, Promega, Southampton, UK). 
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2.2.3 Adherent cells 
 
Adherent cells were maintained in Dulbecco’s modified eagle medium (DMEM, Gibco, Life 
Technologies, Paisley, UK) supplemented with 10% heat inactivated foetal bovine serum 
(Hyclone, Thermo Scientific), 100 IU/ml of penicillin, 100µg/ml of streptomycin and 2mM 
L-glutamine ("complete DMEM"). Cells were initially cultured in T25 culture flasks, 
examined daily and subcultured when confluent. Culture media were changed every 4 to 5 
days. Briefly, the medium was aspirated and 5mls of trypsin were added to cell monolayers 
for 5 minutes at 37oC.  Trypsinised cells were centrifuged at 159g for 5 minutes and new 
cultures were set up in fresh complete DMEM media. Genetically modified cells were 
selected by supplementing the media with 400µg/ml G418 (G418 sulphate, Promega, 
Southampton, UK). 
2.2.4 Cells 
2.2.4.1 Feline lymphoblastoid cells (Mya-1) 
 
The feline lymphoblastoid cell line, designated Mya-1, has been shown to be highly 
susceptible to FIV infection (Miyazawa et al, 1989).  The cell line was developed in 1989 by 
Miyazawa et al, following the inoculation of a 5-month-old specific pathogen free (SPF) cat 
with blood from a male cat testing seropositive for FIV and FeSFV. PBMCs collected from 
the SPF cat were shown to be free of exogenous FIV, FeFSV and FeLV at 9 and 11 months 
post inoculation.  
Mya-1 cells were maintained in complete RPMI 1640 medium supplemented with 100IU/ml 
recombinant human interlukin-2 (rhIL-2). Mya-1 cells express both the primary receptor of 
FIV, CD134, and the co-receptor, CXCR4, with surface expression >90% (our unpublished 
data).  
2.2.4.2 CLL-OX40 
 
CLL-OX40 cells were derived from canine lymphocytic leukaemic cells; an immortalised 
clone was obtained by extensive in vitro passage of the CD3+ CD4- CD8- cells. The resulting 
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cell line was then transduced with a lentiviral vector containing feline OX40 and selected 
with G418 (Willett et al, 2006). Stably transduced cells were maintained in complete RPMI 
supplemented with G418. During these studies, surface expression of feline OX40 was 
>95% and the expression of canine CXCR4 was also >95%.  The expression of the FIV primary 
and secondary receptors renders CLL-OX40 cells highly susceptible to FIV infection.  
2.2.4.3 Human embryonic kidney cells [HEK(293T)] 
 
293T cells are transformed human embryonic kidney (HEK) cells that express the 'T' antigen 
of adenovirus type 5 (Ad5). Developed by Graham et al in 1977, 293T cells were produced 
by calcium phosphate transfection of HEK cells with sheared Ad5 DNA. After extensive 
passage (~550 days) a stable, immortalised cell line was obtained that harboured 
integrated Ad5 'T' antigen DNA. Due to the relative ease with which 293T cells can be 
cultured and manipulated, they are commonly used for the translation of genetically 
modified DNA transcripts.   
293T cells were maintained in complete DMEM and sub cultured into fresh medium, 
containing G418, every 4-5 days. 
2.2.5 Separation of plasma and PBMC from whole blood 
 
Whole blood collected into heparin or ethylenediaminetetraacetic acid (EDTA) 
anticoagulant was centrifuged at 635g for 10 minutes to separate the cellular fraction from 
the plasma which was aliquoted into 200-300µl volumes and stored at -80oC until required. 
The cellular fraction was resuspended in 5mls of sterile PBS and layered over 5mls of Ficoll 
(GE healthcare, Amersham, Buckinghamshire, UK) in a 15ml falcon tube. The tubes were 
then centrifuged at 635g for 30 minutes with no brake and the buffy coats were collected 
into fresh 15ml falcon tubes containing 10mls of PBS. The PBMCs were then and 
centrifuged at 159g for 5 minutes to remove the Ficoll and the washed cells were stored as 
two cell pellets at -80oC. 
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2.2.6 Isolation of FIV 
 
Virus isolation was performed as a confirmatory test as it is considered to be the 'reference 
standard' for FIV diagnosis. Co-cultivation of PBMCs with an FIV susceptible cell line leads 
to viral replication and the appearance of syncytia or cell death. The presence of FIV in 
culture fluids is confirmed using an ELISA detecting FIV p24 antigen.   
Cultures containing 1 x 106/ml Mya-1 cells in 5mls were co-cultivated with PBMC in 
complete RPMI 1640 media containing 100IU/ml rhIL-2 and monitored for 21 days. Cultures 
were inspected daily for the appearance of syncitium formation, 'ballooning' cells and cell 
death, typical of FIV infection. Culture fluids were sampled on day 7 when the cells were 
resuspended in 10mls of fresh medium and transferred to T75 flasks (Corning, Warrington, 
UK). On day 14, the cells were resuspended in fresh culture media following centrifugation 
at 102g for 10 minutes with no brake. On day 21 the culture fluids were clarified and 
screened for FIV p24 by ELISA. 
After 21 days in culture, cells were harvested, washed in PBS for 10 minutes and cell pellets 
were stored at -80oC.  Culture fluids were filtered using a 0.45µm filter (Ministart, Sartorius 
Stedim Biotech, Goettingen, Germany) and stored at -80oC in 1ml aliquots.  
2.2.7 Titration of FIV on Mya-1 cells 
 
Serial fivefold dilutions of each virus stock were made in complete RPMI. In triplicate, 50µl 
volumes of each dilution of virus were incubated with 250µl of Mya-1 cells at 8x105/ml in 
BD FACS tube (Corning, Flintshire, UK) at 37oC for 1 hour in a humidified incubator.  Cells 
were then washed twice in 4mls of sterile PBS by centrifugation at 800rpm with no brake 
and the PBS was removed by aspiration using a Vacusafe bench top aspirator (Integra 
biosciences AG, Zizers, Switzerland). After washing, the cell pellets were resuspended in 
500µl of complete RPMI containing rhIL-2 and cultured in the wells of a 48 well plate. 
Cultures were then incubated for 14 days at 37oC in a humified incubator. On day 7 post 
infection, 250µl of the culture fluids were removed and replaced with fresh medium 
containing rhIL-2. On day 14, 200µl of culture fluid were collected and tested for reverse 
transcriptase activity or FIV p24 and the cells were pelleted and stored. The infectious virus 
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titre was calculated using the Karber formula and expressed as tissue culture infectious 
doses 50% (TCID50). 
2.3 Analysis of viral proteins 
2.3.1 Cell lysate production. 
 
Cell samples (1 x 106 of FIV-infected or –uninfected cells) were collected and centrifuged at 
2152g for 2 minutes and the pelleted cells were then washed in 1ml of sterile PBS. The cell 
pellet was lysed by resuspension in 75µl of NP-40 buffer containing Roche Complete ULTRA 
protease inhibitor cocktail tablets (Roche diagnostics GmbH, Mannheim, Germany) 
followed by incubation on ice for 30 minutes. To each cell lysate, 25µl of X4 reducing 
loading dye (125mM tris-HCL, pH 6.8, 40% glycerol, 4% SDS, 0.1% bromophenol blue, 5% 
β-mercaptoethanol) was added before sonication at 4Hz for 30 seconds to mechanically 
disrupt large cellular proteins. The samples were then heated to 90oC for 10 minutes and 
centrifuged at 16873g for 10 minutes to pellet nuclei, chromatin and other cellular debris. 
The resulting samples of cell lysate were separated and either analysed immediately or 
stored at -20oC.  
2.3.2 Viral lysate production. 
 
1ml of cell free culture fluid was layered over 400µl of 20% sucrose in PBS and centrifuged 
at 16873g for 90 minutes at 4oC. The viral pellet was then washed with 1ml of sterile PBS 
and centrifuged again at 16873g for 40 minutes at 4oC. The supernatant was aspirated and 
discarded and the viral pellet was lysed in 25µl of x4 reducing loading dye and heated to 
90oC for 10 minutes. The mixture was then centrifuged at 16873g for 10 minutes to remove 
viral nucleotides and residual cellular debris before the lysate was either analysed by SDS-
PAGE immediately or stored at -20oC.  
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2.3.3 Reverse Transcriptase (RT) activity assay. 
 
Lentiviral reverse transcriptase (RT) activity was measured quantitatively in culture fluids 
using the Cavidi Lenti RT kit (Uppsala, Sweden). Based on a direct ELISA format, the quantity 
of RT present is determined by comparing the optical densities of sample wells with those 
of known lenti RT standards.  If RT is present in a sample, the enzyme synthesises DNA, 
using Brd labelled nucleotides, from the RNA template. The DNA product is then detected 
using an anti-DNA antibody conjugated to alkaline phosphatase, giving a colorimetric 
change upon the addition of substrate. 
Poly-A wells were first incubated with 200µl of RT reaction mix and incubated at 33oC for 1 
hour. Ten microlitres of cell free culture fluid was added to the wells along with 10µl of 
Lenti-RT standard, and the plate was sealed and incubated at 33oC for 24 hours. Wells were 
then washed 5 times with 200µl of wash buffer (0.75% TritonX-100, deionised water and 
0.25% plate wash concentrate) and 100µl of tracer (anti-bromo-deoxyribouridine 
monophosphate) were added to each well. Plates were sealed and incubated at 33oC for 
90 minutes. The wells were then washed again 5 times with 200µl of wash buffer and 125µl 
of pNPP (paranitrophenylphosphate disodium) substrate were added to each well. The 
plates were sealed and incubated at room temperature for 2 hours. Plates were read at 
405nm on the MultiSkan ascent spectrophometer (MTX labsystems, Virginia, USA) at 30 
minutes and 2 hours after the addition of substrate.  
2.3.4 FIV p24 antigen ELISA 
 
The Vpg62 (Weijer et al, 1995) monoclonal antibody raised against FIV p24 was used in an 
antigen capture ELISA to detect the Capsid protein, p24, in culture fluids to confirm the 
presence of FIV.  
Immulon 2 HB plates (Thermo scientific, UK) were coated with 100µl of Vpg62 at a dilution 
of 1/1000 (2ng/µl) in serum free DMEM. Plates were incubated at 4oC overnight whist being 
agitated at 30rpm. Post adsorption, the coating solution was aspirated and the wells 
washed 5 times in PBST. Unadsorbed sites were blocked with 200µl of blocking solution 
and plates were incubated at room temperature for 1 hour, after which the blocking 
solution was aspirated and wells washed 5 times in PBST. Next, 10µl of sample treatment 
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solution (30mM Tris/HCL pH 7.2, 450mM NaCl, 1.5% Triton X-100, 1.5% sodium deoxycholic 
acid, 0.3% SDS, 10mM EDTA and 0.02% sodium azide: Schupbach et al, 2006) was added to 
each well followed by 100µl of cell free tissue culture fluid. The plate was incubated at 
room temperature for 1 hour before being washed 5 times with PBST. Fifty microlitres of 
αp24 monoclonal antibody conjugated to horseradish peroxidase (IDEXX laboratories, 
Maine, USA) was added to each well and the plate incubated at 37oC for 1 hour. The 
secondary antibody was then removed and the plate washed 5 times in PBST before 50µl 
of 3',3',5'5'-Tetramethylbenzidine liquid (TMB super slow, Sigma Aldrich) were added to 
each well. After incubation at room temperature for 10 minutes, the plates were read at 
650nm on the MultiSkan ascent spectrophometer (MTX labsystems, Virginia, USA). Positive 
samples were defined as having optical density values greater or equal to 3 times the 
optical density of the negative control well.  
2.3.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and Immunostain analysis. 
 
To analyse the protein content of selected samples, reduced cell lysates or purified virus 
were loaded into a reducing polyacrylamide gel for electrophoresis, before the proteins 
were transferred to a PDVF membrane and visualised by staining using a combination of 
primary antibodies, species-specific antibodies conjugated to biotin, streptavidin and a 
chromogenic substrate. The molecular weights of proteins were estimated by comparison 
to known standards (Seeblue plus2 pre-stained protein marker, Invitrogen, Paisley, UK) and 
specific proteins identified using monoclonal antibodies.  
2.3.6.1 SDS-PAGE. 
 
Gradient (4-12%) BisTris gels (Novex, Invitrogen, Paisley) were first washed in x1 NuPage 
MES running buffer (Novex, Invitrogen, Paisley) to remove any unpolymerised acrylamide 
and allowed to equilibrate for 5 minutes in 850mls of x1 NuPage wash buffer in a Novex 
mini-cell (Invitrogen, Paisley). Cell or viral lysates, along with protein standards, were 
loaded into the wells and the lysate was allowed to settle for 5 minutes. Next, current was 
applied to the mini-cell (100 V) and the lysates were allowed to migrate for ~3 hours. The 
proteins were then transferred to a Trans-blot turbo Midi PVDF membrane (Bio-rad, Hemel 
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hempstead, UK) and transferred on the Bio-rad turbo blot using the turbo midi programme 
(25 V for 7 minutes). Unbound sites on the membrane were then blocked in X1 casein 
solution (Vector Laboratories, Peterborough, UK) overnight at 4oC whilst being agitated at 
30rpm. 
2.3.6.2 Chromogenic staining. 
 
Membranes were first washed 3 times for 5 minutes in 5mls of PBST. Membranes were 
then probed with primary antibody in X1 casein solution for 1 hour at room temperature 
whilst being agitated at 30rpm. The membrane was then washed in 5mls of PBST 4 times 
for 15 minutes each, whilst being agitated at 30rpm. A biotinylated species-specific 
secondary antibody was then used to probe the membrane at a dilution of 1/1000 [(1-
1.5µg/µl) Vector Laboratories, Peterborough, UK] in X1 casein solution. Membrane and 
antibody were incubated for 1 hour at room temperature whilst being agitated at 30rpm. 
The membrane was again washed in PBST 4 times for 15 minutes. The membrane was next 
incubated with 20µl of both biotinlyated alkaline phosphatase and streptavidin from the 
Vectastain ABC-Amp kit (Vector Laboratories, Peterborough, UK) at a dilution of 1/500 in 
X1 casein solution. The membrane was incubated for 15 minutes at room temperature 
whilst being agitated at 30rpm after which it was once again washed in PBST 3 times for 10 
minutes at room temperature whilst being agitated at 30rpm. Protein bands were resolved 
using 5'-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium as substrate (BCIP/NBT 
substrate kit, Vector, Laboratories, Peterborough, UK) as per the manufacturer’s 
instructions. Briefly, 1 drop of solutions 1, 2 and 3 were added to every 2.5mls of substrate 
buffer (0.1M TRIS/HCL pH 9.5) and incubated with the membrane for 1-30 mins at room 
temperature whilst being agitated at 40rpm. Upon resolution of the protein bands, the 
membrane was rinsed and then washed in 5mls PBST for 5 minutes at room temperature 
whilst being agitated at 40rpm to stop the enzymatic reaction.  
2.3.7 Analysis of the serological response by immunostaining  
 
To determine the true FIV sero-status of a given sample, a PDVF membrane containing 
known viral antigens was prepared. This membrane was then cut into strips which were 
then probed with serum or plasma samples from individual cats. Following 
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immunostaining, it was then possible to determine which viral proteins were recognised by 
antibodies within the test samples. 
Purified virus was prepared by harvesting culture fluids from FIV infected Mya-1 cells. 
Briefly, cultures were centrifuged at 102g for 10 minutes without no brake. Culture fluid 
was then aspirated, clarified using a 0.45µm filter and layered over 5mls of 20% sucrose 
(that had also been 0.45µm filtered) in thin walled, ultraclear™ SW28 tubes (Beckman 
Coulter, High Wycombe, UK) and centrifuged on the Sovall WX100 ultra-centrifuge for 2 
hours at 116000g at 4oC using the Surespin 360 SW28 rotor (Kendro, Connecticut, USA). 
Ultrafiltrates were poured off and the remaining viral pellets were pooled and washed in 
1ml of sterile PBS at 16873g at 4oC for 1 hour. The PBS was removed and 750µl of NP40 
plus protease inhibitor cocktail tablets were mixed with the viral pellet. The mixture was 
incubated on ice for 30 minutes to ensure thorough lysis of all virions before 250µl of X4 
reducing loading dye was added to the viral lysate.   The mixture was heated to 90oC for 10 
minutes and then the lysate was centrifuged at 16873g for 10 minutes. The resulting 
clarified lysate was aspirated and the optimal loading volume determined for separation 
using a 4-12% Bis-Tris 2D polyacrlyamide gel (Novex, Invitrogen, Paisley) as described in 
2.3.6.1. After the protein transfer and blocking of the membrane, the membrane was cut 
into ~30 strips that were used to detect anti-FIV antibodies using the chromogenic staining 
method described in 2.2.6.2. 
2.3.8 Estimated total protein concentration using the Bradfords Coomassie 
assay. 
 
Eleven protein standards of BSA (New England Biolabs) were prepared from a 2mg/ml stock 
solution, ranging from 0ng/µl to 2µg/ul.  Standards increased in concentration by 200ng/µl 
and the vaccine immunogen was assayed at dilutions of neat, 0.5 and 0.25 in deionised 
water. Ten micro-litres of standard and analyte were mixed with 100µl of Pierce™ 
Coomassie G-250 protein stain in a 96 well plate. The plate was incubated at room 
temperature for 5 minutes and then read at 595nm on the MultiSkan ascent 
spectrophometer (MTX labsystems, Virginia, USA). The total protein concentration was 
estimated by extrapolating the optical density of the analyte against the protein standards. 
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2.4 In silico analysis 
2.4.1 Sequence alignments. 
 
Sequence data were downloaded from the GATC biotech website and analysed using 
DNADynamo sequence analysis software. Sequence reads were analysed for mis-called 
nucleotides and aligned using the CustaL alignment option where complete sequences 
were saved in the .cow format.  
2.4.2 Data analysis 
 
General numerical data analysis was performed using Microsoft Excel 2007 (Microsoft, 
Redmond, Washington, US). 
2.4.3 Graphs and statistical analysis 
 
Statistical analysis and graph generation were performed using the GraphPad Prism 5 
software (La Jolla, California, US). In Chapters three and five non-parametric tests were 
utilised. Although a large number of samples were used in generating the data for chapter 
three (540 samples in total), this was ordinal data collected into categories (Sero-positive, 
sero-negative, male, female) and so non-parametric analysis was performed. Additionally, 
the low optical densities of FIV sero-negative samples and the high optical densities of FIV 
sero-positive samples indicated that statistical analysis was best performed based on 
analysis of the median and not the mean values.  In chapter five, the low study number (8) 
warranted the used of non-parametric statistical analysis. Significant outliers were present 
in this chapter than could not be excluded from analysis and, as such, the data could not fit 
a normal distribution. Therefore, non-parametric analysis was utilised.  
2.4.4 QPCR data analysis 
 
QPCR data were analysed using the 7500 Fast System sequence detection software v1.4 
(Applied biosystems, Thermo scientific). 
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Chapter 3. 
Serological diagnosis of FIV infection using TM peptide 
ELISA. 
 
3.1 Introduction. 
 
The identification of cats that are infected with FIV is confounded by the lack of 
pathognomonic clinical signs displayed by infected cats. Early studies demonstrated that 
clinical signs associated with FIV infection included gingivitis/stomatitis, respiratory 
complications, emaciation and wasting, as well as general lymphadenopathy, neurological 
signs and skin problems (Hosie et al, 1989. Pedersen et al, 1988 and 1989. Sparger et al, 
1989. Ravi et al, 2010. Yamamoto et al, 1989. Muirden, 2002. Ishida et al, 1989). To date, 
no study has examined the relationship between FIV infection and the prevalence of FIV 
associated opportunistic infections. Many epidemiological studies have highlighted an 
increase in degenerative/inflammation disorders in FIV infected cats mostly associated 
with the mouth (gingivitis, stomatitis) although this is also common in FIV negative cats 
(Hosie et al, 1989. Muirden, 2002. Addie et al, 2000). Additionally, there appears to be an 
increase in neoplasia in FIV infected cats (Beczkowski et al, 2015. Hartmann, 2012). This is 
believed to be as a result of deceased immune surveillance due to immunodeficiency, 
however two studies have independently shown that FIV infected cats can live as long as 
FIV uninfected cats (Addie et al, 2000. Ravi et al, 2010). The observed neoplasia in FIV 
infected cats may well be explained by old age rather than FIV infection. Risk factors 
associated with FIV infection include age, sex, neutered status, outdoor access and 
domestication status (Levy et al, 2006. Muirden, 2002. Yamamoto et al, 1989. Gleich et al, 
2009. Hosie and Jarrett, 1989). The picture that emerged was that older male cats that 
were feral, or had unrestricted outdoor access and were known to fight were more likely 
to be infected with FIV than younger cats with no outdoor access. In these studies, FIV 
infected cats that displayed no clinical signs and appeared healthy made up a significant 
proportion of the study group and therefore, outside an experimental setting, these cats 
would not normally have been diagnosed as FIV infected. As infection with FIV is lifelong 
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and associated with non-specific clinical signs, the diagnosis of FIV infection is based on the 
detection of anti-FIV antibodies. 
 
3.1.1 Plasticity of the immunodominant domain of TM. 
As has been documented previously, the immunodominant domain of TM is an important 
epitope for the sero-diagnosis of FIV, with ELISA tests that detect antibodies recognising 
this epitope having sensitivity and specificity values >99%. Furthermore, the inclusion of 
the TM epitope in serological assays permitted detection of anti-FIV antibodies on average 
7 days earlier compared to an ELISA using whole virus alone (Sibille et al, 1995). In a 
comparative study in which TM, SU and p24 proteins were assessed in diagnostic ELISA 
tests, TM performed significantly better as a capture antigen, displaying the lowest pre-
inoculation titres and detecting FIV antibodies at higher titres sooner compared to the 
other capture antigens (Calzolari et al, 1995). Antibodies recognising the TM peptide have 
been detected as early as 2 weeks post infection, with titres persisting for over 97 weeks 
(Fontenot et al, 1992). 
 
Structural studies of the principal immunodominant domain (PID) of the FIV TM have 
shown that the PID can withstand substantial mutation within the region contained within 
the two proximal cysteine residues, including mutation to the sequence of a lentivirus of 
another species, such as HIV-1. The progeny of the mutant virus displayed altered fusogenic 
properties, however, following transfection of Crfk cells; RT activity could be detected for 
up to 9 days and syncytia could be observed up to 72 hours post transfection (Pancino et 
al, 1995). Other viral kinetics were similar to the wild type virus, albeit attenuated. Virus in 
which the entire PID was mutated did not productively infect cells, but the virus retained 
infectivity when mutations occured only within the N-terminal domain of the PID.  
However, FIV positive sera no longer recognised the mutated PID when used as an ELISA 
capture antigen (Pancino et al, 1995. Pancino and Songio, 1997). 
 
In this chapter, a DIVA ELISA measuring FIV antibodies was developed and validated, using 
a peptide corresponding to the PID of the subtype E lion lentivirus (LLV-E). The hypothesis 
that was tested was that samples of serum or plasma collected from cats infected with FIV 
would not recognise a peptide corresponding to the PID of LLV-E. Our rationale was that a 
whole inactivated virus (WIV) vaccine based on an infectious molecular clone of FIV-GL8 
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bearing a mutation that replaced the PID of FIV with that of LLV-E could form the basis of a 
DIVA vaccine.  Cats vaccinated with such a vaccine could be tested for FIV infection by 
detecting antibodies recognising the FIV PID; all vaccinated cats would develop antibodies 
recognising the LLV-E PID, whereas only infected cats would recognise the FIV PID. Hence, 
by utilising the unique characteristics of the PID, it was proposed that it might be possible 
to differentiate infected from vaccinated cats, as well as uninfected from infected, 
vaccinated cats. 
 
3.2 Materials and Methods.  
3.2.1 UK Samples of known FIV sero-status  
(Appendix 3i, Immunostains 1-15. Signalment tables 1a and 1b). 
 
A total of 175 feline blood samples were tested in this study to optimise an ELISA to detect 
antibodies recognising a peptide representing the FIV TM PID. The samples had been 
submitted to the Veterinary Diagnostic Service (VDS), School of Veterinary Medicine, 
University of Glasgow by UK veterinary clinics and comprised plasma or serum collected 
from client-owned, stray or shelter cats.  The samples had been submitted for FIV 
diagnostics and had already tested positive for FIV antibodies by immunofluorescence 
testing conducted by VDS prior to this study. Details of age, sex, breed and clinical signs 
were recorded from the sample submission forms, but all information was not always 
available, particularly for stray or shelter cats.  
 
3.2.2 Samples of indeterminant FIV sero-status  
(Appendix 3ii, Immunostains 1-16. Signalment tables 2a and 2b). 
When inconclusive results were obtained using the IFA for FIV antibodies, further testing 
was conducted as part of this study. These samples had been submitted by veterinarians 
who had suspected FIV infection in cats, the cats had been sampled and tested antibody 
positive using a POC kit, but had then tested inconclusive by IFA and immunostain when 
tested by the commercial VDS laboratory.   A total of 93 samples from 77 cats (62 individual 
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and 31 sequential samples) were tested using the TM peptide ELISA as well as 
immunostaining. As a further confirmatory test, virus isolation was conducted when 
heparinised whole blood samples were available, with virus being detected by reverse 
transcriptase activity or the production of FIV p24, as described in Chapter 2 (Section 2.3.4 
and 2.3.5 respectively).   
 
3.2.3 Criteria for FIV serostatus as determined by IFA. 
Plasma or serum samples were screened for anti- FIV antibodies by VDS, using IFA.  Briefly, 
methanol-fixed, FIV infected CrFK cells were incubated with test samples at tenfold 
dilutions from 1 in 10 to 1 in 10 000 in PBS, followed by a second incubation with 
fluorescein-conjugated goat anti-cat Ig and then examined by fluorescence microscopy to 
determine the titre of anti-FIV antibodies in each sample. Samples testing positive 
underwent confirmatory testing by immunostain analysis, incubating samples with a 
membrane prepared from a lysate of FIV infected CrFK cells to visualise antibodies 
recognising the FIV p24 (CA) and p17 (MA) proteins. Samples with anti-FIV titres of ≥ 1000 
that demonstrated antibodies against both p17 and p24 were reported as positive. Samples 
with anti-FIV titres of 10-100 were classified as inconclusive. If such samples demonstrated 
antibodies recognising both p17 and p24, they were confirmed as positive, whereas 
samples with no antibodies recognising p17 or p24 were confirmed as negative. Samples 
with no antibodies detectable by either IFA or immunostaining were classified as negative.  
 
3.2.4 Fel-O-Vax vaccinated samples collected in Australia  
(Appendix 3iii, Immunostains 1-9. Signalment tables 3a, 3c and 
3d). 
The samples from FIV vaccinated cats that were examined in this study had been analysed 
in a previous study by Westman et al (2015). Samples had been collected between 2013-
14 from client-owned cats in south eastern Australia and then shipped to the University of 
Glasgow for further testing. Samples were classified as “vaccinated” if the cat had received 
the primary immunisation, as per the manufacturer’s recommendations, and had 
subsequently received 3 annual booster immunisations (n=114). Cats that had never been 
vaccinated against FIV and tested FIV antibody negative (using a commercially available 
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test kit) comprised the unvaccinated and uninfected group (n=113). Samples that had 
tested positive for FIV proviral DNA, using a commercially available PCR (FIV RealPCR™, 
IDEXX), were considered to be infected and hence were predicted to be sero-positive 
(n=27). Since the FIV RealPCR™ is not 100% accurate and produced false positive results 
(Nichols et al, 2016) it was imperative to be able to accurately designate the correct sero-
status to the vaccinated, unvaccinated group and uninfected and infected groups. Failure 
to accurately determine this would result in a bias sensitivity and specificity calculation. As 
such, the cats’ clinical history was extensively interrogated whilst plasma samples 
underwent additional screening using three point of care test kits to ensure the recruitment 
criteria was met. Any ambiguous results underwent virus isolation for confirmation.  
 
3.2.5 Fel-O-Vax vaccinated samples collected in US  
(Appendix 3iii, Immunostain 10. Signalment table 3b). 
Whole blood was collected in heparin from eighteen client-owned cats during October 
2012 (comprising part of the cohort described by Litster et al 2014) and shipped to the 
University of Glasgow for analysis. These samples had been collected from cats that had 
tested negative for FIV antibodies prior to vaccination and had received all 3 primary 
immunisations. The FIV infection status of these cats was determined using virus isolation, 
as described in Materials and Methods section 2.2.6.  
 
3.2.6 Genetically modified Crandell feline kidney cells [CrFK 
(FeFab)] 
 
FeFab cells are genetically modified Crandell feline kidney cells (CrFK) that are susceptible 
to feline syncytium forming virus (FeSFV). FeFab cells were developed by Zemba and 
colleagues in 2000 specifically to titrate FeSFV (Zemba et al, 2000). The U3 region of the 
LTR is spliced together, in frame, with the reporter gene β-galactosidase. Upon infection 
with FeSFV, the bel1 gene is expressed and binds to an internal promoter, increasing 
expression of Bel1, as well as binding the U3 region of the 5' LTR.  This leads to increased 
transcription of the integrated viral genome in the FeFab cells and increased β-
galactosidase expression, which is visualised by staining with X-gal solution (3mM 
K4[Fe(CN)6] (ll)/3mM/ K3[Fe(CN)6] (lll)/ 0.02% X-Gal/1.3mM MgCl2). 
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FeFab cells were maintained in complete DMEM and sub cultured into fresh medium 
containing G418 every 4-5 days.  
 
3.2.7 Product enhanced reverse transcription assay 
The product enhanced reverse transcription (PERT) assay is a highly sensitive method used 
to detect and quantify the amount of reverse transcriptase (RT) in a test sample. Based on 
the assay developed by Arnold et al in 1998 (Arnold et al, 1998), the RT within a test sample 
synthesises cDNA from the input RNA transcript. This cDNA is then amplified using PCR and 
the product is detected using a fluorescently labelled probe. Since no additional RT is added 
to the reaction, the only source of RT is that contained within the test sample.  
 
Cell free tissue culture fluids were prepared and diluted 1 in 10 in deionised water (Gibco, 
Life Technologies) in sterile eppendorf tubes. Five microlitres of each sample were added 
to wells of a MicroAmp fast optical 96-well reaction plate (Applied biosystems, Thermo 
scientific, Paisley, UK), together with the reagents listed in Table 3-1. 
 
Table 3-1. PERT reactants and volumes. 
 
Reverse transcription of the input RNA transcript was followed by PCR amplification of the 
cDNA template using the cycling conditions listed in Table 3-2, using the ABI 7500 fast PCR 
machine (ABI, Leicestershire, UK). 
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Table 3-2. PERT reverse transcription and amplification cycling conditions. 
 
PERT data were analysed using Applied Biosystems sequence detection software, 7500 fast 
system SDS software v1.4. Samples were scored positive or negative by comparing the 
mean test value (each test sample was tested in triplicate) to the mean values obtained for 
triplicate tests of a negative control and a range of known RT standards.  
 
3.2.8 ELISA to detect antibodies against FeLV-A SU-Fc  
 
Samples that tested negative for FIV infection but tested positive using the PERT assay were 
assessed for exposure to FeLV using an ELISA to detect antibodies against an FeLV SU-Fc 
fusion protein that had been developed by Ms Yasmin Parr, University of Glasgow. The SU 
protein of FeLV-A had been fused in fame with the conserved region of human IgG (Fc) and 
cloned into the retroviral vector pTORSTEN and then stably expressed in 293 cells. Cultures 
were selected in 200µg/ml of Hygromycin (Sigma-Aldrich UK, Gillingham, Dorset) and 
expanded into five T150 culture flasks before culture fluid was harvested every 3-4 days by 
centrifuging at 159g for 5 minutes and then clarifying the culture fluids by filtration through 
a 0.45µM and then a 0.2µM filter (Millipore UK LTD, Bedfont Cross, Feltham).  The FeLV SU-
Fc fusion protein was then purified from a litre of culture fluid using a protein A column 
(Sigma-Aldrich UK, Gillingham, Dorset). The total protein concentration of the retentate 
was estimated using the Bradford’s Coomassie assay. One hundred nanograms per well of 
FeLV SuFc fusion protein were absorbed onto a 96 well microtiter plate (Immulon 2 HB) in 
sodium carbonate bicarbonate binding buffer and incubated at 4oC overnight whilst being 
agitated at 30rpm. Wells were then aspirated and washed 5 times with 200µl of phosphate 
buffered saline supplemented with 0.1% Tween (PBST). Unabsorbed sites were blocked 
with 200µl of 2% low fat milk powder PBST (MPBST, block) for 1 hour at room temperature. 
Wells were then aspirated and washed 5 times with 200µl of PBST and 100µl of each plasma 
or serum sample were added to triplicate wells, diluted 1 in 200 in block. Plates were sealed 
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and incubated at room temperature for 1 hour, wells were aspirated and washed 5 times 
with 200µl of PBST and then 100µl of a biotinylated anti-cat Ig secondary antibody (Vector 
laboratories, Peterborough, UK) were added to wells at a dilution of 1 in 1000 (1-1.5µg/µl) 
in block. Plates were sealed and incubated at room temperature for a further hour, wells 
were aspirated and washed 5 times with 200µl of PBST and then 100µl of horseradish 
peroxidise conjugated to streptavidin [Vector laboratories, Peterborough, UK] were added 
to wells, diluted 1 in 1000 (1-1.5µg/µl) in block. Plates were sealed and incubated at room 
temperature for 20 minutes before the wells were aspirated and washed 5 times with 200µl 
of PBST and then 100 l of 3',3',5'5'-tetramethylbenzidine liquid (TMB super slow, Sigma 
Aldrich) were added to each well, the plates were sealed and then incubated at room 
temperature for 30 minutes before the absorbance values were read at 650nm on the 
MultiSkan ascent spectrophotometer (MTX labsystems, Virginia, USA). 
 
3.3 Results 
3.3.1 Samples of known FIV infection status 
3.3.2 Study population  
In this study, 175 samples that had been tested for anti-FIV antibodies by VDS were tested; 
62% of the samples had been collected from male cats (46 entire and 62 neutered male 
cats) 33% had been collected from female cats (29 entire and 29 neutered female cats) and 
5% (9 samples) had been collected from cats with no gender recorded on the sample 
submission form. A higher prevalence of FIV was observed in male cats compared to female 
cats, as shown in Figure 3-1 and neutering did not appear to be a risk factor for FIV 
infection. As shown in Figure 3-2, cats testing FIV antibody positive were generally older 
than the cats testing negative and this difference was statistically significant. These data 
supported previous findings that older male cats were more likely to be FIV infected 
compared to female cats. Of the 175 samples tested, 93 tested positive and 82 tested 
negative for FIV by IFA and immunostain analysis. 
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Figure 3-1. Gender distribution in cats testing positive or negative for FIV antibodies 
within the known FIV status group. Male and female cases were equally represented in 
the antibody negative cats (46% male versus 48% female cats), whereas the FIV antibody 
positive group was more likely to contain male than female cats (73% male versus 19% 
female). 
S
er
o-
po
si
tiv
e
S
er
o-
ne
ga
tiv
e
0
5
10
15
20
25
** (p=0.002)
FIV sero-status
A
g
e
 (
Y
e
a
rs
)
 
Figure 3-2. Age distribution of cats testing positive and negative for FIV antibodies within 
the known FIV status group. The interquartile range of the sero-positive group was higher 
at the 25th and 75th percentiles compared to the sero-negative group (25th percentile of 
2.9 versus 1.2 years and 75th percentile of 10 versus 7.4 years of age for sero-positive and 
sero-negative groups respectively). The difference between the median values of the 2 
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groups (5.3 years for sero-positive cats versus 3.1 years for sero-negative cats) was 
statistically significant (p=0.002, Mann-Whitney test). 
  
The clinical signs reported by the veterinarian on the sample submission forms were 
tabulated and examined for associations between FIV sero-status and clinical signs. As 
shown in Table 3-3, a lack of clinical signs within the sero-positive group was commonly 
reported, followed by gingivitis, weight loss and non-specific signs of sickness, lethargy, 
malaise or pyrexia. These signs closely matched their rank within the sero-negative group, 
although overall more of the cats in the seronegative group showed gingivitis or weight 
loss that had been observed in the sero-positive cats. It was noted that 55.5% (10/19) of 
cats displaying gingivitis and/or stomatitis in the sero-negative group had tested positive 
for feline calcivirus (FCV), as well as 66.7% (6/9) of cats in the sero-positive group. Similar 
findings have been reported previously (Hartmann, 2011), indicating that gingivitis and/or 
stomatitis is a common clinical sign reported in FIV-infected cats, often associated with 
coinfection with FCV.  
 
 
Table 3-3. Tabulated and top 15 ranked clinical signs recorded for cats in the known FIV 
status population. Of the 82 sero-negative samples examined, 73 clinical signs had been 
reported for 56 samples, while 26 samples had been submitted to VDS for either routine 
or confirmatory FIV screening or for reasons not disclosed. Of the 98 sero-positive samples 
examined, 75 clinical signs had been reported for 46 samples, while 47 samples had been 
submitted for either routine or confirmatory screening or for reasons unknown.  
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3.3.3 The utility of an ELISA test to detect antibodies against FIV 
TM peptide 
 
The panel of 175 samples of known FIV antibody status were screened using the TM 
peptide ELISA to determine whether the ELISA could be used as a diagnostic test.  As shown 
in table 3-4, the TM peptide ELISA correctly identified 92/93 sero-positive samples and 
82/82 negative samples (Figure 3-3); the one sample with an inconclusive result tested 
positive by immunostain analysis.  The negative fold values were calculated and used to 
differentiate between sero-positive (values 4.59-20.56), sero-negative (values 0.34-1.77) 
and the one inconclusive sample with a value of 3.85.  
 
  IFA TM ELISA 
Reference 
standard 
(Immunostain) 
Positive 93 92 93 
Inconclusive 0 1 0 
Negative 82 82 82 
Total 175 175 175 
 
Table 3-4. Comparison of IFA and the TM peptide ELISA for the detection of anti-FIV 
antibodies. Immunostain analysis (appendix 3i, immunostains 1-15) was used as the 
reference standard as both IFA and the peptide TM ELISA were serological assays and PBMC 
were not available for virus isolation. On this basis, IFA showed specificity and sensitivity 
values of 100%, while the TM peptide ELISA showed a sensitivity of 98.9% and a specificity 
of 100%.  
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Figure 3-3. Negative fold values for the 175 samples of known FIV status tested, grouped 
according to FIV sero-status.  The negative fold values were used to assign samples to three 
groups: sero-negative (n=82), sero-positive (n=93) and inconclusive (n=1). The differences 
between the median negative fold values of the sero-positive and negative samples were 
statistically significant (p=<0.0001. Kruskal-Wallis test). 
 
3.4 Inconclusive samples. 
 
3.4.1 Sampling criteria and sample population. 
In total, 93 samples from 77 cats were examined, comprising both single samples from 
individual cats as well as sequential samples as shown in Figure 3-4. 
 
Figure 3-4. The FIV inconclusive sample population. Individual samples comprised 64.5% 
and sequential samples comprised 35.5% of the sample population. Sequential samples 
were tested to confirm the results of previous tests, as cats that had been in the initial 
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stages of infection when first tested could be shown to have seroconverted at the time of 
later samplings.  
 
As these samples had tested inconclusive by IFA, a panel of additional tests was conducted 
to investigate the true FIV status of each sample. The additional tests that were performed 
depended on the sample type submitted for testing, as shown in Table 3-5.  
 
 
 
  
 
 
 
Table 3-5. Additional validation assays performed to confirm TM ELISA results. As most 
of the serum samples were over 7 days old or had been submitted in serum separating 
tubes, it was not possible to purify PBMC for virus isolation. At the start of the study, it was 
thought that virus isolation could be performed only on PBMC derived from whole blood 
collected in heparin and not EDTA, since EDTA is toxic for Mya-1 cells. However, it was 
demonstrated that extensive washing of the PBMC in PBS removed residual EDTA so that 
virus isolation could be performed on these samples, with no evidence of EDTA toxicity. 
 
3.4.2 Sample population and clinical signs. 
In the population of 77 cats examined in this study, 54.5% were male (23 entire males and 
19 neutered males) and 36.4% were female (14 entire females and 14 neutered females). 
For 7 cats (9.1%), this information was not available. As shown in Figure 3-5, FIV infection 
was more prevalent in male cats, whereas similar numbers of male and female cats were 
observed in the uninfected group. This gender distribution reflected that of the samples of 
known FIV status, confirming that gender is a strong risk factor for FIV infection, regardless 
of neutering status. As shown in Figure 3-6, the age distributions of both infected and 
uninfected cats were similar; the median ages of the two groups were not statistically 
significantly different. This was most probably a result of the small numbers of positive 
samples within the tested population.  
Sample type 
TM 
ELISA 
VI 
p24 Ag 
ELISA 
PERT Immunostain 
Serum + N/A N/A N/A + 
Heparinised 
blood 
+ + + + + 
EDTA blood + + + + + 
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Figure 3-5. Gender distribution of the FIV inconclusive sample population. More male 
than female cats were observed in the sero-negative group (52% males versus 36% 
females) and can most likely be explained by the increased likelihood of male cats being 
tested for FIV infection. There were significantly more samples from male than female cats 
in the sero-positive group (70% males versus 30% females).  
 
 
S
er
o-
po
si
tiv
e
S
er
o-
ne
ga
tiv
e
0
5
10
15
20
25
p=0.255
FIV sero-status
A
g
e
 (
Y
e
a
rs
)
 
Figure 3-6. Age distribution of infected and uninfected cats from the FIV inconclusive 
population. Both groups displayed similar 25th percentile and 75th percentile values (2 and 
8 years respectively) and the difference between the median ages (7.5 years for sero-
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positive cats versus 4 years for sero-negative cats) was not statistically significant (p=0.255, 
Mann-Whitney test). 
 
When the clinical signs were tabulated and ranked, as shown in Table 3-6, weight loss and 
gingivitis ranked highest; however, gingivitis and fight-related abscesses were more closely 
associated with FIV infection than weight loss. Samples that had been sent to VDS for 
confirmatory testing had tested positive for FIV using one of the commercially available 
point of care (POC) tests (Snap, Witness or Snap duo). Of the 40 samples submitted for 
confirmatory testing, only 3/40 samples were confirmed as positive by immunostaining, 
raising concerns about how the POC tests had been conducted, since independent 
evaluation demonstrated that these tests were highly sensitivity and also highly specific 
(Hartmann et al, 2007). 
 
 
Table 3-6. Top 15 ranking clinical signs reported from the FIV indeterminant population. 
For the 77 cats tested in this study, 30 clinical signs had been recorded on the sample 
submission forms. However, many samples had been submitted for confirmatory testing 
following positive POC test results. 
 
3.4.3 The TM ELISA can be used to confirm IFA inconclusive 
samples. 
Of the 77 samples for which IFA results were inconclusive, 67 (87%) tested negative, 8 
(10.4%) tested positive and 2 (2.6%) gave inconclusive results using the TM peptide ELISA. 
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One of the samples that gave an inconclusive result had been collected from a cat that had 
been sampled sequentially (2 samples); this cat was shown to have seroconverted by the 
time of the second sampling. The negative fold values obtained from the TM peptide ELISA 
were examined for samples with inconclusive IFA results and it was demonstrated that the 
TM peptide ELISA could be used to accurately identify the IFA inconclusive samples as 
either sero-positive or sero-negative, with similar statistical power as was demonstrated 
previously for samples of known serological status (Figure 3-7). 
 
Figure 3-7. Summary of the number of animals and samples and negative fold values 
(determined by TM ELISA) for samples according to FIV antibody status.  The negative fold 
values calculated from the sample absorbance results could be used to confirm the FIV 
sample status. The difference between the median negative fold values for the positive and 
negative samples was statistically significant (p=<0.0001. Kruskal-Wallis test). 
 
3.4.5 Validation of the TM ELISA result. 
 
Of the 93 samples received, 66 had been collected in heparin or EDTA and 27 had been 
submitted to the laboratory as sera. The number of samples undergoing further testing are 
shown in Table 3-7. 
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 Serology Virus detection 
Sample type TM ELISA Immunostain VI 
p24 antigen 
ELISA 
PERT 
Sera (n=27) 27 27 N/A N/A N/A 
Plasma (n=66) 66 66 65 65 53 
 
Table 3-7. Numbers of samples for which additional tests were performed to validate the 
TM ELISA results. To confirm the TM ELISA results, immunostain tests were performed. 
When PBMC were available, attempts were made to isolate FIV following co-cultivation 
with Mya-1 cells, using either a retrovirus specific assay (PERT) or an FIV specific assay (p24 
antigen ELISA) to monitor FIV infection.  
 
Immunostaining is the reference standard for FIV diagnosis (Wang et al, 2010. Hartmann 
et al, 2007, Hosie et al, 2009). In this study, the results of immunostaining were classified 
using the following criteria: antibodies recognising at least two FIV core proteins (p55, p24, 
p17, p10) or gp95/gp41 were required for a sample to be confirmed as positive. When the 
two samples that had tested inconclusive using the TM ELISA (and 8 samples that had 
tested positive) were examined, all samples tested positive by immunostain analysis using 
these criteria (Figure 3-8).  
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Figure 3-8. Immunostain analysis of samples testing positive or inconclusive using the TM 
peptide ELISA from the inconclusive sample population. All samples demonstrated strong 
antibody reactivity to at least two specific viral proteins during the optimisation procedure. 
These additional immunostain results are shown in Appendix 3ii. * samples that tested 
inconclusive by TM ELISA. 
 
3.4.6 Detection of virus. 
As a further step to validate the serological testing of the inconclusive samples, attempts 
were made to isolate virus from all plasma samples (whether collected in heparin or EDTA). 
Virus isolation was conducted on 65/66 available samples and cultures were monitored for 
the production of FIV p24 by ELISA (65/65) or RT activity using PERT (53/65), with the results 
shown in table 3-8.  
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Table 3-8. Detection of FIV in the culture fluids of the FIV inconclusive samples. Culture 
fluids were screened for the presence of FIV p24 by ELISA, or for the presence of reverse 
transcriptase by PERT. 
As PERT has been reported to be more sensitive for virus detection compared to an ELISA 
detecting FIV p24 (Arnold et al, 1998), the five sero-negative samples that displayed RT 
activity were examined further. Since the serological tests and virus isolation tests had 
detected 8 positive and 2 inconclusive samples, it was possible that the RT activity detected 
in cultures from the FIV sero-negative samples might have been associated with infection 
with a feline retrovirus other than FIV.  Alternatively, the TM ELISA might have resulted in 
a false negative result. As 3/5 samples that showed RT activity in cultures had been 
collected from cats that had been sampled sequentially, additional testing was conducted 
on these follow-up samples. 
 
In total, 8 samples collected from 6 cats were screened for the presence of the other feline 
retroviruses, FeSFV and FeLV. Upon X-Gal staining of FeFab cells that had been cultured 
with the original virus isolation culture fluid, 0/8 samples showed blue staining, indicating 
that 8/8 samples tested negative for FeSFV. Next, the samples were tested by ELISA to 
detect antibodies recognising the SU (gp70) protein of FeLV-A. As shown in Figure 3-9, 6/11 
samples tested displayed antibodies recognising the FeLV SU recombinant protein (4/6 
cats). Cats represented by the purple, orange and yellow columns showed antibody binding 
to the recombinant FeLV SU, whereas the binding observed in sample 347266 and 347445 
(from a single cat, green columns) was likely non-specific. However, when sample 347266 
was screened on the IDEXX p27 ELISA, a marginal increase in absorbance was observed, 
although the value was below the threshold for a positive result. Samples from the cat 
represented by the yellow columns displayed a dramatic decrease in antibody titre 
between the two samplings. It was not possible to conduct virus isolation for FeLV on the 
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first sample received from this cat (346170), but the second sample (347929) was 
borderline positive on the PERT assay (2/3 replicates were RT positive). It is tempting to 
speculate that this cat might have been sampled as it was recovering from FeLV infection, 
having developed nAb, although this was not investigated further. The results of the FeLV 
SU ELISA were confirmed by immunostaining (Figure 3-10).  
 
Figure 3-9. FIV sero-negative, RT positive samples reactivity to recombinant FeLV SU.  
FeLV antibody status was determined using an empirical cut-off value; the absorbance of 
the negative control was subtracted from the sample absorbance to give the absolute 
absorbance. Samples represented in the same colour were collected from the same cat, 
with superscript numbers (x-axis) used to denote the order of sampling.  
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Figure 3-10. Immunostain analysis to detect antibodies recognising recombinant FeLV SU 
protein. Strips were probed with sera or plasma samples diluted 1 in 400 in X1 casein 
solution. Antibody binding to the recombinant FeLV SU protein detected in samples 3, 5, 6 
and 10, confirming that these cats had been exposed to FeLV infection. Plasma collected 
from a cat vaccinated against FeLV was used as the positive control, as well as an anti-FeLV 
gp70 monoclonal antibody to confirm that the FeLV SU was detected. The negative control 
sample was collected from an FIV vaccinated cat.   
 
These data demonstrated that the TM ELISA could be used to identify FIV sero-positive 
samples as the results were confirmed and validated by immunostain and virus isolation. 
The FIV sero-negative samples that displayed RT activity were shown to have been exposed 
to FeLV (Table 3-9), confirming that the TM ELISA did not yield false negative results and it 
appeared that FIV testing could be performed using the TM ELISA to test old, sub-optimal 
samples in poor condition.  
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Table 3-9. Results for FIV sero-negative, RT positive samples. a, individual samples shown 
in green and sequential samples highlighted in purple. The order of sampling is denoted in 
superscript. b, the sensitivity limit of the PERT assay was 40 cycles. The number of asterisks 
beside the Ct values indicates the number of triplicate wells in which RT was detected. If 
no asterisk is present, 3/3 wells tested RT positive; n/a, not applicable (serum samples); +/-
, faint band. 
 
3.4.7 TM ELISA performed better than IFA. 
The results of this study demonstrated that IFA could not be used to reliably determine the 
sero-status of any of the 93 samples sent for sero-diagnosis, whereas the TM ELISA 
performed well, as illustrated in Figure 3-11. It was evident that the IFA assay produced 
both false negative and false positive results when used to screen many samples collected 
over a 12-month period.  
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Figure 3-11. Comparison of IFA antibody titres to the negative fold of the sample 
absorbance obtained using the TM ELISA. It was evident that some samples with IFA titres 
of 0 tested positive by TM ELISA (false negative by IFA), while some samples with IFA titres 
of 1000 tested negative by TM ELISA (false positive by IFA). In contrast, there was close 
agreement between the two tests in samples with IFA titres > 1000. False positive results 
likely resulted from antibodies in the sample recognising cellular proteins, while false 
negative results might have been obtained with samples from cats in either the initial or 
terminal stages of FIV infection.  
 
As the samples in the known sero-status group had previously had their FIV status 
determined, the sampling of this population was biased and was not representative of the 
true prevalence of FIV in the UK. It was therefore not feasible to calculate positive or 
negative predictive values for either IFA or the TM ELISA in this study. A more appropriate 
calculation was to determine the specificity and sensitivity of IFA and the TM ELISA 
comparing the results to immunostaining as the ‘reference standard’ test (table 3-10). 
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Table 3-10. Comparison of the specificity and sensitivity of IFA and the TM ELISA. To 
ensure that only the test result is considered in the calculations (and not the methodology 
that determines the category of infection status), any samples giving an IFA titre greater 
than 0 were deemed positive and any sample giving a negative fold of less than 4 were 
considered negative on ELISA. This essentially removes the redundancy from both test and 
forces the assay to give a clear-cut positive or negative result. When both populations of 
samples were examined together (samples of a known sero-status and inconclusive 
samples), both diagnostic test displayed identical levels of specificity at 98%, however the 
TM ELISA has substantially better sensitivity at 100% compared to 86.6% for IFA.  
 
The TM ELISA demonstrates greater specificity than IFA, a result that confirms Figure 3-11. 
The better rate of specificity can be explained by the simplicity of the TM ELISA. The TM 
ELISA uses a single 11 amino acid peptide that corresponds to the PID of the 
transmembrane region of the envelope, whereas IFA uses infected, inactivated Crfk cells. 
By utilising a single epitope in the TM ELISA, the vast majority of cross reactive antibodies 
are rendered useless as there is very little for the antibodies to bind to, whereas they have 
an unlimited array of conformational and linear epitopes to cross react with when used in 
the IFA platform. 
 
3.5 Use of the TM peptide as a DIVA epitope. 
A recent report suggested that the serological response to the TM epitope could be used 
to differentiate infected from vaccinated animals (Westman et al, 2015).  In this published 
study that was conducted in Australia, plasma samples from vaccinated cats were screened 
using three FIV POC antibody test kits to detect antibodies recognising viral proteins (Figure 
3-12) 
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Figure 3-12. Viral antigens contained within 3 point of care test kits used to differentiate 
infected from vaccinated animals. Figure reproduced from Westman et al 2015. 
 
Although the SNAP FIV/FeLV Combo test detected antibodies against p15 and p24 in 
119/119 samples tested, the Witness FeLV/FIV and Anigen rapid FIV/FeLV test kits detected 
FIV specific antibodies in only 11/119 (9.25) and 5/119 (4.2%) of the samples respectively. 
As TM antigen is a major component of both the Witness and Antigen rapid tests, it was 
hypothesised that the humoral immune response against the TM epitope would permit 
differentiation of infected from vaccinated animals.  
 
In the present study, the same samples that had been tested in the study of Westman and 
colleagues were screened for anti-TM antibodies using the TM ELISA. In total 256 Australian 
samples were screened comprising 114 vaccinated/uninfected samples, 115 
unvaccinated/uninfected samples and 27 infected/unvaccinated samples were screened 
(Appendix 3iii, immunostains 1-9, signalment 3a, 3c and 3d). Another 18 samples from cats 
in the USA that had been vaccinated with the Fel-O-Vax FIV vaccine and were uninfected 
were tested in parallel (Appendix 3iii, immunostain 10, table 3b). As demonstrated in Figure 
3-13, the ELISA appeared to differentiate infected from vaccinated cats to some extent, 
with the differences between the median values for each category being statistically 
significant. However, there was substantial cross-over between the highest negative fold 
values observed in one category and the minimum negative fold value of another category 
(e.g. highest negative fold value of the vaccinated group overlaps with the minimum 
negative fold of the infected group). 
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Figure 3-13. The relationship between FIV status and negative fold. Although the TM ELISA 
showed some differentiation between the three groups, based on the difference between 
the median values, there was substantial cross-over between the maximum and 75th 
percentile values of the vaccinated group (6.9-2.5 respectively) with the minimum value 
(2.4) of the infected group.   (p=<0.0001. Kruskal-Wallis test). 
 
When FIV status was cross-referenced with the FIV sero-status for each sample, as shown 
in Table 3-11, it was apparent that the TM ELISA alone could not be used to differentiate 
infected from vaccinated cats. The TM ELISA could be used to differentiate uninfected and 
infected cats, but 67.4% of the vaccinates (89/132) were classified as sero-negative, 22.7% 
as inconclusive and 9.8% as sero-positive using the TM ELISA. 
 
 
 
 
Table 3-11. Relationship between FIV vaccination or infection status and FIV sero-status 
as determined using TM ELISA.  
 
It has been stated that vaccination with the Fel-O-Vax FIV vaccine induces antibodies that 
interfere with the sero-diagnosis of FIV (Kusuhara et al, 2006, Crawford and Levy, 2004, 
  FIV antibody status  
  Positive Inconclusive Negative Total 
FIV 
status 
Uninfected 0 1 112 113 
Vaccinated 13 30 89 132 
Infected 26 1 0 27 
 Total 39 32 201  
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Hartmann et al, 2007, Andersen and Tyrrell, 2004). As most samples from vaccinated cats 
that were tested in this study were shown to test negative using the TM ELISA, the humoral 
immune response to vaccination with Fel-O-Vax FIV was examined further. As the TM ELISA 
is based on a single, highly conserved epitope representing the PID of the FIV Env, 
immunostain analysis was performed to determine whether antibodies were induced by 
vaccination to FIV epitopes other than TM. As shown in Figure 3-14, the major difference 
between the responses of vaccinated and infected cats was the lack of antibodies 
recognising the Env proteins (gp95 and gp41) detected by immunostaining. Similar levels 
of reactivity were observed against the core structural proteins (p55, p24, p17, p10) 
between the vaccinated and infected cats. The lack of antibodies elicited against the Env 
proteins was surprising, since it has been suggested that vaccination with Fel-O-Vax FIV 
induces broadly neutralising antibodies against Env (Coleman et al, 2014. Pu et al 2004, Pu 
et al, 2001).  Based on the criteria for immunostaining outlined in Materials and Methods, 
43/132 (32.6%) of the samples from vaccinated cats were classified as sero-positive and 
89/132 (67.4%) were sero-negative.  
 
 
Figure 3-14. The percentage of each FIV group reacting to viral proteins by 
immunostaining. A viral lysate of the vaccine strain of FIV (FIV-FL4) was prepared and 
probed with plasma samples from each of the FIV groups.   
 
Selected samples from vaccinated cats were also screened for antibodies against FIV by IFA 
to determine whether this method would detect more sero-positive samples. When the 
IFA titres of the vaccinated samples were examined (Figure 3-15), all but one sample tested 
sero-positive.  
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A.                                                                           B. 
 
Figure 3-15. Detection of anti-FIV antibodies by IFA titre (A) and immunostain (B). Three 
samples were sero-positive based on IFA titre alone (A), while the remaining samples 
(except FIV-342) were sero-positive by immunostaining (B). Green shading denotes 
samples testing negative by TM ELISA; Yellow, inconclusive; Pink, positive.  
 
These results demonstrated that the TM ELISA could not be used to differentiate infected 
from vaccinated animals. It has been shown that vaccination with Fel-O-Vax FIV does 
induce antibodies against major structural FIV proteins, however only few vaccinated cats 
in this study population produced anti-Env antibodies. It was also shown that IFA detected 
anti-FIV antibodies in samples from vaccinated animals, since 14/15 samples from 
vaccinates tested by IFA would have been submitted for further examination by 
immunostaining for confirmation and would then have tested positive. It was concluded 
that conventional serological diagnostics using the methods and antigens/epitopes 
described above could not be used to differentiate vaccinated from infected cats. 
 
3.5.1 Differentiation of infected from vaccinated animals (DIVA) 
To determine whether the chimaeric virus expressing the PID of LLV-E could be used as the 
basis of a DIVA vaccine, plasma samples were screened against both the FIV and LLV-E TM 
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peptides on the same ELISA plates (DIVA ELISA). Samples were screened against both 
capture antigens at the same time to reduce the variability in absorbance values that can 
arise between ELISA plates and normalised absorbance ratio values were calculated as 
described in 2.1.7. In total, 268 samples were screened; 175 samples were of known FIV 
sero-status (determined by IFA and confirmed by TM ELISA and immunostain). These 
samples constituted the ‘known’ population and were either sero-negative or sero-
positive. Neither of these groups had received any FIV vaccination. An additional 93 
samples with inconclusive FIV sero-status by IFA were also tested. This group comprised 
the ‘inconclusive’ group and were either sero-negative or sero-positive. Neither of these 
groups had received any FIV vaccination. Table 3-12 summarises the number of FIV sero-
positive and negative samples derived from each group. 
 Known Inconclusive 
Sero-positive 93* 10** 
Sero-negative 82 83 
Total 175 93 
 
Table 3-12. Summary of the FIV sero-status of the samples derived from both the known 
and inconclusive populations. * Samples were tested FIV sero-positive by IFA, TM ELISA 
and immunostain. ** Samples tested sero-positive by TM ELISA, immunostaining and virus 
isolation. Although virus could not be unequivocally isolated from 2/10 of these samples, 
they were classified as sero-positive because they displayed negative fold values greater 
than 2 and demonstrated reactivity against at least 2 specific viral bands by 
immunostaining.  
 
3.5.2 DIVA of known samples 
Of the 175 samples from the ‘known’ group, the DIVA ELISA was able to differentiate all 
175 samples as illustrated in Figure 3-16. 
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Figure 3-16. Normalised absorbance ratio values of samples derived from the known 
group. As the plasma samples used in this study had been collected from domestic cats 
exposed to FIV, one would predict little or no cross-reactivity between the two capture 
antigens. This is highlighted by the statistically significant difference between the medians 
of the samples tested against the FIV and DIVA peptides. (p=0.0001, Mann-Whitney U-test)  
 
3.5.3 DIVA of inconclusive samples. 
Of the 93 samples from the ‘inconclusive’ group, the DIVA ELISA could be used to 
differentiate all 93 samples as illustrated in Figure 3-17. 
 
Figure 3-17. Normalised absorbance ratio values of samples derived from the 
inconclusive group. Differentiation of FIV sero-positive samples is evident but FIV sero-
negative samples showed false positive results. The differences between the median values 
of the groups were statistically significant (p=0.0001, Mann-Whitney U-Test).   
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Although the DIVA ELISA could be used to differentiate all FIV sero-positive samples, the 
FIV sero-negative samples within this group gave false positive results. As none of the 
samples used in this study had been collected from cats that had been exposed to the LLV-
E TM PID, it was concluded that the false positive results could be attributed to cross-
reactive antibodies. To identify any causative agent/condition that might have accounted 
for false positive results, the clinical information for these 10 samples (collected from 8 
cats) was examined and 7/8 of these cat samples had been submitted for a confirmatory 
test following a positive FIV result using a POC test (Table 3-13).   These results were shown 
to be false positive on subsequent laboratory serological testing.  As no further information 
could be obtained about these cats, it was concluded that the DIVA positive result likely 
arose from cross-reactive antibodies, elicited by an unknown infectious agent or condition.  
Evidence in support of this conclusion could be found by examining the cats that had been 
sampled sequentially.  Two of the 3 sequentially sampled cats were sampled 4 and 8 weeks 
apart, however both samples tested positive for antibodies against the LLV-E TM peptide. 
A third cat was sequentially sampled on two occasions just 6 days apart and clearly 
demonstrated different reactivity compared to the original sampling (the first sample 
364503 tested LLV-E sero-positive and FIV sero-negative while 6 days later, the second 
sample 364637 tested LLV-E sero-negative but FIV sero-positive). It appeared therefore 
that the production of anti-TM antibodies early in FIV infection was associated with 
reactivity against the conformational epitope of the PID. As the antibodies matured and 
underwent class switching/somatic hypermutation, the affinity of the antibody was 
focused towards the linear component of the PID.  The fact that no FIV sero-positive sample 
cross reacted with the LLV-E peptide, and that FIV sero-negative, LLV-E cross-reactive 
samples maintained a similar reactivity profile for 4-8 weeks, suggested that the LLV-E sero-
positive samples contained cross-reactive antibodies. 
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Table 3-13. Summary of the serological profiles of samples producing false positive absorbance ratios. Sample 364637 is included as the first sampling 
from this cat was contained anti-LLV-E TM antibodies, while the second sampling was shown to contain only anti-FIV TM antibodies. As this cat originated 
from a shelter that was keen establish the FIV status of the animal to re-home it, a second sample was taken 6 days after the first. *, samples shaded in 
purple collected from the same cat, with the superscript number denoting the order in which the samples were collected. +, immunofluorescence 
antibody assay; ns, non-specific fluorescence; Ф +, strong band visualisation; -, no band visualisation; (+), weak band visualisation.
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These results indicated that the TM ELISA and DIVA ELISA tests are highly sensitive and 
specific for the detection of anti-FIV TM and anti-LLV-E TM antibodies. The TM ELISA 
displayed a sensitivity of 100% and a specificity of 98%, while the DIVA ELISA displayed a 
specificity of 94.9%. The 0% sensitivity figure regarding the DIVA ELISA resulted because 
none of the samples tested during the optimisation of the ELISAs had been raised against 
LLV-E or the chimaeric vaccine virus which contain the PID of LLV-E. Based on the results 
presented in this chapter, the following diagnostic algorithm is proposed to establish 
whether a test sample is FIV positive or negative, from a cat that has been vaccinated or 
unvaccinated, or from a cat that has been infected and has been vaccinated. 
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Figure 3-18. Diagnostic algorithm for determining the FIV infection and vaccination status 
of cats. *As some FIV sero-negative plasma samples (3.2 %) were shown to contain 
antibodies that cross-reacted with the LLV-E peptide, immunostaining is used to confirm 
the absence of antibodies recognising FIV (checking for a false positive vaccination result). 
The absence of virus specific bands would indicate that the cat had not been vaccinated 
and therefore cross-reactive antibodies had likely been elicited by other infectious agents 
another condition. 
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3.6 Conclusions. 
 
Infection with FIV elicits high titres of antibodies recognising the PID of FIV. Although clade 
A is the predominant subtype of FIV found in the UK (Samman et al, 2011), in this study it 
was demonstrated that plasma raised against subtype C isolates also recognises the PID; 
plasma raised against the highly pathogenic FIV-CPG41 isolate (Diehl et al, 1995, De 
Rozieres et al, 2004) tested positive using the TM ELISA. The reactivity of plasma samples 
raised against diverse stains of FIV confirms the conserved, immunodominant nature of the 
PID, supporting the results of Avrameas et al (1992 and 1993) and Kania et al (1997). 
Additionally, the sensitivity and specificity values displayed by the TM ELISA (100 % and 
98% respectively) are similar to those reported by others (Avrameas et al, 1993. Kania et 
al, 1997). The TM ELISA produced no false positive or false negative results and detected 
anti- FIV TM antibodies in one sample that had been collected during the period of sero-
conversion, early post infection.  
 
The inclusion of FIV inconclusive samples in this study demonstrated the usefulness of the 
TM ELISA. However, it was possible to assign the FIV sero-status of such samples following 
testing using the TM ELISA. The 93 inconclusive samples (77 animals) represented the most 
challenging samples for FIV diagnosis that a large veterinary diagnostic laboratory would 
receive. The advantage of implementing the TM ELISA as a screening test is the removal of 
the cost of additional sampling and screening; in general, such costs are met by the 
laboratory when sample results are inconclusive. As the samples used in this study had 
been collected from companion animals, the samples contained antibodies to other 
infectious agents and yet no non-specific cross-reactivity was demonstrated. The results 
presented in this chapter demonstrated that the TM ELISA is a reliable and robust assay for 
the detection of antibodies to FIV, with a format that may easily be used for large-scale 
screening of samples.  
 
The use of the TM peptide corresponding to the PID has been shown to useful in the sero-
diagnosis FIV infection in the domestic cat (Felis catus), African lion (Panthero leo), puma 
(Puma concolor) and pallas cat (felis manul) (Avrameas et al, 1993, Fontenot et al, 1992, 
Kania et al, 1997, van Vuuren et al, 2003). Peptides corresponding to the PID have been 
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assessed also for the sero-diagnosis of HIV-1 (Gnann et al, 1987) and HIV-2 (Petrov et al, 
1990. Shin et al, 1997). The specificities of ELISA using FIV PID as the capture antigen ranged 
from 96-100% with sensitivities ranging from 78.6-100%, depending on the species of FIV 
against which the serological response is being examined. Similar specificities and 
sensitivities have been reported for the detection of HIV-1 and HIV-2 PID antibodies 
(specificities of 99.8-100% and sensitives of 99.7-100%). The conserved nature of the PID, 
accompanied by the species-specific nature of the epitope not only make TM an attractive 
and useful target for the sero-diagnosis of lentiviral infection but also a potential candidate 
epitope for inclusion in a DIVA vaccine.  
 
Previous studies have demonstrated that the PID can withstand substantial genetic 
mutations, especially at the 3’ end of the cysteine loop, and that altering the amino acid 
sequence of the PID abolished immunogenicity to the wild type PID sequence (Richardson 
et al, 1997, Pancino et al, 1995, Pancino and Songio, 1997). For these reasons, the LLV-E 
PID sequence was incorporated into a FIV chimaera that could be tested as a vaccine 
candidate while assessing the potential for the PID mutation to permit differentiation of 
vaccinated from infected cats.  The identification and characterisation of such an FIV 
vaccine candidate are described in Chapter 5, section 5.3 of this thesis. 
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Chapter 4 
 
Pathogenesis of FIV ΔV2 chimeric virus. 
 
4.1 Introduction 
 
FIV was originally isolated from a sick cat with an immunodeficiency like syndrome 
(Pedersen et al, 1987). Originally named feline T-lymphotropic lentivirus, the virus was 
renamed feline immunodeficiency virus based on its morphological, genomic, protein and 
reverse transcriptase similarities to the human and simian immunodeficiency viruses.  As 
FIV does not typically induce pathological clinical signs, rather the signs of infection 
displayed tend to be non-specific, the major determinants of FIV pathogenesis have been 
elucidated from experimental infection studies (Pedersen et al, 1989. Yamamoto et al, 
1998. Ishida and Tomoda, 1990). From early transmission studies, it was shown that FIV 
could be isolated from the saliva of infected cats and this finding led to the hypothesis that 
FIV was transmitted mainly through biting, although experimental transmission was 
demonstrated via the oro-nasal route (Yamamoto et al, 1989b. Matteucci et al, 2000. 
Kusuhara et al, 2005). The primary or acute stage of infection with FIV typically results in 
sero-conversion to the major structural proteins, p24, p17 and p55 and the envelope 
glycoprotein (Env) by 4-6 weeks post infection (Figure 4-1). During this time, virus can be 
isolated from PBMC, although in some very rare cases virus can be isolated from sero-
negative cats (Egberink et al, 1992. Yamamoto et al, 1988. Hopper et al, 1988). The isolation 
of virus from PBMC corresponds with a peak in viremia approximately 5 – 10 weeks post 
infection (Hosie et al, 2002 & 2005. Dunham et al, 2006). The major consequence of FIV 
infection is the gradual depletion of CD4+ T cells (Hofmann-Lehman et al, 1996.) that ocurs 
through the virus targeting cells expressing the T cell activation marker CD134 (Shimojima 
et al, 2004). Initial reports suggested that the chemokine receptor CXCR4 was the primary 
receptor for FIV (Nakagaki et al, 2001), however it was later shown that CXCR4 is the co-
receptor and that FIV displays a wide tropism, infecting T cells expressing CD4+ or CD8+, 
macrophages, CD25+CD4+ Treg cells, B-cells and astrocytes (English et al, 1993. Vahlenkamp 
et al, 2004). FIV infection leads to a gradual depletion of cells at the foundation of the 
adaptive arm of the immune system that characterises the asymptomatic stage of infection 
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(Figure 4-1).  Cats may appear relatively healthy during the asymptomatic stage, with the 
only indicators of infection being the persistence of anti-FIV antibodies and a gradual 
decline in the numbers of CD4+ T-cells. During the asymptomatic stage of infection, the 
CD8+ T-cell compartment expands, resulting in an inversion of the CD4+:CD8+ T cell ratio 
(Willett et al, 1996). Cats can remain in this asymptomatic stage of infection for weeks or 
years depending on the virulence of the infecting strain of FIV (Diehl et al, 1995. Addie et 
al, 2000). The secondary phase of infection is characterised by pronounced immune 
dysfunction, including a significant reduction in T cell proliferative responses (Torten et al, 
1991) and polyclonal B cell activation leading to hypergammaglobulinemia (Flynn et al, 
1994). The pronounced immunodeficiency caused by FIV predisposes cats to secondary 
opportunist infections that can be fatal (de Rozieres et al, 2004.  Diehl et al, 1995. Pedersen 
et al, 1987).   
 
Figure 4-1. Schematic diagram summarising the pathogenesis of FIV. An Initial blip in 
viremia during the primary stage of infection is brought under control by both the humoral 
and cellular immune response resulting in the cat entering the asymptomatic stage. During 
this time the CD4+ t-cell numbers decline whilst the CD8+ t-cell numbers expand resulting 
in an inversion of the CD4+/CD8+ t-cell ratio. In the second stage of infection the immune 
system is no longer able to control infection and immunodeficiency develops.   
 
Although the pathogenesis of FIV follows the general trend described above for the 
majority of infected individuals, the time between infection and death can vary greatly 
between cats. Because of this and the non-specific clinical signs displayed by FIV infection, 
112 
 
it is difficult to accurately stage infection (Hosie and Beatty, 2007). As shown in table 4-1, 
the virulence of different FIV isolates can vary. Experimental infection with FIV-Petaluma 
or FIV-M2 resulted in modest viral burden and negligible inversion of the CD4+:CD8+ ratio, 
while infection with in vivo passaged FIV-CPG41 resulted in a high viral burden, significant 
loss of CD4+ T cells (with numbers decreasing to 52% of those in uninfected control cats) 
and death by 8 weeks post infection. Hence FIV infection can be difficult to stage and the 
differences in the pathogenicity of different isolates might explain the differences in 
vaccine protection that have been observed between challenge viruses that belong to the 
same clade and display similar degrees of Env amino acid sequence divergence from the 
vaccine virus.  
 
 
Table 4-1. Spectrum of pathogenicity of selected FIV strains observed following in vivo 
infection.  The pathogenicity of isolates varies from clade to clade, with some evidence to 
suggest that clade B is less virulent than clade A. Extensive in vivo passage of the CPG-41 
isolate led to the development of a super pathogenic isolate of FIV, capable of causing 
death within 8 weeks. + low/negligible, ++ moderate, +++ high/pronounced, ++++ very 
high/severe. 
 
In this study the pathogenesis of a chimaeric FIV was studied.  The chimaeric virus 
contained the Env of a field isolate that contained a unique mutation at the apex of the 
second hypervariable loop 2 [figure 4-2 (V2)] within a backbone derived from the FIV-
Glasgow8 molecular clone. Characterisation of the novel field isolate Env, designated 
206394 (Samman, 2010), identified an asparagine to serine mutation at position 298 
(N298S) that ablated a potential N-linked glycosylation site (PNGS), revealing a 
neutralisation sensitive epitope.  The homologous plasma collected from cat 206394 
contained potent broadly neutralising antibodies (BnAb) that neutralised FIV isolates 
derived from clades A, B and C, as shown in table 4-2. This led us to test whether a chimaeric 
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FIV in which the 206394 Env (comprising both SU and TM) replaced the Env of the infectious 
FIV GL8 molecular clone, might elicit BnAb with the potential to neutralise a broad range 
of isolates, including FIV GL8.   
 
 
Figure 4-2. Schematic diagram of 206394 SU, showing the position of the ablated PNGS 
at the apex of the second hypervariable loop (V2). Blue forks represent PNGS; those 
highlighted in blue are predicted to be missing in FIV-Petaluma, the prototype FIV vaccine 
strain, and the PNGS highlighted in red indicates the unique mutation that was observed in 
Env 206394. 
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Table 4-2. Broad cross neutralisation by plasma from cat 206394, shown as percentage 
neutralisation. Cat 206394 was a 14-year-old cat with chronic, age-related renal problems 
but was otherwise healthy (Samman, 2010). Plasma from cat 206394 neutralised HIV(FIV) 
pseudotypes bearing Envs of FIV isolates from clades A, B and C (percentage neutralisation 
relative to a no plasma control ≥ 90%). Figure reproduced from Hosie et al, 2011.  
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4.2 Materials and Methods. 
4.2.1 Construction of a chimaeric infectious molecular clone of FIV (FIV ΔV2)  
 
The chimaeric infectious molecular clone of FIV GL8 containing the novel Env 206394 was 
constructed by Ms Nicola Logan of the Retrovirus Research Laboratory. Briefly, the env 
gene of 206394 was amplified from gDNA derived from virus isolation cultures. Cultures 
were centrifuged for 5 minutes at 1000rpm, the culture fluid discarded and the cell pellet 
washed by resuspending the cells in 10mls of PBS followed by centrifugation for 5 minutes 
at 1000rpm. The PBS was then aspirated and the gDNA from the pelleted cells was 
extracted as described in Materials and Methods (Chapter 2). First round PCR was 
performed using degenerate primers IF4/XR2, the PCR product was separated on a 0.7-
0.8% agarose gel, excised, purified and then sent for sequencing to determine the sequence 
of the second-round PCR primers. Second round amplification was performed from the 
product of the first round of PCR using primers complementary to the 5’ and 3’ prime ends 
of the env gene. Mlu1 and Nde1 restriction endonuclease sites were engineered into the 
primers at the 5’ and 3’ ends respectively. Following the second round of PCR, the product 
was separated on a 0.7-0.8% agarose gel, excised, purified and eluted in 50µl of EB buffer 
and then stored at -20oC until required.  
  
4.2.2 Restriction digests 
 
The concentration of DNA to be digested was first determined using the Nanodrop 
(Thermo-scientific). One microlitre of each of the Mlu1 and Nde1 restriction enzymes (New 
England biolabs, Hitchen, Hertsfordshire) were added to 1µg of purified PCR 
product/molecular clone and 5µl of cut smart restriction digest buffer. The reaction volume 
was made up to 50µl using deionised water and then incubated in a 37oC water bath for 5 
hours. The DNA was then purified using the Qiagen gel extraction kit as per the 
manufacturer’s instructions. The product was eluted and stored at -20oC until required. 
 
4.2.3 Ligation 
 
The vector (FIV GL8 molecular clone in the vector PBR328) and insert were mixed at a 
vector: insert ratio of 3:1with 4µl of ligation buffer and 1µl of T4 DNA ligase (Invitrogen, 
Paisley, UK). Ligation reaction volumes were made up to 20µl with deionised water and 
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incubated in a circulating water bath at 14oC overnight. Ligations were then used 
immediately to transform DH5α cells.  
 
4.2.4 Transformation 
 
Escherichia coli Max efficiency® DH5α™ competent cells [Invitrogen, Paisley, UK 
(phenotype: F- φ80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk+) phoA 
supE44 λ- thi-1 gyrA96 relA1)] were transformed using the heat shock method (which relies 
on the porosity of the bacterial cell wall being governed, in part, by temperature), as per 
the manufacturer’s instructions. Hence regulation of the reaction temperature controls the 
reactants entering the bacteria.  Briefly, 3µl of ligated product were added to 30µl of DH5α 
max efficiency cells and then incubated on ice for 30 minutes. Cells were then heat shocked 
at 42oC for 40 seconds. Cells were then incubated on ice for 2 minutes after which 400µl of 
SOC broth were added. The culture was agitated at 250rpm at 37oC for 1 hour to recover 
the transformed cells and 200µl of culture were spread onto ampicillin-selected LB agar 
plates and incubated at 30oC overnight.  
  
 
4.2.5 Mini-prep DNA preparation 
 
Colony screening was performed using the QIAprep® spin miniprep kit (Qiagen, 
Manchester, UK). The assay utilises alkaline lysis of bacteria that are then centrifuged 
through a silica membrane in a high salt environment, which facilities DNA binding. 
Residual RNA, proteins and cell debris are then washed away and bound DNA is eluted 
using a low salt, pH 7-8 elution buffer. 
 
One millilitre of bacterial culture was centrifuged at 16873g for 5 minutes to pellet cells. 
The ultrafiltrate was aspirated and the cells resuspended in 250µl of buffer P1 followed by 
lysis in 250µl of P2 and incubated for 5 minutes at room temperature. Three hundred and 
fifty microliter of buffer N3 were added to neutralise the reaction and the solution was 
centrifuged at 16873g for 10 minutes, pelleting all of the precipitated cellular debris and 
leaving an aqueous fraction that contained the bacterial and plasmid DNA. The aqueous 
fraction was then passed through a QIAprep spin column at 14549g for 1 minute. The flow-
through was discarded and the bound DNA was washed with 750µl of PE wash buffer at 
14549g for 1 minute. The flow-through was again discarded and a dry spin at 16873g for 1 
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minute removed any residual wash buffer. The bound DNA was then eluted in 50µl EB 
elution buffer into a sterile 1.5ml eppendorf tube and stored at -20oC until required.  
 
Colonies expressing the FIV Env were screened by Mlu1/Nde1 double digest as described 
previously and visualised on a 0.7-0.8% ethidium bromide agarose gel. Positive clones were 
sequenced to confirm the sequence of the cloned envs. Colonies expressing the cloned 
novel FIV env gene 206394 were used in further studies, the virus and clones hereafter 
being referred to as FIV ΔV2.  
 
4.2.6 Maxi-prep DNA preparation 
 
 
Selected colonies were grown in bulk in 400mls of ampicillin LB broth. Cultures were 
agitated at 250rpm at 30oC overnight and then centrifuged at 2540g for 10 minutes at 4oC 
using the Beckman Coulter centrifuge. The ultrafiltrate was aspirated and the pelleted cells 
were then processed to obtain plasmid DNA. 
 
Bacterial lysates were process using the PureLink™ Hipure plasmid filter purification kit 
(Invitrogen, Paisley, UK). Using this method, plasmid DNA was separated and purified from 
bacterial cell lysates by anion exchange chromatography. The DNA was washed and then 
eluted using a high salt elution buffer, de-salted and precipitated, resulting in the purified 
plasmid solution. 
 
After centrifugation of the bacterial culture, the ultrafiltrate was aspirated and the cell 
pellet was resuspended in 10mls of buffer R3 and lysed by the addition of 10mls of L7 lysis 
buffer. Lysis was allowed to proceed for 5 minutes at room temperature. The bacterial 
lysate was then neutralised and salt-buffered following the addition of 10mls of N3 
neutralisation buffer. The solution was then allowed to pass through an equilibrated filter 
column. The filter column allowed the aqueous fraction containing plasmid DNA to pass 
through whilst retaining precipitated cellular debris. The aqueous fraction then entered the 
anion exchange resin filter that bound the negatively charged phosphate group of the DNA 
backbone. Once the aqueous fraction has passed through the filter and the ion exchange 
column, the filter was discarded and the bound DNA was washed in 50mls of W8 wash 
buffer. The washed DNA was then eluted in 15mls of E4 elution buffer and 10.5mls of 
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isopropanol was then added to precipitate the DNA. The precipitate was then centrifuged 
at 2540g for 30 minutes at room temperature. The ultrafiltrate was then aspirated and the 
DNA pellet was resuspended in 1ml of 70% ethanol and centrifuged at 16873g for 5 minutes 
at room temperature. The ethanol was then aspirated and the resulting DNA pellet was 
allowed to air dry for 5-10 minutes, allowing residual ethanol to evaporate. The DNA pellet 
was then dissolved in 400µl of TE buffer and stored at -20oC until required.   
 
 
4.2.7 Pathogenesis trial of FIV ΔV2 chimaeric virus 
 
The aim of the study was to examine the pathogenesis of the FIV ΔV2 chimaeric virus and 
to determine whether infection would elicit BnAb. Since BnAb have been shown to take up 
to months or years to develop (Hosie et al, 2011), the infected cats were monitored for 52 
weeks. Four specific pathogen free (SPF) kittens of mixed European breed had been 
specifically bred for experimental use and were allowed to acclimatise to the study 
conditions at the trial facility (Charles River Laboratories LTD, Co Mayo, Ireland) for 2 
weeks.  All of the kittens were inoculated with 2000 TCID50 of FIV ΔV2 that had been titrated 
in vitro using Mya-1 cells. Following infection with FIV ΔV2, the kittens were monitored for 
infection and for the development of antibodies, as detailed in Table 4-3.  At the end of the 
trial, the cats were anaesthetised before they were euthanised, exsanguinated and 
examined post mortem. Blood and tissue samples were collected for further examination. 
Blood samples were collected into either lithium heparin or EDTA, packaged and shipped 
at 4oC to the Retrovirus Research Laboratory at the University of Glasgow. Ethical approval 
for the study was obtained from the Charles River Laboratory Ethics Committee.  
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Week 
of 
study 
Age 
(weeks) 
Sample Procedure Experimental notes 
aAssays 
performed. 
-2 6 0.5ml EDTA, 0.5ml hep Pre-bleed 1  Acclimatisation 1,2,3,4,5 
0 8 1ml EDTA, 1ml hep 
Pre-bleed 2/ day of 
challenge. 
Acclimatisation/ 2000 
TCID50 FIV ΔV2 1,2,3,4,5 
4 12 2ml EDTA, 2ml hep Blood sample   1,2,3,4,5 
8 16 2ml EDTA, 2ml hep Blood sample   1,2,3,4,5 
12 20 2ml EDTA, 2ml hep Blood sample   1,2,3,4,5 
16 24 2ml EDTA, 2ml hep Blood sample   1,2,3,4,5 
20 28 2ml EDTA, 2ml hep Blood sample   1,2,3,4,5 
24 32 2ml EDTA, 2ml hep Blood sample   1,2,3,4,5 
28 36 5ml EDTA, 5ml hep Blood sample   1,2,3,4,5 
32 40 5ml EDTA, 5ml hep Blood sample   1,2,3,4,5 
36 44 5ml EDTA, 5ml hep Blood sample   1,2,3,4,5 
40 48 5ml EDTA, 5ml hep Blood sample   1,2,3,4,5 
44 52 5ml EDTA, 5ml hep Blood sample   1,2,3,4,5 
48 56 5ml EDTA, 5ml hep Blood sample   1,2,3,4,5 
52 60 5ml EDTA, 5ml hep PM examination 
Exsanguation and post 
mortem examination. 
Tissue collection 1,2,3,4,5 
 
Table 4-3. Schedule of the FIV ΔV2 pathogenesis study. a1. DIVA ELISA, 2. Gag qPCR, 3. Immunostain, 4. Neutralisation assay, 5. Virus isolation. 
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4.3 Results. 
 
4.3.1 Inoculation of Cats 
 
Cats were inoculated with 2000 TCID50 (0.5mls clarified culture fluid) of FIV ΔV2 via the 
intramuscular route. None of the cats displayed any signs of swelling, erythema or pain at 
the inoculation sites. During the trial, none of the cat displayed evidence of haematoma at 
the sites of blood collection on any of the sampling days and all cats remained healthy until 
the end of the trial. 
 
4.3.2 Recovery of virus from PBMC 
 
Virus was recovered from PBMC, following virus isolation, by week 8 of the study and was 
repeatedly isolated at each time point when the cats were sampled (Figure 4-3)  
 
 
Figure 4-3. FIV p24 antigen production detected in the clarified culture fluid from co-
cultivations of cats A831-4 at day 21. FIV p24 was first detected in cultures set up from 
PBMC collected from cats A831-834 at 8 weeks post infection and all co-cultivations tested 
positive thereafter. Mya-1 indicates uninfected cells that were not co-cultivated with 
PBMC; negative and positive controls were also included in the assay for FIV p24 detection.  
The lower absorbance values observed at week 52 could reflect the lower proviral loads 
that were observed in the cats at the end of the study. However, the method of virus 
isolation used in his study was not quantitative, and so this difference might indicate that 
fewer PBMCs had been available for co-cultivation at the later time point. 
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4.4 Serological response to infection with FIV ΔV2 chimaera  
 
4.4.1 All cats developed anti-Env antibodies detectable by immunostain 
analysis 
 
To examine the serological responses of the cats following infection with FIV ΔV2, we first 
determined the time to seroconversion for each of the viral proteins using immunostain 
analysis (Figure 4-4). By 12 weeks post infection, 3/4 cats (all cats except A834) had 
developed antibodies that recognised all of the major viral proteins. Seroconversion was 
detected as early as 4 weeks post infection, with antibodies recognising p24, p10 and TM 
being detected in 3/4 cats.  In contrast, antibodies recognising Env (SU) were not detected 
until 8-12 weeks post infection.  Cat A834 showed delayed sero-conversion compared to 
the other cats, with antibodies recognising TM, p24 and p10 detected 8 weeks post 
infection. Indeed, cat A834 did not appear to fully seroconvert until week 34, when a weak 
antibody response against SU was detected. These results confirmed that the FIV ΔV2 
chimaera was fully immunogenic and elicited a defined humoral immune response. It was 
also demonstrated that the FIV ΔV2 chimaera was replication competent in vivo and that 
the novel Env was recognised in the context of the FIV GL8 backbone.  
 
4.4.2 Demonstration of antibodies recognising the FIV TM peptide   
 
To compare the antibody response to both the FIV and LLV-E TM peptides (as described in 
Chapter 2) during the early stage of FIV infection, plasma samples were tested for 
antibodies recognising the TM peptides of FIV and LLV-E (Figure 4-5). From 4 weeks post 
infection, anti FIV TM peptide antibodies were detected in 4/4 cats infected with the FIV 
ΔV2 chimaera. The antibody response against the FIV TM peptide increased until week 20 
when a plateau was reached. The antibody response against the LLV-E peptide was less 
marked during the initial stages of infection, with absorbance values never exceeding 6 
times the negative fold value of the negative control. When the negative fold and 
absorbance ratios were calculated (Figure 4-5), minimal cross reactivity with the LLV-E 
peptide was detected. This finding was consistent with the immunostain data, as anti-TM 
antibodies were detected at the same time points using two different methods. It was likely 
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that the discrepancy between the results of the DIVA ELISA and immunostain analysis for 
cat A834 reflected the different sensitivities of the two assays.
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Figure 4-4. Serological responses of cats A831-4 infected with FIVΔV2 as determined by immunostaining. The black arrow indicates the day of challenge. 
Strong antibody responses against the core structural proteins p24, p17, p10 and the precursor p55 developed soon after challenge in 3/4 cats, as well 
as antibodies recognising the TM protein. Strong anti-Env (SU+TM) responses were observed 12 weeks post infection in cats A832 and A833, whereas 
the anti-Env response of cat A831 was much weaker (although anti-Env antibodies were detected at a similar time). Cat A834 did not develop detectable 
anti-Env antibodies until 32 weeks post infection.
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Figure 4-5. Antibody response of cats A831-4 against the FIV and LLV-E TM peptides. The 
normalised optical density value was used to compare the antibody responses to FIV TM 
(red symbols) and LLV-E TM (green symbols).  
 
 
4.5 Pathogenesis of FIV ΔV2. 
 
4.5.1 Induction of homologous neutralising antibodies. 
 
To assess whether ablation of the PNGS at the apex of V2 resulted in the production of 
BnAb, neutralisation assays were performed using pseudotypes bearing the Envs of FIV 
isolates representative of clades A, B and C. The luciferase count results (Figure 4-6) 
demonstrated that homologous neutralising antibodies were detectable, since plasma 
samples collected from 3/4 infected cats neutralised pseudotypes bearing the homologous 
Env 206394 by 20 weeks post infection. Expressing the results as fold neutralisation (Figure 
4-7) indicated that strong homologous neutralising antibody responses were produced in 
3/4 cats by 28 weeks post infection, with >90% neutralisation of pseudotypes bearing the 
homologous 206394 Env. In contrast, cat A831 did not develop homologous neutralising 
antibodies until 40 weeks post infection. 
125 
 
 
Figure 4-6. Homologous and heterologous virus neutralising antibody responses of cats A831-4.  Neutralisation (indicated by decreased luciferase 
activity) responses of cats A831 to A834 following infection with the FIV ΔV2 chimaera, expressed as mean Log10 luciferase activity +/- SEM. Heparinised 
plasma samples were screened for neutralisation against the homologous ΔV2 pseudotype and the heterologous pseudotypes GL8 (Clade A), PET (KKS, 
Clade A), B2452 (Clade B) and CPG41(Clade C).
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Figure 4-7. Neutralisation of homologous pseudotype 206394 by cats A831-4. Neutralisation expressed as fold neutralisation. Fold neutralisation 
values >10.0 (broken line) are equivalent to >90% neutralisation (Beczkowski, 2012). 
127 
 
No correlation was observed between neutralisation response and the development of 
anti-Env antibodies detected by immunostain (table 4-4).  Anti-Env antibodies were 
detected approximately 4-8 weeks before neutralising antibodies were detected, with the 
exception of cat A834 that developed neutralising antibodies before antibodies recognising 
Env were detected by immunostain analysis. It appeared that cats that developed anti-Env 
antibodies earlier in infection developed stronger neutralising responses against the 
homologous pseudotype. On the other hand, cat A834 appeared to develop neutralising 
antibodies before anti-Env antibodies were detected by immunostaining, suggesting that 
neutralising antibodies might recognise conformational epitopes or might occur at low 
titres that were not detected by immunostaining. Three of four cats demonstrated maximal 
homologous neutralising titres at 40-48 weeks post infection, 28-40 weeks after anti-Env 
antibodies were detected by immunostain. In contrast, cat A834 demonstrated the 
maximum homologous neutralising titre and anti-Env antibodies were detected by 
immunostaining at 32 weeks post infection.  
 
 
Table 4-4. Detection of anti-Env antibodies and nAb. Anti-Env antibodies were detectable 
by immunostain on average 15 weeks post infection, with homologous neutralising 
antibodies detected on average 14 weeks post infection. This discrepancy could be due to 
the sensitivities used to detect antibody/neutralisation, or cat A834 displaying neutralising 
antibody considerably sooner than antibodies were detected by immunostain.  
 
These results demonstrated that infection with the FIV ΔV2 chimaeric virus induces 
homologous neutralising antibodies relatively soon post infection. The presence of anti-
Env antibodies detectable by ELISA or immunostaining did not correlate with 
neutralisation, with low titres of anti-Env antibodies being potently neutralising in one cat, 
although these antibodies were not detectable by immunostaining. 
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4.5.2 Heterologous neutralisation. 
As shown in Figure 4-8, no heterologous neutralising antibodies were observed in the 
plasma samples from the cats infected with FIV ΔV2. There was no reduction in luciferase 
activity for the heterologous pseudotypes tested and the values for fold neutralisation 
indicated the absence of heterologous neutralisation (Figure 4-7). Even when the fold 
neutralisation values against the heterologous strains were examined at the time points 
when the highest values for homologous neutralisation were observed for each cat (table 
4-5), none of the cats showed any evidence of heterologous neutralisation.  
 
 
Table 4-5. Fold neutralisation of homologous and heterologous pseudotypes by cats 
A831-4 at the time point when the homologous neutralisation was at its highest in each 
cat. Red cells indicate >90% neutralisation whilst yellow cells indicate the absence of 
neutralisation. 
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Figure 4-8. Heterologous neutralisation responses of cats A831-4 infected with FIV ΔV2. No neutralisation of pseudotypes bearing Envs of the 
heterologous clade isolates FIV-GL8 and FIV-PET (KKS) were observed, with fold neutralisation values lower than 1.6 (broken line). Cats A832 and A834 
showed evidence of weak neutralisation of B2452 (A832 at week 32) and CPG41 (A834 at week 16) pseudotypes, but these responses were not sustained. 
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4.5.3 Lower proviral loads in cats that developed more rapid neutralisation 
responses 
 
To examine the proviral loads that were established in the early phase of infection with FIV 
ΔV2, QPCR was performed on genomic DNA extracted from PBMC isolated at the time 
points shown in Table 4-3. For each cat, 106 PBMC were analysed and no more than 3% 
(30,000 cells) were infected with detectable virus (Figure 4-9). Indeed, only 0.5% of 
sampled PBMC contained virus in 3/4 cats. There was a peak in viral load 8 weeks post 
infection in all cats before the loads decreased to near undetectable levels by 28 weeks 
post infection in 3/4 cats, with cat A834 displaying a markedly reduced proviral load by 32 
weeks post infection. In all cats the decrease in proviral load correlated with the 
development of strong homologous neutralising antibody responses, however the proviral 
loads appeared to increase gradually subsequently, in spite of the homologous 
neutralisation responses induced in each cat. Indeed, cat A834 displayed its peak proviral 
load 4 weeks after its highest neutralisation response.  These data indicated that although 
homologous neutralising antibodies initially controlled virus replication and reduced the 
proviral burden to near undetectable levels, this suppression was overcome before the set 
proviral load was established.  
 
In this study it appeared that the observed reduction in the proviral load correlated with 
the development of a strongly homologous neutralising antibody response and no evidence 
was found that the decreased proviral loads were associated with decreased numbers of 
target cells available for viral infection (Figure 4-10). 
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Figure 4-9. The development of the homologous neutralisation response in relation to the proviral load in cats A831-A834 following infection with FIV 
ΔV2.  The blue line shows homologous neutralisation (fold neutralisation) whist the red line depicts the proviral load (percentage of infected PBMC).
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Figure 4-10. The percentage of activated T-lymphocytes expressing CD4 and CD134 for 
cats A831-4. As is evident in all four cats, a rhythmic cycle of expansion of the activated T-
cell subset appears to occur every 16 weeks. Although a relevant observation, as this could 
potentially afford a larger target cell population to infect, the cause of this activated T-cell 
expansion was not further investigated.  
 
 
4.5.4 CD4:CD8 lymphocyte ratio inversion in cats infected with FIV ΔV2. 
 
To determine whether the chimaeric virus FIV ΔV2 was virulent or attenuated in cats, the 
CD4+:CD8+ T lymphocyte ratio was determined by FACS analysis (Figure 4-11), revealing a 
gradual inversion of the CD4+:CD8+ ratio that was most marked at 20 weeks post infection. 
As demonstrated in Figure 4-12, there was a marked CD4+:CD8+ inversion at 20 weeks’ post 
infection, coinciding with the initial peak of viral replication, reflected by the high mean 
proviral load. It appears that CD4+ lymphocyte numbers showed a significant gradual 
reduction (p=0.025) that correlated with time post infection. These data demonstrated that 
the FIV ΔV2 virus was virulent and targeted CD4+ lymphocytes. Despite the chimaeric virus 
containing the gag and pol genes of FIV-GL8, the viral loads induced post infection were 
lower than had been observed following infection with a similar dose of the FIV-GL8 
molecular clone (our unpublished data), suggesting that the novel env gene that was 
incorporated into the chimaeric virus was likely responsible for the decreased virulence of 
FIV ΔV2 relative to FIV-GL8.  
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Figure 4-11. CD4+:CD8+ lymphocyte ratios of cats A831-A834. The gradual inversion of the 
CD4+/CD8+ t-cell ratio demonstrates that the chimaeric virus was indeed virulent and 
targeted the CD4+ t-cell compartment whilst expanding the CD8+ t-cell compartment. This 
observed pathogenesis is consistent with the published literature (see section 1.5, chapter 
1). 
 
 
 
Figure 4-12. Mean CD4+:CD8+ ratios and proviral loads of cats A831-4. The negative 
correlation between time post infection and CD4+:CD8+ ratio was statistically significant (p= 
0.025, R2=0.378, Pearson r correlation).  
 
4.5.5 Consensus sequence of FIV ΔV2 recovered from infected cats. 
 
The stability of the unique PNGS was investigated, to determine if the potent humoral 
immune responses had resulted in mutations occurring in the PNGS at the apex of V2. The 
env gene was amplified and sequenced from genomic DNA extracted from the virus 
isolation cultures. The amino acid sequence of the predominant env gene appeared to be 
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stable, with the env genes from all of the infected cats retaining the same sequence as the 
original challenge virus, although the env gene did become more difficult to amplify from 
later cultures, indicating that either the primer annealing sites may have mutated or the 
viral copy number had decreased following the early stage of infection. However, this could 
not be investigated further because of time limitations. A comparison of the amino acid 
sequences of the V2 region of the amplified env genes (Figure 4-13) showed that the V2 
PNGS mutation was present in all of the sequences derived from all of the infected cats at 
the time points examined. This demonstrated that the V2 PNGS mutation of the FIV Δ2 
virus was stable for at least 52 weeks post infection. 
 
Figure 4-13. Consensus sequence of the major species of env gene amplified from cats 
A831-4. The sequences shown represent the apex of variable loop 2 with the N298S 
mutation boxed in red. Sequences from all 4 cats derived from week 8 (first virus isolation 
positive result, red) week 24 (midway through the study period, light blue) and week 52 
(end of study, green) are aligned with the challenge virus, FIV ΔV2 and the original novel 
field isolate (206394) from which the FIV ΔV2 env was derived.  
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4.6 Discussion.  
 
The ancestral virus that the FIV Δ2 envelope glycoprotein was derived from was isolated 
from a 14-year-old cat that displayed chronic age-related problems but was otherwise 
healthy. Although the length of time that the cat had been infected was unknown, since 
the cat was adopted from the feral population, it would be expected that the cat was 
infected for some time based on the known risk factors associated with FIV. This would 
therefore make this cat a long-term survivor, the same as the cats from which the two FIV 
vaccine strains were isolated from (Yamamoto et al, 2007). Vaccine efficacy appears to be 
greatest when attenuated strains of FIV, derived from long term survivors, are used as the 
immunogen as protection appears to be refectory to virulence (Yamamoto et al, 2007). 
Therefore, this makes the use of the FIV ΔV2 as a vaccine immunogen an attractive target. 
Infection with FIV ΔV2 elicited a strong humoral immune response detectable 4 weeks after 
infection and containing substantial homologous VNA. The initiation of homologous VNA 
appears substantially sooner than previously reported for FIV-Glasgow8 (Hosie et al, 2011) 
indicating that the inclusion of the envelope containing the V2 PNGS mutation can induce 
a neutralisation sensitive profile. Indeed, when the mutation was included into the 
envelope glycoprotein of HIV(FIV) pseudotyped FIV-Glasgow8, the pseudotyped virus was 
5 times more sensitive to neutralisation. The PNGS mutation was under considerable 
selection pressure in vivo, as the glycosylation site had been repaired when the cat was 
sampled again, some 5 months after the original sampling (Samman 2010). This is 
consistent with the V2 PNGS playing a role in the development of a neutralisation resistant 
escape mutant. In this study the V2 mutation was stable for the duration of the study period 
(52 weeks). Although the method used to amplify and sequence the envelope in this study 
would only detect the major species of envelope glycoprotein circulating in PBMCs, it 
became evident that amplification and sequencing of the envelope became more difficult 
as the study progressed. In particular, the chromatograph of the sequence data become 
more difficult to read. This is indicative of mutations within the sequence primer binding 
sites and the amplification of more than 1 species of envelope glycoprotein resulting in 
‘dirty’ reads. As the original PCR product is stored at -80oC, it would be possible to more 
thoroughly re-examine the envelope glycoprotein amino acid sequence by cloning the 
envelope into the VR1012 expression vector and examining how many env variants can be 
obtained.  This is a particularly pertinent point as the sequence data became more difficult 
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to generate from around week 32-36 of the study which coincides with a gradual increase 
in the proviral load seen in all 4 cats (to a greater or lesser extent), but also the 
development of especially potent homologous VNA. 
 
Although the role of cell mediated immunity was not investigated in this study, the low 
proviral load observed in the study may have been to do, in part, cell mediated immunity. 
Cell mediated immunity was not measured in this study for several reasons. Primarily the 
main hypothesis being tested in this study was whether or not inoculation with the unique 
envelope of the FIV ΔV2 could elicit broadly neutralising antibodies, as in vitro mutagenesis 
studies had demonstrated that the V2 PNGS mutation to be a neutralising sensitive epitope 
when incorporated onto other envelopes from different FIV isolates, and the plasma from 
the cat from which the ancestral FIV isolate of FIV ΔV2 was derived from was shown to 
contain potent broadly neutralising antibody. Secondly, although inoculation with ‘live’ 
virus is known to elicit a strong cellular immune response, a more appropriate candidate 
immunogen for assessing the cellular immune response would have been immunisation 
with DNA or inactivated infected cell vaccine (Flynn et al, 1996. Flynn et al, 2000. Omori et 
al, 2004). Regardless of these facts the assessment of what type of cytotoxic T lymphocyte 
(CTL) response could inform on the possibility of protection using FIV ΔV2 as a candidate 
immunogen. It is known that vaccinated cats that are protected from FIV infection produce 
a specific type of CTL response. Protected cats produce a CD8+ CTL response that are 
predominantly Env specific, can be detected in the blood during the initial stages of 
infection but then are detected almost solely in the lymphoid tissues. In contrast 
unprotected cats predominantly produce a Gag specific CTL response (Flynn et al, 1996. 
Flynn et al, 2000. Omori et al, 2004. Aranyos et al, 2016). By assessing the effector type of 
CTL response, an indication of the potential performance of the FIV ΔV2 as a vaccine could 
have been attained. Regardless of these facts, challenge with FIV ΔV2 elicited a potent 
homologous neutralising antibody response that did correlate with a decrease in proviral 
load.  
 
Many BnAb have recently been identified that are able to efficiently neutralise a diverse 
range of HIV-1 isolates derived from tier 1, 2 and 3 viruses. Many of these antibodies target 
N-linked glycans at the apex of the V1/V2, including PG9 and PG6, CHO1 and CHO4, PGT141 
and PGT145. The V1 and V2 regions of the envelope has been demonstrated as being a 
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global regulator of neutralisation sensitivity in HIV-1 (McLellan et al, 2011. O’Rourke et al, 
2012. Rolland et al, 2012. Pinter et al, 2004). The majority of these papers describe 
mutations affecting PNGS either at the apex or the base of V1/V2 region, similar to the 
mutated PNGS described in this study and those seen in the FIV-Petaluma strain (Samman, 
2010). However, the characterisation of neutralisation sensitive epitopes is restricted to 
the technology available to identify VNA or BnAb bound to its cognate epitope and 
precisely determine the neutralisation of the virus. A recent study has suggested the 
possibility of V1/V2 glycan shielding of neutralisation sensitive epitopes in V3 (Rusert et al, 
2011). In this study the shielding of V3 by V1/V2 glycans was determined by the use of 
monoclonal antibodies (many of which have been shown to be broadly neutralising) and 
V1/V2 deleted virus. The authors propose the model depicted in Figure 4-14, where by the 
glycosylation of the V1 and V2 loop shields the neutralisation sensitive V3 loop, in a trimer 
dependant manner.  
 
Figure 4-14. Proposed model of V3 protection by neighbouring V1/V2 glycosylation. The 
neighbouring protection model suggest that the glycosylation of the V2 loop of one 
monomer of gp120, shields neutralisation sensitive epitopes (V3) on a neighbouring gp120 
monomer. This is consistent with mutations affecting PNGS within the V1/V2 loops 
resulting in neutralisation sensitive virus. Figure adapted from Rusert et al, 2011. 
 
Therefore, the characterisation of an apparent neutralisation sensitive epitope located at 
the apex of V2, may actually expose the hypervariable loop 3. Hypervariable loop 3 of FIV 
has been shown to be an immunodominant domain of the FIV SU (Avrameas et al, 1992), 
to contain a neutralisation sensitive region (Lombardi et al, 1993) and to interact with FIV 
co-receptor, CXCR4 (de Parseval et al, 2006), yet vaccine trials using a peptide derived from 
the V3 neutralisation sensitive region failed to protect against infection but induce 
neutralising antibodies (Lombardi et al, 1994).  
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Although a neutralisation sensitive epitope has been discovered, and that epitope is able 
to elicit strong homologous VNA, the development of BnAb may require the co-evolution 
of the viral epitope and the reactive B-cell. Broad neutralisation has been correlated with 
time spent infected and BnAb are believed to require extensive somatic hypermutation 
driven by long periods of viral replication (Liao et al, 2013). The majority of BnAb 
characterised in HIV-1 infection harbour unusual features including long third 
complementary determining region, polyreactivity to none viral antigens, and the inability 
of the unmutated common ancestral B-cell (that BnAb eventually are derived from) to bind 
Env with sufficient affinity (Liao et al, 2013. McLellan et al, 2011. Haynes et al, 2012). The 
priming of a broadly neutralising antibody response to HIV has been attempted by utilising 
an immunogen that targets the activation of rare B-cell receptor gene combinations 
(Jardine et al, 2015). The aim of the study was to elicit the VRC01 class of BnAb (which 
targets the CD4 binding site) by immunising with a self-assembling nanopeptide that 
corresponds to the core of gp120. Activation of the VRC01 class of genes was achieved that 
created a pool of memory B-cells that could likely be boosted by a more native like 
immunogen (Jardin et al, 2015). It is thought that the generation of BnAb will require the 
germline targeted priming and subsequent selective boosting using antigenically related, 
but progressively more native immunogens (Jardine et al, 2015. Liao et al, 2013. Haynes et 
al, 2012). 
 
As this mutated PNGS had been observed in patients with HIV-1 where BnAb have been 
isolated, it would appear that the V1/V2 homologue is also a global regulator of virus 
neutralisation in FIV as well as HIV-1. (Sanchez-Merino et al, 2016. McLellan et al, 2011. 
O’Rourke et al, 2012. Rolland et al, 2012. Pinter et al, 2004.) 
 
Taken together it has been shown that infection with FIV ΔV2 elicits a strong humoral 
immune response that contains substantial homologous VNA. The virus has been shown to 
be pathogenic, as determined by the CD4+/CD8+ ratio inversion, however no BnAb were 
elicited. Had the trial been conducted for longer the appearance of BnAb may have 
occurred. The induction of such a strong homologous VNA appeared to correlate with the 
reduction in proviral load and thus qualifies the FIV ΔV2 virus as a candidate immunogen. 
The nature of the VNA response needs to be further characterised to determine if the 
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neutralisation target is the V1/V2 homologue or is facilitated by the unmasking of V3 
neutralisation sensitive epitopes by V1/V2 de-glycosylation.  
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Chapter 5 
 
Differentiation of infected from vaccinated cats in a trial 
testing a vaccine based on a chimaeric molecular clone of 
FIV  
 
5.1 Introduction 
 
The relatively lower cost of housing cats compared to non-human primates and the 
similarities between FIV and HIV-1 have allowed studies of FIV pathogenesis and the 
investigation of correlates of immunity to inform future research to develop an efficacious 
HIV vaccine. Prior to the licensing and release of the commercially available FIV vaccine Fel-
O-Vax FIV, a plethora of vaccine studies had tested different viral proteins presented in a 
variety of ways to stimulate different arms of the immune system with variable outcomes.  
To date, the most success has been achieved with whole inactivated virus (WIV) and/or 
inactivated infected cell vaccines (ICV), however some of the first FIV vaccine trials utilised 
recombinant technology to produce subunit vaccines. 
 
5.1.2 Subunit vaccines.  
 
Subunit vaccines typically use viral proteins as the source of immune stimulation. Proteins 
that have been evaluated for their protective effect include recombinant p24, p17, TM and 
SU incorporated in to immune stimulating complexes (ISCOMs). Due to the purity of the 
candidate immunogen, vaccinates seroconvert to only the viral proteins contained within 
the vaccine prior to challenge. Although several FIV vaccine trials utilising subunit vaccines 
have been performed, none have resulted in significant protection and some have even 
shown enhancement of infection (Hosie et al, 1992. Siebelink et al, 1995. Huisman et al, 
1998. Richardson et al, 1997). Siebelink and colleagues (1995) analysed the observed 
enhancement and demonstrated that the enhancement effect could be passively 
transferred to SPF cats. This indicated that the cause of enhancement was likely to be 
antibody mediated, however this was not replicated in a later study (Huisman et al, 1998).  
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5.1.3 Recombinant vaccines. 
 
The use of DNA as a recombinant vaccine has yielded variable results. The viral genes 
incorporated into candidate recombinant vaccines include whole provirus harbouring 
essential deletions in the replication machinery, the entire env gene or fragments of the SU 
gene (Dunham et al, 2006. Hosie et al ,1998 & 2000. Richardson et al, 1997 & 1998. Broche-
Pierre et al, 2005. Gupta et al, 2007). Theoretically, recombinant vaccination using FIV 
provirus containing deletions allows expression of the native form of the viral proteins 
devoid of inactivation artefacts. Accompanied to this is the ability to use biological 
adjuvants instead of conventional adjuvants. Homologous protection was demonstrated 
using this method when cats were challenged with the homologous FIV-Petaluma isolate, 
and decreased viral burdens were observed in vaccinated cats (Hosie et al, 1998). However, 
depending on the strain of challenge virus used, the results were inconsistent and levels of 
protection were consistently lower than using WIV or ICV as immunogens.  
 
5.1.4 WIV and ICV vaccines and the development of Fel-O-Vax FIV. 
 
Protection against FIV infection was first demonstrated following vaccination with WIV and 
ICV by Yamamoto et al (1991). In both cases the FIV-Petaluma isolate was used to elicit 
protection to low dose homologous challenge. The titre of virus neutralising antibodies 
induced by vaccination correlated with protection, however higher virus neutralising 
antibody titres were achieved with ICV compared to WIV, as were T-cell proliferation 
responses. The protection afforded by vaccination with FIV-Petaluma WIV and ICV was 
shown to extend to low dose, intra-clade heterologous challenge with FIV-Dixon, an isolate 
with an Env amino acid sequence that differed by 11% compared to the vaccine strain 
(Yamamoto et el, 1993). However, the Env divergency of the challenge virus is not a 
measure of virulence.  The authors highlight that the amino acid sequence divergency 
observed between FIV-Petaluma and FIV-Dixon is similar to that observed between FIV-
Petaluma and both FIV-Glasgow8 and FIV-PPR. Vaccination with FIV-Petaluma WIV did not 
afford protection to challenge with low dose FIV-Glasgow8 (Hosie et al, 1995), 
demonstrating a disparity between Env amino acid sequence divergence and virulence. It 
was confirmed that the homologous protection reported by Yamamoto et al, (1991, 1993) 
could be reproduced (Hosie et al, 1995) and the titre of anti-Env antibodies correlated with 
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protection, as did the titre of neutralising antibodies (nAb). In a series of experiments in 
which FIV-Petaluma WIV or ICV were assessed for protection against distinct heterologous 
challenge virus strains, only 1/10 cats were protected against FIV-Shizuoka challenge. The 
protected cat had been vaccinated with ICV and it was concluded that protection could not 
be extended to challenge with a virus that differed significantly (21% amino acid 
divergence) in the Env sequence (Johnson et al, 1994). In an effort to broaden immunity to 
heterologous challenge, a dual subtype ICV was developed, consisting of the chronically 
FIV-Petaluma-infected cell line FL4 and FeT1 cells infected with FIV-Shizuoka. FL4 cells are 
IL-2 independent and were derived from FeT1 cells by the gradual depletion of IL-2 from 
infected cultures (Yamamoto et al, 1991). Hohdatsu and colleagues (1997) demonstrated 
no heterologous protection against FIV-Shizuoka following vaccination with a single type 
ICV (FIV-Petaluma) but cats were protected against FIV-Shizuoka challenge when 
vaccinated with a dual subtype vaccine. Unlike previous trials, in which protection was 
associated with the titre of anti-Env antibodies and the titre of nAb, no nAb were detected 
against the FIV-Shizuoka strain of the vaccine, suggesting that protection was mediated by 
cytotoxic T-lymphocytes or other immune effector mechanisms (Hohdatsu et al, 1997). 
However, it is important to note that since the vaccine contained two subtypes of FIV, 
derived from clades A (Petaluma) and D (Shizuoka), the efficacy demonstrated in this study 
constitutes homologous protection. Deviations of this study (dual subtype vaccination of 
FIV-Petaluma and FIV-Shizuoka WIV) showed that 80% of cats could be protected against 
low dose challenge using the distinctly heterologous subtype A/B recombinant virus FIV-
Bangston (Pu et al, 2001). Until this study, the majority of challenge viruses had been 
derived from minimally passaged in vivo derived virus. However, this study used pooled 
plasma or PBMC rather than tissue culture fluid (TCF) as this was thought to represent a 
more realistic challenge to mimic natural infection (Pu et al, 2001. Matteucci et al, 1996).  
 
The dual subtype vaccine was licensed for commercial use in 2002 in the USA based on two 
year-long efficacy studies against challenge with a subtype A virus that differed by 9% and 
20% at the Env sequence compared to the vaccine strains (Pu et al, 2004). The commercial 
vaccine contains 50µg FIV-Petaluma and FIV-Shizuoka WIV and 1.5 – 2.5 x 107 inactivated 
infected FeT-J cells, supplemented with human recombinant IL-12 at 5µg per dose (Omori 
et al, 2004. Coleman et al, 2014). As the commercial vaccine differed from the prototype 
vaccine, further studies were performed to assess protection against low dose subtype B 
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challenge. Protection was demonstrated against FIV-FC1 (Pu et al, 2005), FIV-Amori2 
(Kusuhara et al, 2005) and the heterologous protection was shown to last for a least one 
year after the final immunisation (Huang et al, 2010). However, in a recent study the overall 
protection rate of Fel-O-Vax FIV was 70% when vaccinated cats were challenged with a 
range of isolates that included FIV-Petaluma (Clade A), FIV-Glasgow8 (Clade A), FIV-
Bangston (Clade A/B), FIV-FC1 (Clade B) and FIV-NZ1 (Clade F/C). This protection rate was 
marginally better than that afforded by immunisation with the prototype WIV vaccine and, 
importantly, showed efficacy (40% protection) against challenge with FIV-Glasgow8 
(Coleman et al, 2014). This finding contrasted with the results of a study performed by 
Dunham et al (2006) in which enhancement was observed following low dose FIV-Glasgow8 
challenge. In addition, enhancement and increased susceptibility to infection were also 
reported following vaccination of cats with Fel-O-Vax FIV (Berlinski et al, 2003). 
 
Due to the concerns raised about interference with the sero-diagnosis of FIV and the lack 
of protection against FIV field isolates, the Fel-O-Vax FIV vaccine has not been licenced in 
Europe. In countries where Fel-O-Vax FIV is licensed, veterinary practitioners do not 
routinely vaccinate against FIV and Fel-O-Vax FIV is not considered to be a core vaccine. 
Indeed, the vaccine is no longer manufactured in North America (Nichols et al, 2016), 
whereas vaccination against FIV remains high in Australia (Westman et al, 2016). 
 
The aim of the study described in this chapter was to evaluate the use of a chimeric WIV 
candidate vaccine containing a mutation in the PID of the transmembrane (TM) region of 
Env. By mutating the PID of the FIV ΔV2 virus to that of lion lentivirus subtype E (LLV-E), it 
was predicted that nAb could be elicited and perhaps afford protection against a low dose 
challenge with the virulent isolate FIV-Glasgow8. In addition, by mutating the PID to that 
of LLV-E it was proposed that vaccination with the FIV ΔV2 PID mutant would permit 
differentiation of infected from vaccinated animals.  
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5.2 Method and materials 
 
5.2.1 Principal immunodominant domain (PID) mutation. 
 
The FIV ΔV2 virus was further genetically manipulated so that the PID of this virus was 
mutated to that of FIVple- subtype E. Briefly, the FIV ΔV2 molecular clone was used as a 
template to amplify a segment comprising approximately 500 base pairs of the envelope 
gene. The sequence of the reverse primer was 5'- AAT GGA TTC ATA TGA CAC ATC TTC CTC-3' 
and contained the restriction site for the endonuclease Nde1 (highlighted in red). The 
sequence of the forward primer was 5'- GAG CAT CAA GTA CTA GTA ATA GGA TTA AAA GTA GAA 
GCT ATG GAA AAA TTC TTA TAT ACT GCT TTC GCT ATG CAA GAA TTG GGA TGT AGA GAA CAA CAA 
TTT TTC TGT AAA GTC CCT TTT-3' and contained the restriction site for the endonuclease Spe1 
(highlighted in red). This primer also contained the sequence corresponding to the FIVple-
E PID (highlighted in bold and underlined).  PCR reactions contained 25µl of 2X Roche 
Master mix, 1µl of forward and reverse primers at 100pmol/µl, 1µl of FIV ΔV2 molecular 
clone at 100ng/µl and 22µl of deionised water. The target sequence was amplified using 
the following cycling conditions: 94oC for 5 minutes, then 35 cycles of 94oC for 30 secs, 55oC 
for 30 secs, 72oC for 1 minute, followed by a final extension of 72oC for 10 minutes. The 
amplicon was visualised on a 0.8% agarose gel containing ethidium bromine and then 
extracted, purified and double digested using Nde1 and Spe1(New England Biolabs, Hitchin, 
UK) at 37oC for 3 hours. The digested ends of the PCR product were removed by purifying 
the amplicon through a QIAquick gel extraction column and eluting in 50µl of EB buffer. 
The mutated and digested amplicon was then ligated back into the FIV ΔV2 molecular clone 
(which had also been double digested and purified) by incubating the molecular clone and 
PCR product at a ratio of 1:3 with 1µl of T4 DNA ligase at 5U/µl in a total of 20µl (Invitrogen, 
Paisley, UK). The reaction was then incubated at 14oC overnight, after which DH5α 
Maximum efficiency cells Genotype:  F- Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (rk-, mk+) phoA supE44 λ-thi-1 gyrA96 relA1(Invitrogen, Paisley, UK) were 
transformed using the ligation reaction. Briefly, 3µl of ligated DNA were incubated with 
30µl of DH5α cells at 4oC for 30 minutes. The cells were then heat shocked at 42oC for 40 
seconds and allowed to cool on ice for 2 minutes. Four hundred microliters of SOC broth 
were added to the cells and the culture was incubated at 37oC for 1 hour. The cultures were 
then added to kanamycin selection plates (200µl of culture per plate) and incubated 
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overnight at 30oC. Colonies were picked and re-cultured into ~5mls of kanamycin selection 
LB broth and incubated at 30oC overnight whilst being agitated at 250rpm. Plasmid DNA 
was then extracted from the cultures using the Qiagen miniprep kit and positive colonies 
were identified by double digestion of the plasmid DNA with Nde1/Spe1. Colonies that 
were positive had their entire envelope sequenced to ensure that the V2 PNGS mutation 
was still intact and that the PID had been mutated to that of FIVple-E. DNA from colonies 
that retained the same envelope sequence as the FIV ΔV2 envelope but carried the PID 
sequence of FIVple-E was used. Fifteen micrograms of this DNA were used to transfect 293T 
cells, as described in Materials and Methods (Chapter 2) and the resulting virus was named 
the DIVA virus. Initial stocks of DIVA virus were grown in Mya-1 cells, after which the culture 
fluids were clarified through a 0.45µM filter, aliquoted and stored at -80oC until needed. 
 
5.2.2 FIV envelope DNA sequencing 
 
DNA sequencing was performed to obtain the consensus nucleotide sequence of either 
amplified or cloned DNA.  First, 5µl of amplified DNA (20-80ng/µl) or 5µl of plasmid DNA 
(80-100ng/µl) were mixed with 5µl of primer at 5pmol/µl in an eppendorf tube. The 
nucleotide sequences of the primers used in sequencing reactions are shown in Appendix 
1. Eppendorf tubes were labelled with barcodes and shipped to the GATC Biotech European 
Custom Sequencing Centre in Cologne, Germany. Using the Lightrun sequencing service, 
DNA was sequenced using the Sanger method. Sequence data were downloaded from the 
GATC Biotech website (www.GACT-biotech.com) in the .ab1 format and analysed using 
DNADynamo (Bluetractor software). 
5.2.3 HIV(FIV) luciferase pseudotype production. 
 
HIV(FIV) pseudotypes carrying the firefly luciferase reporter gene (HIV(FIV)-luc) were 
prepared using the HIV pNL4-3 construct kindly provided by Dr N Landau.  This construct 
contains the firefly luciferase gene in place of the deleted nef gene (pNL4-3.Luc.R-.E-).  
Figure 5-1 briefly illustrates the methodology for pseudotype production. For each 
pseudotype, a 10cm2 petri dish (Corning, Warrington, UK) was seeded with 2x106 293T cells 
in 10mls of complete DMEM and incubated overnight at 37oC in a humidified incubator to 
allow the cells to adhere. The following day, 7.5µg of both pNL4-3.Luc.R-.E  and the VR1012 
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vector containing full-length FIV env were mixed with 300µl of serum free DMEM. The DNA 
was precipitated into complexes following the addition of 60µl of polyethylenimine (PEI). 
The reactants were briefly vortexed and centrifuged and the DNA allowed to precipitate at 
room temperature for 20 minutes. The transfectants were added to the 10cm petri dish 
and incubated at 37oC for 72 hours in a humidified incubator. The culture fluids containing 
the pseudotype was then centrifuged at 1000rpm for 5 minutes, filtered using a 0.45µm 
filter, aliquoted and stored at -80oC.  
 
 
Figure 5-1. A schematic representation of HIV(FIV) pseudotype production. After co-
transfection of both plasmids, translation produces the structural and replication 
apparatus of HIV. The HIV gag protein facilitates formation of immature, naked virions 
containing two copies of the HIV genome captured by the signal sequence (Ψ). Upon 
budding, FIV envelope glycoproteins are incorporated onto the virion surface. This allows 
for the creation of a pseudotype particle that is capable of entry into FIV susceptible cells, 
but are restricted to one round of infection, since the genome contains no FIV env gene. 
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5.2.4 Neutralisation assay 
 
Samples of plasma collected in heparin or as sera were screened for FIV neutralising 
antibodies (nAb) using the HIV(FIV) luciferase pseudotype assay that has been described 
previously (Beczkowski et al, 2015). The work flow and principle of the assay is illustrated 
in figure 5-2. 
 
  
Figure 5-2. A schematic representation of the neutralisation assays work flow. Plasma 
containing FIV antibodies are incubated with pseudotype for one hour before the addition 
of FIV susceptible cells. After 72 hours, substrate is added and luminescence is detected by 
the 1460 microbeta liquid scintillation and luminescence counter. The principle of the 
assays is based on the incubation of the pseudotyped virus with plasma containing FIV 
antibodies that will inhibit cell entry should virus neutralising antibodies be present in the 
plasma. As the pseudotyped virus contains two copies of the HIV genome, that is nef 
deleted and carries the firefly luciferase gene in its place, translation of the luciferase gene 
produces the enzyme luciferase. Upon addition of luciferin substrate, luminescence is 
produced that can then be measured. Should the plasma sample contain virus neutralising 
antibodies, the pseudotype is prevented from cell entry and no luciferase luminescence is 
produced (neutralisation). Should the plasma sample contain no virus neutralising 
antibodies, the pseudotyped virus can enter the cell and large amounts of luciferase 
enzyme are produced, resulting in a large amount of luminescence being produced upon 
addition of luciferin substrate. As the pseudotyped virus contains only FIV envelope 
glycoproteins, since it was translated from a pure plasmid preparation, the assay is highly 
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specific for FIV virus neutralising antibodies. Additionally, due to the 72-hour incubation 
time, any pseudotype that is not neutralised and enters the cell is able to produce large 
amounts of luciferase that is readily detected upon substrate addition. 
 
Firstly, plasma samples were heat inactivated for 30 minutes at 56oC to inactivate 
complement before 4 serial 10 fold dilutions of the plasma were prepared in complete 
RMPI media. Plasma dilutions (25µl) were added to the wells of 96 well opaque culture 
plates (Perkin Elmer, Seer Green, UK) and incubated with 25µl of HIV(FIV) pseudotype for 
1 hour at 37oC in a humid incubator. After incubation, 50µl of CLL-OX40 cells at 5 x 105/ml 
were added to each well and the plates were incubated at 37oC for 72 hours in a humid 
incubator. Next, 100µl of Steadylite HTS substrate (Perkin Elmer, Seer Green, UK) were 
added to each well, the plates were sealed (Perkin Elmer optical plate seals, Perkin Elmer, 
Seer Green, UK) and the reactions allowed to develop for 10 minutes. Luminescence was 
measured on the 1460 Microbeta liquid scintillation and luminescence counter (Microbeta, 
California, USA). 
 
The neutralising activity of each sample was determined by calculating the percentage and 
fold neutralisation using the following equations: 
 
 Percentage neutralisation = 
        mPS-mNPC     x 100 
           mNPC   
 
Where mPS = mean luciferase count of sample wells in counts per minute (cpm) 
           mNPC = mean luciferase count of the no plasma control wells in cpm 
 
Fold neutralisation =   mNPC/mPS 
 
 
5.2.5 Immunogen production. 
 
DIVA virus was grown to large volumes in CLL-OX40 cells as detailed in table 5-1. After the 
virus in the culture fluids had been inactivated using 0.5% (w/v) paraformaldehyde, the 
fluids (approximately 1L in volume) were concentrated approximately 5-fold using the 
Centramate™ tangial flow concentrator with the Omega 300kDa medium screen channel 
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(Pall life sciences, Portsmouth, UK). The retentate was layered over 5mls of 0.45µm-
filtered, 20% sucrose solution in thin walled, ultraclear™ SW28 tubes (Beckman Coulter, 
High Wycombe, UK) and centrifuged on the Sovall WX100 ultra-centrifuge for 2 hours at 
107000g at 4oC using the TH-641 SW28 rotor (Thermoscientific).  The ultrafiltrate was 
aspirated and discarded and the viral pellets were resuspended in 6mls of sterile PBS and 
loaded into thinwalled, ultraclear™ SW41 tubes (Beckman Coulter, High Wycombe, UK) and 
centrifuged on the Sovall WX100 ultra-centrifuge for 90 minutes at 116000g at 4oC using 
the Surespin 630 SW41 rotor (Kendro, Connecticut, USA). The ultrafiltrate was aspirated 
and the pelletted virus was resuspended in 2mls of sterile PBS and dialysed extensively 
against 10 changes of 2L sterile PBS at 4oC. Post dialysis, the total protein concentration of 
the whole inactivated virus (WIV) immunogen was estimated by the Bradfords Coomassie 
assay and stored frozen at -80oC until immunisation was due to take place.     
 
5.2.6 Experimental vaccination using the DIVA virus. 
 
For logistical reasons, the DIVA WIV was combined with Versifel FeLV vaccine that 
contained a commercial adjuvant with proven safety and efficacy in cats (Zoetis, Brabant 
Wallon, Belgium). Briefly, 4 doses of Versifel FeLV were pooled in a 15ml falcon tube using 
a sterile 22G needle. Four doses of DIVA WIV (250µg per dose) were added to the pooled 
Versifel FeLV vaccine and mixed before the di-valent vaccine was replaced in the Versifel 
FeLV vials using a 22G needle (approximately 1.2mls per vial). This process was repeated 
with another 4 doses of Versifel FeLV using sterile PBS instead of DIVA WIV to prepare the 
control vaccine. 
 
Eight specified pathogen free (SPF) kittens of 8 weeks of age were divided into two groups 
of 4 kittens. This allocation was based on an arbitrary equal distribution of males in both 
groups (in case castration had any effect upon challenge) and that both groups had roughly 
the same average age, again to remove any bias.  Following a week of acclimatisation, the 
kittens in Group 1 (vaccinates) were vaccinated subcutaneously at study weeks 0, 3 and 6 
(at 15, 18 and 21 weeks of age respectively) with 1.2ml of the test FIV vaccine. At the same 
time, the kittens in Group 2 (controls) received the control vaccine containing PBS alone. 
At weeks -6 and 1 of the study (9 and 16 weeks of age respectively), both groups received 
additional vaccinations with PureVax-RCP plus FeLV to protect against feline herpesvirus, 
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feline calicivirus and feline panleukopaenia virus, since the cattery had a history of feline 
herpesvirus infection. Ten weeks after the final test FIV vaccination, all of the kittens were 
challenged with 20 cat infectious doses 50% (ID50) of the infectious molecular clone FIVGL8-
414 that had previously been titrated in vivo. FIVGL8-414 is a highly pathogenic primary UK 
isolate of FIV that is thought to be representative of isolates that are transmitted in the 
field. Vaccinates and controls were bled according to the schedule shown in Table 5-2 from 
the jugular or cephalic vein using 20-22G needles. Blood samples collected in heparin and 
EDTA were shipped overnight from the trial facility (Charles Rivers Laboratories, Co Mayo, 
Ireland) to the Retrovirus Research Laboratory at the University of Glasgow by courier and 
were processed within 24 hours of collection.
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Table 5-1. Production of DIVA virus immunogen in CLL-OX40 cells.
Days post 
infection.  
Action.  
0 
5mls of CLL-OX40 cells at 1 x 106/ml were infected with 2000 TCID50 of DIVA virus (TCID50 calculated 
following titration on Mya-1 cells). Cells were incubated in a T25 culture flask at 37oC overnight in a 
humidified incubator. 
1 
The cells were centrifuged at 1000rpm for 5 minutes and a culture was set up in 5mls of fresh complete 
RPMI. The infected cells were incubated in a humidified incubator at 37oC. 
4 
The cells were added to 10mls of complete RPMI and transferred to a T75 culture flask. The flask was 
incubated at 37oC in a humidified incubator.  
7 The infected culture was subcultured (cells and SN) and added to 30mls of 1 x10
6/ml of fresh CCL-OX40 
cells in 2xT150 culture flasks. Flasks were incubated at 37oC in a humidified incubator. 
11 
The cultures were centrifuged at 1000rpm for 5 minutes. The supernatant was aspirated and clarified 
through a 0.45µm filter and stored in a sterile glass bottle at 4oC. The cell pellet was counted and cells 
were recultured at 1x 106/ml in fresh complete RPMI in 4 T150 flasks. Fresh cells were added to 
maintain the cell density at 1 x 106/ml if required. Cultures were incubated at 37oC in a humidified 
incubator. 
15 The infected cultures were subcultured 1 in 2 (cells and SN) and added to 20mls of 2 x10
6/ml of fresh 
CCL-OX40 cells in 8xT150 culture flasks. Flasks were incubated at 37oC in a humidified incubator 
18 20mls of culture (cells + SN) were added to 20mls of fresh complete RMPI and set up in 16xT150 culture 
flasks. Flasks were incubated at 37oC in a humidified incubator 
21 
Cultures were centrifuged at 1000rpm for 10 minutes to pellet the cells. The supernatant was aspirated 
and pooled with the supernatant that had been collected on day 11. The pooled supernatant was twice 
clarified through a 0.45µm filter and treated with 0.5% formaldehyde for 24 hours at 4oC to inactivate 
the virus. The culture fluids were agitated using a magnetic stirring rod to ensure thorough inactivation 
of the virus.  
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Table 5-2. Immunisation, sampling and analysis schedule of the experimental DIVA FIV vaccine trial. a#, Vaccination with PureVax-RCP and FeLV 
(inactivated feline herpesvirus (FHV) strain F2, inactivated feline calcivirus (FCV) strain 431/G1, attenuated feline panleukopaenia virus (FPV), FeLV 
recombinant canarypox virus (solvent) and 23µg gentamicin. b, 1. DIVA ELISA, 2. Gag qPCR, 3. Immunostain analysis, 4. Neutralisation assay, 5. Virus 
isolation. 
Week of 
study 
Age of 
subjects 
(weeks) 
Sample Procedure aExperimental notes bAssays performed. 
-7 8   0.5ml EDTA, 0.5ml hep Blood sample  1,2,3  
-6 9 None PureVax-RCP + FeLV #   
-3 12 0.5ml EDTA, 0.5ml hep Blood sample  1,2,3 
0 15 0.5ml EDTA, 0.5ml hep FIV Immunisation 1  1,2,3 
1 16 None PureVax-RCP + FeLV #   
3 18 2.0ml EDTA, 5.0ml hep FIV Immunisation 2  1,2,3 
6 21 2.0ml EDTA, 5.0ml hep FIV Immunisation 3  1,2,3 
10 25 2.0ml EDTA, 5.0ml hep Blood sample  1,2,3 
13 28 2.0ml EDTA, 5.0ml hep Blood sample  1,2,3 
16 31 2.0ml EDTA, 5.0ml hep Day of challenge 20 ID50 FIV-GL8 414 1,2,3,4,5 
19 34 2.0ml EDTA, 5.0ml hep 3wpc  1,2,3,5 
22 37 2.0ml EDTA, 5.0ml hep 6wpc  1,2,3,5 
25 40 2.0ml EDTA, 5.0ml hep 9wpc  1,2,3 
28 43 2.0ml EDTA, 5.0ml hep 12wpc  1,2,3 
28 43 Exsanguination 12wpc 
Exsanguination and post mortem 
examination. Tissue collection. 
1,2,3 
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5.3 Results. 
 
5.3.1 Immunogen production. 
 
To determine the optimal time to harvest the DIVA virus, time course experiments were 
performed to monitor the growth of both the DIVA and FIV ΔV2 viruses. Initial virus stocks 
were grown on the primary feline lymphoblastoid Mya-1 cells. However, Mya-1 cells are an 
unattractive target cell for the large-scale production of vaccine immunogen because of 
their slow rate of growth, sensitive nature and dependence on IL-2. In contrast, the CLL-
OX40 cell line that stably expresses feline OX40 is IL-2 independent, grows rapidly and is 
more robust than Mya-1 cells. For this reason, we compared the growth kinetics of both 
viruses in the CLL-OX40 cell line to determine whether it would be a suitable cell line for 
the production of large quantities of DIVA vaccine virus.  
 
5.3.2 Growth of FIV ΔV2 and DIVA viruses in CLL-OX40 cells 
 
CLL-OX40 cells were infected with 2000 TCID50 of either FIV ΔV2 or the FIV DIVA virus and 
the cultures were monitored by p24 ELISA and by immunostaining of 1ml samples of 
purified culture fluid. As shown in Figure 5-3, the CLL-OX40 cells produced more DIVA virus 
than FIV ΔV2 in the early stages of infection. This difference is likely attributable to the PID 
mutation, since both viruses are otherwise identical. It is possible that the PID mutation 
facilitates a more rapid/secure binding of the fusion peptide with the cell membrane, 
increasing viral entry; however, this was not investigated further. The levels of p24 
continued to increase until day 18 when there was a dramatic decrease in virus production. 
To investigate this further, the cell counts of the infections were analysed (Figure 5-4) to 
assess whether the reduction in p24 production could be explained by the lack of viable 
cells. However, the cell numbers did not explain the dramatic reduction in p24 levels as the 
cell counts increased from day 21. FACS analysis of the cells from both infections (Figure 5-
5) revealed that the number of target cells decreased by approximately 60% at 29 days’ 
post infection and by almost 95% by day 36 post infection. This finding explained the 
dramatic reduction in p24 levels and the increase in CLL-OX40 cell numbers. Although the 
cells were engineered to stably express feline OX40, the virus growth selected for cells that 
did not express feline OX40. This resulted in an expansion of the wild type CLL cells that 
154 
 
were not susceptible to virus infection and so the cell count was maintained or even 
increased while the level of virus production decreased.  
 
It was concluded that CLL-OX40 cells were suitable for the large-scale production of vaccine 
virus and the immunogen production method described in Table 5-1 was developed. 
 
 
Figure 5-3. Growth kinetics of FIV ΔV2 and DIVA viruses in CLL-OX40 cells. Peak virus 
production, as determined by FIV p24 production, was observed at day 18 of the infection. 
Therefore, culture fluids were collected on day 21 for the production of the vaccine 
immunogen. 
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Figure 5-4. CLL-OX40 cell growth during the production of FIV ΔV2 and DIVA viruses. 
Green arrow indicates that fresh cells were added to the FIV ΔV2 infection to maintain a 
cell density of 1 x 106/ml. The red arrow indicates that fresh cells were added to the DIVA 
virus infection to maintain a similar cell density  
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Figure 5-5. OX40 expression on CLL-OX40 cells during the propagation of FIV ΔV2 and 
DIVA viruses. The surface expression of OX40 was markedly reduced in both infections by 
day 36 post infection. Infected cultures were supplemented with fresh CLL-OX40 cells after 
sampling on day 36. This accounted for the increase in OX40 expression observed between 
days 36 and 39. CLL-OX40 = Uninfected CLL-OX40 cells stained for feline OX40, No Ab = 
Unstained, uninfected CLL-OX40 cells. 
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5.3.3 Immunostain analysis 
 
Immunostain analysis revealed that the DIVA virus grew more rapidly than FIVΔV2 in CLL-
OX40 cells. Four days’ post inoculation, immunostaining of viral lysates using a pooled 
polyclonal FIV anti-serum revealed all of the major viral bands from the DIVA virus 
infection, whereas a strong response to p24 but only weak responses to p55 and p10 were 
evident in the FIVΔV2 infection (Figure 5-6) 
 
Figure 5-6. Immunostain analysis of virus collected on days 4 and 7 from cultures of CLL-
OX40 cells infected with the FIV ΔV2 and DIVA viruses. Although only semi-quantitative, 
it appeared that more DIVA than FIV ΔV2 virus was released into the culture fluid early in 
infection. This finding was consistent with the p24 production observed during the early 
stages of infection. 
 
The appearance of both the DIVA and FIVΔV2 envelope glycoprotein (Env) on immunostain 
was similar to that previously observed for the FL4 vaccine strain of FIV (Figure 5-7). The 
predicted amino acid sequence of the Env of FIV derived from FL4 cells suggests that two 
potential N-linked glycosylation sites (PNGS) at the base of the V2 loop are absent 
(Samman, 2010). Similarly, the DIVA virus has a single PNGS that is missing at the apex of 
the V2 loop (Samman, 2010). The lack of the single PNGS within the DIVA virus Env would 
not account for the appearance of the Env observed by immunostain, as the amino acid 
sequence of the DIVA virus Env showed no additional mutations of PNGS had occurred 
during mutation and cloning of the DIVA virus. To investigate this observation further, we 
compared the Env of both the FIV ΔV2 and DIVA viruses when grown in either Mya-1 or 
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CLL-OX40 cells. As can be seen in Figure 5-5, both viruses displayed Envs of lower molecular 
weight when grown in CLL-OX40 cells compared to Mya-1 cells. The ‘sharpness’ of the 
bands also indicated that the Envs were either less heavily glycosylated or had different 
glycosylation as a result of having been grown in canine cells rather than feline cells. This 
might imply that the Env would be less shielded by glycosylation and hence be more 
accessible to neutralising antibody if the DIVA virus was grown in CLL-OX40 cells. 
 
Based on all these findings, it was decided to grow the DIVA virus in CLL-OX40 cells for 21 
days. The rapid virus growth kinetics, robustness, IL-2 independence and high levels of Env 
produced by CLL-OX40 cells made them an ideal candidate for vaccine virus production.    
 
 
Figure 5-7. The envelope phenotype of FIV ΔV2 and DIVA virus grown in both CLL-OX40 
and Mya-1 cells compared to FL4 vaccine virus. The altered phenotype of the viral 
envelope when grown in CLL-OX40 cells is predicted to expose more of SU potentially aiding 
in the development of VNA. M = Mya-1, B = CLL-OX40. Proteins stained with the 
monoclonal antibody Vpg71.2 recognising FIV envelope.  
 
5.3.4 Virus inactivation. 
 
To ensure that the vaccine preparation had been completely inactivated, a single dose of 
purified and dialysed virus (250µg) was incubated with Mya-1 cells and FIV p24 levels in the 
culture fluids were monitored, following the procedure outlined in Table 5-3. 
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Days post 
inoculation 
Action O.D. 650nm 
-1 
250µg inactivated DIVA virus cultured 
with 5mls of Mya-1 cells at 1 x 106/ml 
N/A 
0 Cells washed with 3x 13mls PBS N/A 
3 Sampled- Washed with 3x 13mls PBS 0.220 
6 Sampled 0.053 
9 Sampled - Cultured in T75 0.040 
12 Sampled and media changed 0.044 
15 Sampled 0.041 
18 Sampled 0.049 
20 Sampled 0.039 
Mya-1 N/A 0.041 
DIVA (positive) N/A 0.898 
Negative N/A 0.044 
Table 5-3. The FIV p24 levels of the cultured inactivated DIVA virus.  Although FIV p24 
could be detected in culture fluid three days post inoculation, it could not be detected six 
days post inoculation once another wash step had been performed. FIV p24 could not be 
detected at any time point after day six of inoculation, indicating that the virus was indeed 
inactivated.  
 
When residual inactivated DIVA virus had been thoroughly washed away, the levels of FIV 
p24 detected in the sampled culture fluid were similar to those of the negative control. This 
confirmed that the DIVA virus was not actively replicating. Importantly this process 
confirmed the effectiveness of the dialysis step as Mya-1 cells are particularly sensitive to 
culture additives. The Mya-1 cells remained confluent and healthy throughout the 20-day 
experiment, indicating that all of the paraformaldehyde inactivating agent had been 
removed. On this basis, it was concluded that the DIVA virus had been inactivated 
completely and was safe to be administered to the study animals.  
5.4 Vaccination of cats using the DIVA virus. 
 
5.4.1 Immunisation of cats with DIVA WIV. 
 
All cats received the experimental FIV vaccine (vaccinates) or control vaccine (controls) 
according to the immunisation schedule in table 5-2. There were no reported adverse side 
effects at the sites of injection or as a result of the immunisations. At -6 week of the study, 
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1 cat (A842) displayed clinical signs of mild oedema of the conjunctiva of the left eye and 
mild epiphora. This kitten was treated with 10mg of oral Veraflox once daily for 7 days, and 
the remaining 7 kittens received prophylactic treatment with the same drug at the same 
dose. No further clinical signs were reported and all kittens were healthy on the day of the 
first immunisations. 
 
5.5 Serological analyses 
 
5.5.1 Immunostain analysis. 
 
Of the 4 cats that received the FIV vaccine, all developed antibodies recognising the 
structural proteins p55, p24 and p17 by week 3 of the study (Figure 5-8). By week 10 of the 
study, when all 3 immunisations had been administered, all of the cats had fully 
seroconverted to all of the major structural viral proteins. This response was maintained in 
3/4 vaccinated cats until the day of challenge. No antibody response to the SU protein was 
detected in cat A842 until week 10 of the study and this response appeared to be transient, 
as no anti-SU response was subsequently detected until after the day of challenge. Since 
the antigen on the PVDF membrane was purified FIV ΔV2 (containing the wild type PID) and 
the vaccinates had been immunised with the DIVA virus containing the mutated PID, it 
might be expected that the antibody response to the TM protein would be absent or 
diminished. This was indeed evident in all vaccinates until week 19 of the study (Appendix 
5) when vaccinates developed antibodies recognising the wildtype PID, 3 weeks after 
challenge. None of the 4 unvaccinated control cats showed evidence of seroconversion 
until week 22 of the study; all had sero-converted to all the major structural viral proteins 
by the end of the study at week 28. 
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Figure 5-8. Serological responses of representative vaccinated and control cats. Results 
are shown for vaccinate A843 and control A847. (Responses of all cats shown in Appendix 
5). Sero-conversion to viral proteins was evident at 3 weeks’ post immunisation in the 
vaccinated cat. There was no antibody response to FIV in the control cat prior to challenge. 
Small blue arrows indicate timings of immunisations, whilst the large red arrow indicates 
the day of challenge.  
 
5.5.2 DIVA ELISA 
 
All 4 vaccinated cats responded strongly to the LLV-E peptide and maintained a   strong 
reaction to it until the day of challenge (Figure 5-9). Very little cross reactivity could be 
demonstrated against the FIV peptide, although one cat (A841) exhibited marginal cross 
reactivity. Following challenge, a dramatic increase in reactivity against both the LLV-E and 
FIV peptides was observed. The finding that the LLV-E reactivity was boosted post challenge 
indicated that immunological memory might have been induced by vaccination with the 
DIVA virus. However, the dramatic prolonged increase in reactivity to the FIV peptide 
observed post challenge suggested that the challenge virus actively replicated in the kittens 
and that the vaccinates were not protected against the FIV-GL8 414 challenge. The 4 
control cats did not demonstrate an antibody response to either peptide until week 19 of 
the study (3 weeks post challenge). This finding confirmed the specificity of the peptide 
encoding the FIV PID (since the control cats have been vaccinated against the retrovirus 
FeLV). The cross reactivity between the 2 peptides, post challenge, was substantially less in 
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the controls than the vaccinates and can be explained as minimal cross reactivity as 
observed in the pathogenesis trial (Chapter 4).  Despite the concerns regarding protection 
against challenge, immunisation with the DIVA virus allowed the differentiation of infected 
from vaccinated animals.  
 
5.5.3 Virus neutralising antibody responses  
 
To determine whether the SU specific antibody response induced following immunisation 
included the production of virus neutralising antibodies (nAb), neutralisation assays were 
performed using the heparinised plasma samples collected from each cat on the day of 
challenge. No significant decrease in the luciferase activity was observed compared to the 
no plasma control (Figure 5-10) indicting that no nAb were detected. Based on these finding 
alone it was concluded that immunisation with the DIVA vaccine elicited envelope specific 
antibodies, however these were not neutralising.
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Figure 5-9. Serological differentiation of infected and vaccinated cats. Vaccinates (A841-4) and controls (A845-8) clearly displayed different reactivities 
against the two TM peptides tested. Until the day of challenge (large arrow) vaccinates demonstrated antibodies recognising the LLV-E TM, the antibody 
responses increasing with each immunisation (small arrows).  
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Figure 5-10. No neutralising antibodies were produced prior to challenge.  The mean luciferase activity (Left) and fold neutralisation (Right) of vaccinates 
and controls, tested on the day of challenge, are shown. The mean luciferase activity observed for both vaccinates (Orange) and controls (Black) were 
both similar to that of the no plasma control (NPC), consistent with a lack of neutralisation. This was confirmed when the fold neutralisation was calculated 
(Right); no nAb were detected, responses were absent when fold neutralisation was related to percentage neutralisation (Right legend).  
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5.5.4 Virus isolation and proviral load.  
 
Although the complete inactivation of the vaccine virus had previously been established in 
vitro, it was important to determine if any residual infectivity remained in vivo, since cats 
might be more sensitive to lower infecting doses than cells in culture. Since virus isolation 
is considered the reference standard for diagnosing FIV infection, PBMCs were purified 
from each cat on the day of challenge and cultured with Mya-1 cells for 21 days, as 
described in materials and methods. As shown in figure 5-11, no FIV p24 was detected in 
culture fluids after 21 days of co-cultivation. Next, DNA was extracted from the cultures 
and a nested PCR was performed that would amplify the env gene (data not shown). No 
env genes could be amplified from any sample, confirming that there had been no residual 
infectivity in the vaccine preparation. Additionally, this validates the inactivation protocol. 
 
 
Figure 5-11. No FIV p24 was detected in the VI culture fluids derived from the day of 
challenge (as determined by p24 ELISA). Orange bars represent vaccinates and black bars 
controls. The negative control (Mya-1, green bar) was culture fluid collected from 
uninfected Mya-1 cells and the positive control (DIVA, red bar) was culture fluid derived 
from Mya-1 cells infected the DIVA virus.  
 
Virus isolation was performed at study weeks +3 and +6 (Figure 5-12). At week +3 of the 
study, FIV p24 was detected in culture fluids from all but one cat (A846) after 21 days of 
co-culture. At study week +6, FIV p24 was detected in culture fluids of all co-cultures after 
7 days.  As the one cat that virus could not be isolated from at study week +3 was in the 
control group, it was possible that immunisation with the DIVA vaccine might have led to 
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enhanced infection, as virus was readily isolated from all the vaccinates before the controls. 
To assess whether or not enhancement had occurred, proviral load was determined using 
a qPCR method designed to amplify a conserved region of the gag gene.  
 
Figure 5-12. Levels of p24 detected in VI culture fluid at study weeks +3 and +6. At Study 
week +3 the individual co-cultures were maintained for 21 days and then the culture fluid 
tested in triplicate by ELISA.  At study week +6, all samples tested positive by day 7; these 
samples were tested singularly. Virus isolation is used as a binary measure of FIV infection 
whereby samples are either positive or negative. As all individual co-cultivations had tested 
positive by day 7 on study week +6, it was deemed unnecessary to continue the 
experiment, resulting in enough material from each individual co-cultivation to be screen 
singularly for the presence of p24 antigen.    Orange bars represent vaccinates and black 
bars controls. The negative control (Mya-1, green bar) is culture fluid from uninfected Mya-
1 cells and the positive control (DIVA, red bar) is culture fluid derived from Mya-1 cells 
infected with the DIVA virus.  
 
 
As shown in Figure 5-13, all cats displayed increasing proviral loads after challenge, which 
then decreased to the set point. However, it was noted that cat A842 displayed a markedly 
higher initial proviral load compared to the other cats. The proviral load of cat A842 then 
decreased to a level more similar to that of the other cats, however by study week +9 the 
viral load had increased again and continued to increase until the end of the study. When 
comparing the mean proviral loads of the 2 groups, it was clear that the vaccinates had a 
higher mean proviral load from study week +3 until the end of the trial. This difference in 
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proviral load was statistically insignificant between the 2 groups (p= 0.15, Kruskal-Wallis 
test). 
 
 
 
Figure 5-13.  Proviral load of vaccinates and controls from the day of challenge until the 
end of the study. When the proviral loads of each cat at each time point was compared 
(Left) it was difficult to identify a trend between the vaccinates (Orange) and controls 
(Black).  However, the proviral loads were comparable with other studies where FIV GL8 
414 had been used as the challenge virus. When the mean proviral loads of both groups 
were compared at each time point (Right), an insignificant difference was observed, with 
the lower mean proviral load in the control group (p= 0.15, Kruskal-Wallis test). 
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5.5. Conclusion. 
 
In this vaccine trial, it has been demonstrated that vaccination with DIVA WIV does not 
protect cats against low dose FIV-Glasgow8 challenge. Refectory to protection, vaccination 
with DIVA WIV appeared to enhance infection as demonstrated by the higher proviral load 
and the ability to isolate virus from PBMCs in all vaccinates sooner than the controls. The 
aim of this trial was to attempt and elicit protection against FIV-Glasgow8 by the production 
of VNA. Previous research on the ancestral envelope glycoprotein of the DIVA virus, 
designated 206394 (Samman, 2010. PhD thesis), characterised a unique mutation at the 
apex of hypervariable loop 2 (V2). Incorporation of the V2 PNGS mutation into the FIV-
Glasgow8 env rendered the pseudotyped virus approximately 5 times more sensitive to 
neutralisation by plasmas containing BnAb. The evaluation of the chimeric virus, FIV ΔV2, 
demonstrated that the V2 PNGS mutation elicits strong homologous VNA but failed to elicit 
heterologous VNA (Chapter 4). In this study neither homologous or heterologous VNA were 
elicited. The prototype Fel-O-Vax FIV vaccine inactivates the incorporated virus in 1.25% 
paraformaldehyde compared to our inactivation method of 0.5%. This concentration of 
inactivate had been used previously by our lab (Hosie et al, 2000) and was chosen as it 
completely inactivated the virus and was believed to preserve the immunogenicity of the 
envelope glycoprotein, preserving the envelopes neutralisation sensitive phenotype. Other 
FIV vaccination trials utilising paraformaldehyde as the inactivating agent have reported it 
be a mild inactivant, however no studies have assessed the degree of cross-linkage induced 
by paraformaldehyde inactivation nor the preservation of immunogenic determinants. 
Studies by Rosso et al (1998) demonstrated that inactivation of HIV-1MN/HIV-1LAI and SIVmne 
by formalin treatment to be as harsh as heat inactivating the virus at 56oC for 2 hours with 
a resulting loss of around 75% of the antigenicity, when measured by whole virus 
precipitation using the HIV-1 monoclonal antibody gp120 d48.  This protein modification of 
antigenicity was also shown for cellular derived proteins demonstrating that the loss of 
antigenicity to a function of the inactivating method and not the antigen. Preservation of 
antigenicity by inactivating HIV-1MN and SIVmne using 1,5 iodonaphthylazide (INA) was also 
demonstrated as determined by an ELISA utilising the BnAb as capture antibodies (Raviv et 
al, 2005). Extensive cross linkage of the viral envelope may explain the lack of detectable 
homologous and heterologous VNA. It has previously been demonstrated that alterations 
to the net charge of the V3 loop can facilitate alterations to the tropism and neutralisation 
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sensitivity of FIV (de Parseval et al, 2006. Lombardi et al, 1993). Should challenge with the 
FIV ΔV2 virus elicit V3 specific VNA, chemical inactivation of the DIVA virus may render it 
neutralisation resistant/inaccessible. 
 
Although there was no statistically significant difference in proviral load between 
vaccinates and controls it is apparent that the vaccinates became infected before the 
controls. Regardless of whether one or all cats demonstrate enhancement, it is the third 
documentation of enhancement when using FIV-Glasgow8 as the challenge strain (Hosie et 
al, 1992. Dunham et al, 2006). Although in this study the causes of enhancement were not 
further examined, the use of FIV-Glasgow8 as a challenge strain offers the opportunity to 
study the mechanisms of lentivirus enhancement of infection. Since there appears to be no 
increase in the titre of pseudotyped virus when performing the neutralisation assay, this 
would indicate that the observed enhancement is not antibody mediated. As enhancement 
of infection has been demonstrated when vaccinating animals with FIV envelopes 
harbouring mutated PIDs (Richardson et al, 1997) it is not possible to claim the 
enhancement observed is mediated by complement as further studies would need to be 
carried out to delineate the cause of enhancement. Adding to this problem is the nature of 
the vaccine preparation administered.  
 
Although the induction of immunological memory was not directly measured, the ELISA 
results would indicate that memory B-cells have been elicited. The large and rapid 
anamnestic antibody response observed immediately after challenge supports this 
hypothesis. Initially we wanted to assess the strength of the CTL response induced by 
vaccination with the DIVA virus, however as none of the cats were protected and the 
ELIspot assay is time consuming, we decided not to investigate this further. A positive 
aspect of the vaccination trial was the ability to differentiate infected from vaccinated 
animals using the DIVA virus. We observed an increase in the titre of antibodies recognising 
the LLV-E peptide with every boost immunisation. In two of the cats (A843 and A844) this 
titre remains at relatively high levels until the day of challenge, in cats A841 and A842 the 
titre drops to relatively low levels by the day of challenge, however it was still possible to 
DIVA at this point. The duration of the antibody response to the LLV-E peptide remains to 
be established and the usefulness of the DIVA ELISA would need to be evaluated for its 
ability to DIVA on plasma samples derived from cats that were last immunised further than 
169 
 
6 months ago. This is however the first documented case of DIVA of FIV, and unlike other 
FIV DIVA strategies, this allows for the differentiation of vaccinated from uninfected 
animals unlike previous attempts (Kusuhara et al, Levy et al, Westman et al, Litster et al). 
Due to the incorporation of the mutated PID in the vaccine it is also possible to identify 
vaccine break through cases as demonstrated in Figure 5-9, and differentiate infected from 
vaccinated animals. Although the vaccine did not protect, the plasma reactivities to either 
FIV or LLV-E peptide would be need to assessed in cats protected from FIV infection. For 
this reason, it would be of value to assess the utility of the DIVA epitope in the prototype 
Fel-O-Vax FIV vaccine (FIV-Petaluma WIV) to determine the ability of the mutated PID to 
DIVA cats upon challenge.  
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Chapter 6  
Final discussion. 
 
The aim of the studies described in this thesis was to investigate whether a DIVA FIV vaccine 
could be constructed, by exploiting the PID within TM as a DIVA epitope. We vaccinated 
cats with a WIV vaccine based on a chimaeric FIV that contained a mutated TM region and 
showed that it was possible to differentiate vaccinated from infected cats using a peptide 
ELISA test to measure antibodies recognising either the wild type FIV TM or the TM derived 
from LLV-E.  
Although the WIV vaccine based on a chimaeric FIV showed promise as a DIVA vaccine, 
there was no evidence that the vaccine could protect cats against challenge with the 
virulent primary isolate FIV-GL8. Indeed, there was some evidence that vaccination 
enhanced infection, although this enhancement was largely attributed to one of the 
vaccinated cats.  Clearly it will be important to identify the mechanism(s) of enhancement, 
as this is the first case of enhancement following vaccination with a WIV immunogen. It is 
not clear whether enhancement was antibody or complement mediated, or if the inclusion 
of the DIVA epitope played a role in the observed enhancement. In vaccine studies 
performed by Richardson et al (1997), randomly mutated PIDs were included in a DNA 
vaccine that induced little or no anti-Env humoral response and significant enhancement 
of infection was reported. The vaccine tested in this study did elicit a significant humoral 
immune response against FIV Env (as detected by immunostain and ELISA) and therefore 
antibody-mediated enhancement cannot be ruled out, although no enhancement of 
pseudotype entry was observed when plasma samples collected from vaccinated cats on 
the day of challenge were tested for neutralisation. To define the mechanism(s) of 
enhancement would inform future vaccine design and determine the utility of including 
mutated PIDs in the next generation of FIV vaccines. 
It remains to be determined why none of the vaccinated cats developed homologous nAb. 
Since cats infected with the FIV ΔV2 chimaera demonstrated a rapid and robust 
homologous nAb response, it might have been predicted that immunisation with the WIV 
(which was based on this chimaera and differed from the FIV ΔV2 virus only in the PID 
amino acid sequence) might also induce similar, or higher, titres of nAb. It is unlikely that 
the lack of homologous nAb induced by the DIVA vaccine reflected low levels of Env in the 
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virus as, during experiments to optimise the growth of the DIVA virus in CLL-OX40 cells, 
high levels of Env were detected by immunostaining (Figure 5-4, chapter 4, section 5.3.3). 
One hypothesis for the lack of homologous nAb response is that nAb epitopes on Env were 
altered following paraformaldehyde inactivation, during the preparation of the WIV.  
Indeed, studies comparing the inactivation of HIV-1 and SIV showed that formalin 
inactivation is as severe as heat inactivation of viruses, with significant loss of protein 
antigenicity (Rosso et al, 1998). 
Support for this hypothesis is derived from immunostain data generated from Fel-O-Vax 
FIV vaccinated samples. Serum samples from vaccinated cats failed to recognise 
homologous Env (FIV-Petaluma derived from FL4 cells) by immunostaining (Appendix 3iii- 
Immunostains of samples from Australian and US vaccinates). The commercial vaccine is 
produced using paraformaldehyde at 1.25% w/v for inactivation, inducing significant cross-
linkage of the viral Env and potentially altering the antigenicity (as determined by 
immunostain). The DIVA vaccine virus tested in this study inactivated using 0.5% 
paraformaldehyde w/v. This appeared to retain the antigenicity of the Env as it was 
recognised by homologous (FIV ΔV2) and heterologous plasma (FIV-Glasgow8 and FIV-
Petaluma). The degree of cross-linkage, however, could still be too great to permit the 
induction of nAb, by invoking mild conformational changes in Env.  
Another potential explanation is that the strong homologous nAb response observed in the 
cats infected with FIV ΔV2 were induced by a fully replicating virus so that Env would be 
processed fully and presented to the immune system such that the appropriate immune 
response was obtained. The use of WIV circumvents the antigen processing and 
presentation that are likely required for the induction of nAb, for the lack of homologous 
nAb induced following vaccination.  
A successful outcome of the vaccination trial was the incorporation of the DIVA epitope 
that allowed the differentiation of infected from vaccinated animals. Unlike previous 
attempts, the approach to constructing a DIVA vaccine described in this thesis allowed the 
differentiation of infected and uninfected cats and also vaccinated and uninfected cats. 
This differentiation has not been possible using either formalin inactivated virus and TM 
(Kusuhara et al, 2006. Levy et al, 2008), combinations of point of care kits (Westman et al, 
2015), PCR (Wang et al, 2010. Ammersbach et al, 2013) or florescence activated cell sorting 
(Litster et al, 2014).  
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When developing a potential DIVA vaccine, it is necessary also to develop an appropriate 
DIVA assay. Other DIVA viral vaccines have utilised deletion mutants as the DIVA 
immunogen and rely on competition ELISAs to serve as the discriminatory test (Vu et al, 
2013. van Oirschot et al, 1990). Competition ELISAs generally display lower sensitivities 
than conventional direct, indirect or sandwich ELISAs and are appropriate screening tests 
to assess the exposure of large numbers of animals to an infectious agent.  However, such 
tests are not appropriate for screening companion animals for infection with infectious 
agents. By targeting the PID of FIV as the DIVA epitope, and exploiting the serological 
diagnosis of FIV using the DIVA ELISA, it should be possible to differentiate infected from 
vaccinated cats irrespective of FIV infection or vaccination status. As the PIDs of lentiviruses 
are highly conserved, the mutation of the PID could theoretically allow DIVA for any 
lentiviral infections should the vaccine contain the TM domain of Env.  
Prospects for future work. 
 
While the studies described in this thesis have demonstrated that it is possible to construct 
a DIVA vaccine for FIV, the duration of the humoral response to the mutated PID has yet to 
be determined. The antibody response against the LLV-E peptide decreased to low levels 
by the day of challenge. It will therefore be necessary to test cats that have been vaccinated 
with the DIVA virus, to assess the duration of the humoral antibody response recognising 
the DIVA epitope and to evaluate whether it will still be possible to differentiate vaccinated 
from infected cats 6-12 months after the final vaccination. 
As the DIVA WIV used in this study did not protect cats from challenge with the virulent 
primary isolate GL-8, it is not known what the serological profile of DIVA vaccinated cats 
might have been had the vaccinated cats been protected. Therefore, it would be valuable 
to incorporate the DIVA mutation into the prototype FIV vaccine (WIV of FIV-Petaluma). As 
a WIV based on FIV-Petaluma has been shown to protect against low dose homologous and 
heterologous challenge (Yamamoto et al, 1991 and 1993), it would be possible to assess 
the serological profile of DIVA-vaccinated and protected cats. 
The identification of potential immunogens that are capable of eliciting BnAb should be 
pursued further. Utilising complex gene screening assays and computational modelling, 
researchers are assessing HIV-1 Envs capable of eliciting BnAb in a prime boost regime by 
germline targeting (Jardine et al, 2015).  Another possible approach is to utilise the FIV 
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model of lentivirus infection. Should FIV positive cats that have mounted a BnAb response 
be bred, the selected uninfected offspring should, theoretically, contain the optimal alleles 
required for the formation of BnAb, as well as the optimal combinations of VDJ genes 
required for BnAb production. Should the offspring be infected with a low dose of FIV (5 
CID50), it is possible that a BnAb response could be induced. By determining the structure 
of the Env of the circulating FIV, and comparing that with the development of BnAb, it might 
be possible to identify certain characteristic of the virus associated with the development 
of BnAb. Stocks of virus could then be expanded from selected time points (preceding the 
development of BnAb) and, used in a prime boost regime to test whether it is possible to 
elicit BnAb by vaccination. 
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Appendices 
Appendix 2. Names, orientations and sequences of primers and 
probes used in this study. 
 
PCR and sequencing primers 
Primer 
Forward (F) 
/reverse (R) 
Sequence 
1F4 F 5' -TGT AAT CAA CGY TTT GTK TCT CCT TAC AG- 3' 
XR2 R 5' - CCT CAA AGG GAA GAA ATC AGC TCA-3' 
GL8-Sal F  5'- GGG TCG ACA CCA TGG CAG AAG GGT TTG CAG CA -3' 
GL8-Not1 R 5'- GGG CGG CCG CCA TCA TTC CTC CTC TTT TT-3' 
550F F 5'-TTT TTT GGG ATT GTT GGG C-3' 
7223F F 5'- GTA CAG ACC CAT TAC AAA TCC-3' 
8461R R 5'- CCC CCA AAG TTA TAT TTT C-3' 
FIV-env_890 R 5'- TCC CTT GTA ACC AAG TAT CTA CTC - 3' 
BNC5 Nde1 R 5'- AAT GGA TTC ATA TGA CAC ATC TTC CTC-3' 
BNC5 PID/Spe1 F 
5'- GAG CAT CAA GTA CTA GTA ATA GGA TTA AAA GTA GAA 
GCT ATG GAA AAA TTC TTA TAT ACT GCT TTC GCT ATG CAA 
GAA TTG GGA TGT AGA GAA CAA CAA TTT TTC TGT AAA GTC 
CCT TTT-3' 
   
Sequences highlighted in red denote restriction sites. Sequences underlined in bold 
highlight mutagenesis sequences.             
 
QPCR/PERT primer and probes 
 
Primer/probe 
Forward (F) 
/reverse (R) 
Sequence 
FIV-1360F F 5'- GCA GAA GAA AGA TTT GCA CCA-3' 
FIV-1437R R 5'- TAT GGC GGC CAA TTT TCC T-3' 
FIV Gag Probe F 5' FAM- TGC CTC AAG ATA CCA TGC TCT ACA CTG CA-BHQ1-3' 
rDNA 343F F 5'- CCA TTC GAA CGT CTG CCC TA- 3' 
rDNA 409R R 5'- TCA CCC GTG GTC ACC ATG-3' 
rDNA 370 Probe F 5' FAM- CGA TGG TAG TCG CCG TGC CTA-BHQ1-3' 
MS2 RNA F F 5'-GCC TTT CTC ATT CGT TGT CG-3' 
MS2 RNA R R 5'-GCT TAT GAT GGA CTC ACC CG-3' 
MS2 probe F 5'-FAM-CCG TGG GAT GCT CCT ACA TGT CAG GA-TAM-3' 
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Appendix 3i. Serology of samples of a predetermined FIV sero-status. 
Immunostain 1. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 2. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 3. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 4. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 5. 
 
 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
180 
 
Immunostain 6. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 7. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive. 
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Immunostain 8. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 9. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 10. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 11. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 12. 
 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 13. 
 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 14. 
 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 15. 
 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Appendix 3ii. Serology of samples with an inconclusive FIV sero-status. 
Immunostain 1. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 2. 
 
 Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive. 
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Immunostain 3. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 4. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 5. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 6. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 7. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 8. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 9. 
 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive 
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Immunostain 10. 
 
Green = Sero-negative, Yellow= inconclusive, Red = Sero-positive. 
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Immunostains 11-13 
 
 
201 
 
Immunostains 14-16. 
 
 
 
202 
 
 
Tabulation of all IFA inconclusive, TM ELISA positive samples. Sample 364503 is included in the tabulation as this the first or 2 sequential samples 
taken from this animal. The cat was re-sampled just 6 days later (364637) and clearly shows a different anti-FIV serology profile. Out the 10 cats 
represented by the 11 samples, IFA was unable to detect antibodies in 3/10 of these samples. Although 2 of these cats gave an inconclusive result by 
TM ELISA, immunostain analysis clearly shows specific FIV antibodies are present in the sera of these cats. Although the remaining 7 IFA positive cats 
gave high titres of FIV antibodies, these results could not be reproduced by VDS immunostain and thus were classed as inconclusive. Green= negative 
result, Yellow = inconclusive result, Pink= positive result. + = present, - = not present, +/- = very weak presence/not specific, *= RT activity detected 
in 1 well of the triplicate, # = Tabulated immunostain data from several screenings. 
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Appendix 3iii. Serology of the Australian and American samples. 
Immunostain 1. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 2. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 3. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 4. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 5. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 6. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 7. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 8. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 9. 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Immunostain 10. 
 
 
aRed = infected, Yellow = vaccinated, Grey = None infected. bPink = Positive result, Yellow= inconclusive, Green = Negative result 
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Signalment table 1a. Samples of a known FIV sero-status (Sero-negative) 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
133 0.5 MN DSH 0 0.564   Severe gingivitis 
132 12.5 F NG 0 0.585   Inflammation conjunctiva, oedema 
131 6.9 MN DSH 0 0.850 FCV positive Severe gingivitis and weight loss 
127 5.5 FN DSH 0 0.641 FCoV 320 
Gastroenteritis and very large 
mesenteric lymph nodes 
124 5.0 MN DSH 0 0.654 FCV positive Unknown 
123 4.9 F DSH 0 0.671 FCV positive Moderate/severe dental disease 
120 0.6 F DSH 0 0.526 FeLV/FIV neg Routine screen  
116 9.8 FN BSH 0 0.526   Disorientated 
129 9.8 FN BSH 0 1.068 FeLV/FIV neg Weight loss 
122 0.6 F DSH 0 1.017 FeLV/FIV neg Routine screen 
114 NG F DSH 0 0.419   Confirmatory screen 
111 4.2 MN DSH 0 0.530 FCoV 0 Pyrexic and enlarged kidneys 
104 7.0 M  DSH 0 0.821   Confirmatory screen 
103 2.1 MN Siamese 0 0.748 FCoV 80, α1-AGP 2000 Abdominal discomfort 
101 2.0 FN DSH 0 0.453 FCoV 80, α1-AGP 1260 FeLV/FIV neg Unknown 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection. 
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Table 1a continued. Samples of a known FIV sero-status (Sero-negative) 
. 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
96 8.7 MN BSH 0 0.641 FCoV>1280, α1-AGP 2460 Lethargy and weight loss 
95 3.5 MN BSH 0 0.688 FeLV/FIV/FCoV neg Neutropenia, gingivitis and UTI 
94 NG NG NG 0 0.534 FeLV/FIV/FCV/FHV neg Gingivitis. 
93 3.2 M NF 0 0.500 FCV positive. FIV/FeLV neg Gingivo-stomatitis 
84 3.0 MN DSH 0 0.526 FeLV/FIV/FCoV/Toxoplasma neg Unknown 
83 0.5 F DLH 0 0.425 FeLV Ag Pos. FeLV/FIV/FCoV ab neg 
Acute onset dysponea, ataxia and 
pyrexia 
80 0.5 F DLH 0 0.517 Positive in house Unknown 
78 8.6 MN NG 0 0.538   Panleukapaenia 
62 8.0 MN DSH 0 0.563   Confirmatory screen 
61 1.6 FN Bengal 0 0.446 FCV positive Gingivitis. 
77 7.0 MN DSH 0 1.329 FCoV 80 Weight loss 
64 NG M DSH 0 1.033 FCV positive History of severe stomatitis  
55 13.2 FN DR 0 0.641 FCoV >1280 Unknown 
54 7.6 MN BSH 0 0.739 FeLV/FIV/FCoV neg Weight loss.   
52 3.0 MN DSH 0 0.714 FHV positive Anorexia. 
 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection. 
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Table 1a continued. Samples of a known FIV sero-status (Sero-negative) 
 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
50 2.3 F DSH 0 0.487 FCV positive Severe gingivitis. 
49 2.3 FN DSH 0 0.637   Seizures 
47 10.0 MN AB 0 0.679 FCV positive Stomatitis 
46 Adult F DLH 0 0.855   Unknown 
30 1.4 F DSH 0 0.551 1 Snap +, 1 Snap -. Confirmatory screen 
74 0.4 F Siamese 0 0.534 FCoV 160 Extended abdomen  
21 1.1 MN MC 0 0.423 FCV positive History of URT disease 
26 0.6 M Siamese 0 0.487   Chronic gingivitis 
33 NG NG NG 0 0.747 α1-AGP 500 Progressive ataxia 
11 1.4 FN DLH 0 0.437   Severe gingivitis. 
12 9.7 MN DSH 0 0.833   Routine screen 
16 4.0 MN BI 0 0.820 FCoV >1280 
Weight loss. Mass in abdomen. 
Anaemia. 
17 19.7 F DSH 0 0.597   Disorientated 
367607 0.9 M DSH 0 0.387 FeLV/FIV/FCV/FHV neg URT signs 
367626 3.0 MN DSH 0 0.670 Toxoplasma Ab >50. FeLV/FIV/FCoV neg Ataxic fore limbs 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection 
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Table 1a continued. Samples of a known FIV sero-status (Sero-negative) 
 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
367595 5.0 FN DSH 0 0.340 FCV positive. FIV/FeLV neg Gingivitis  
66 4.0 FN DLH 0 0.383 α1-AGP 2740. FeLV/FIV/FCoV neg Rapid weight loss 
142 NG NG NG 0 0.365 FeLV/FIV neg Weight loss 
149 5.0 F DSH 0 0.528 FCoV 40. FeLV/FIV neg Unknown 
153 1.8 MN DSH 0 0.475 FCV positive FeLV/FIV neg Gingivo-stomatitis 
155 8.0 MN DSH 0 0.550 FeLV/FIV/FCoV neg Lethargy and neutropenia 
156 6.0 F DSH 0 0.504 FeLV/FIV neg Gingivitis 
157 NG FN DSH 0 0.574 FIV neg Unknown 
185 NG  F DSH 0 0.569 Faint in house positive weight loss 
154 1.8 FN DSH 0 0.663 FeLV Ag neg/FIV/FHV/FCV neg Gingivo-stomatitis 
180 0.6 M DSH 0 0.955 FCoV 40 (None specific) FIV/FeLV neg Chronic diarrhoea 
178 0.8 F DSH 0 0.390 FeLV/FIV/FCoV/Toxoplasma neg History and ongoing pyrexia 
176 2.5 MN DLH 0 0.602 FCV positive FeLV/FIV neg Gingivitis. 
173 1d FN DSH 0 0.476 FeLV/FIV/FCoV neg Seizures 
172 0.8 F MC 0 0.488 FCoV >1280 FeLV/FIV/Toxoplasma neg  Poor development 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection 
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Table 1a continued. Samples of a known FIV sero-status (Sero-negative) 
 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
171 7.8 MN DSH 0 0.467 FeLV/FIV neg  Sick  
168 3.0 F DSH 0 0.650 FCoV 80, α1-AGP 1420 FIV/FeLV neg Dsyponea 
179 0.2 M BSH 0 1.329 FCoV >1280, α1-AGP 1520. FeLV/FIV neg Lethargy. Inappetence. Pyrexia 
147 2.0 M DSH 0 0.516 FeLV/FIV neg Mandibular symphysis 
166 0.6 MN DSH 0 0.399 FeLV Ag neg/FIV/FHV/FCV neg Unknown 
159 1.0 F NG 0 0.477 FeLV/FIV neg Routine screen 
158 0.8 M DSH 0 0.453 FeLV/FIV neg Routine screen 
320544 4.0 MN DSH 0 0.659 Feral. FeLV/FIV neg Plasma cell pododermatitis 
320560 1.7 F Birman 0 0.516 FCoV positive Unknown 
320571 1.9 MN DSH 0 0.469 FeLV/FIV/FCoV neg Unexplained weight loss 
179562 1.0 M Bengal 0 0.470 FCoV >1280. α1-AGP 2240. FeLV Ag/Ab neg. FIV neg Unknown 
134 Adult MN DLH 0 1.765 FeLV/FIV neg Plasma cell pododermatitis 
378633 Adult F DSH 0 0.552 FeLV/FIV neg  Sanctuary cat 
377299 6.0 FN DSH 0 0.686 FeLV/FIV/FCoV neg 
Weight loss, pale mms, chronic 
vomiting. 
378305 13.0 NG Bengal 0 0.648 VDS FIV neg Confirmatory screen 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection. 
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Table 1a continued. Samples of a known FIV sero-status (Sero-negative) 
 
 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
378352 5.1 FN DSH 0 0.719 FeLV/FIV/FCV/FHV neg Gingivostomatitis 
378358 13.0 MN DLH 0 1.067 FeLV/FIV/FCV/FHV neg Gingivitis 
367644 15.0 FN PLH 0 0.519 FeLV/FIV neg Confirmatory screen 
367645 4.2 FN DSH 0 0.586 FeLV/FIV neg. FCV positive Gingivitis, moderate dental disease 
378188 11.6 FN DSH 0 0.642 VDS FIV neg Confirmatory screen 
378263 3.0 FN DSH 0 0.920 FeLV/FIV neg 
Lethargy, inappetence, weight loss 
?FIP 
182631 9.0 MN DSH 0 0.481 FeLV/FIV neg Unknown 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection 
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Signalment table 1b. Samples of a known FIV sero-status (Sero-positive) 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
119 5.0 MN DSH 1K 5.496 Previous FIV inconclusive. FCoV= 640 
Recurrent pyrexia. Treated for abscess and 
neutering 
115 NG M DSH 1K 16.684   Well but abscess. 
108 12.0 MN DSH 10K 16.368 FeLV Ag neg/ FCV positive Gingivitis. Confirmatory screen. 
79 21.9 M DSH 10K 17.646   Conjunctivitis left eye. Sneezing 
72 4.0 M DSH 10K 18.913   Confirmatory screen 
71 NG M DSH 10K 18.938   Unknown 
57 6.9 MN DSH 10K 17.400 
FHV/Mycoplasma felis/Chlamydophila felis 
negative 
Unilateral conjunctivitis  
51 NG MN PL 10K 17.427   Confirmatory screen 
35 6.5 MN  DSH 10K 16.231   Anaemic/not eating. Confirmatory screen. 
14 15.6 MN DSH 10K 18.056 FCV/FeLV neg Severe gingivitis. All teeth removed 
25 2.0 MN DSH 10K 15.643 FeLV neg Confirmatory screen 
367517 0.6 F DSH 10K 11.897 FeLV Ag/FIV positive. FCV positive 
Enlarged submandibular Lymph node. Pyrexia, 
gingivitis 
42 NG MN DSH 10K 5.050   Unknown 
141 NG MN DSH 10K 5.936   Confirmatory screen 
146 6.0 M DSH 10K 14.904   Confirmatory screen 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. ‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection. 
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Table 1b continued. Samples of a known FIV sero-status (Sero-positive) 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
183 5.0 MN DSH 1K 6.728   Confirmatory screen 
175 4.0 M DSH 10K 19.557   Confirmatory screen 
160 2.9 M DLH  10K 20.333   Confirmatory screen 
182942 Adult M  NG 1K 19.298 FeLV Ag neg/ FCoV 0 Stray 
182455 NG F DSH 10K 16.845   NG 
183053 Adult F DSH 10K 20.434   Healthy, previous positive 
182461 12.0 M DSH 10K 19.853   Sick 
182246 9.0 MN DSH 10K 15.029   Sick, severe gingivitis 
182312 7.8 MN  DSH 10K 15.379 FeLV Ag neg/FCoV 0 Sick, severe depression. Normal TPR 
180914 5.0 MN DSH 10K 15.340 FeLV Ag neg Sick, lethargy, mild dysponea, history of fights 
182304 1.8 M DSH 10K 14.239 FeLV Ag neg Off food, mild dehydration, lameness 
180949 Adult M  DSH 10K 15.484 NG NG 
182189 10.9 MN DSH 10K 15.350 FeLV Ag neg lethargy, weight loss 
181143 Adult FN DSH 10K 15.791 NG NG 
180961 5.0 MN DSH 10K 14.180 FeLV Ag neg   
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection. 
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Table 1b continued. Samples of a known FIV sero-status (Sero-positive) 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
181294 5.7 M DSH 10K 11.412   History of fights 
181259 2.0 MN DSH 10K 14.118   Stray- fighter 
367516 6.0 M DSH 10K 15.173   Confirmatory screen 
180911 2.0 F DSH 10K 13.102 FeLV Ag neg   
182249 NG NG NG 10K 12.855   NG 
182285 7.0 FN DSH 10K 9.785 FeLV Ag neg/ FCoV 0 NG 
181218 0.3 NG DSH 10K 12.543   NG 
181948 5.0 M DSH 10K 7.621   Chronic weight loss 
181256 0.9 F DSH 10K 12.282   
General Malaise. Lingual ulcers, halitosis, 
marginal anaemia 
181215 14.0 M DSH 10K 13.164 FeLV Ag neg Weight loss. Tongue ulceration. 
181146 0.4 M DSH 10K 12.524 NG NG 
182193 NG M DSH 10K 10.460 FeLV Ag neg Stray 
186496 11.1 MN DSH 10K 12.868 FCoV 40, α1-AGP 620, FeLV Ag neg NG 
179114 10.1 MN DSH 10K 17.467 FeLV Ag neg NG 
179105 3.0 M DSH 10K 16.361 FeLV Ag neg NG 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection 
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Table 1b continued. Samples of a known FIV sero-status (Sero-positive) 
Cat I.D. Age  
Sex
* 
Breed
# 
IFA 
Negativ
e fold. 
Other† Clinical signs‡ 
179181 2.9 MN DSH 10K 16.022 FeLV Ag neg NG 
179176 
Adul
t 
MN DSH 10K 17.689   Healthy 
179120 NG MN DSH 10K 12.489 FeLV ag neg/FCoV >1280 Healthy 
179118 8.0 M DSH 10K 7.506 FeLV Ag neg Sick, weight loss. 
179117 0.9 MN DLH  10K 11.450   Healthy 
179297 7.4 MN  DSH 10K 17.939   Healthy 
179288 3.0 MN DSH 1K 12.183 FeLV Ag neg/FCV neg Gingivitis. Neck lesion 
179200 10.0 MN DSH 10K 8.117   Weight loss, lethargy, pyrexia 
179323 10.9 M DSH 10K 12.278 FeLV Ag neg/FCoV 320 Raised liver enzymes. Abdominal fluid 
179369 
Adul
t 
M DSH 10K 14.444 FeLV Ag neg NG 
179898 NG FN DSH 1K 7.687 FCoV >1280 NG 
179876 10.0 FN DSH 10K 15.081 FeLV Ag neg General malaise- neutropaenia 
179195 NG NG NG 
1K/10
K 
14.657 FeLV Ag neg/ FCoV 0 
Intermittent vomiting, weight loss. Pale 
mucous membrane 
179837 1.4 NG PL 10K 10.995   NG 
179845 11.8 MN DLH  10K 13.157 FeLV Ag neg. FCoV 0 
Gingivitis, pancytopaenia, hypoalbuminaenia, 
hyperglobulinaemia 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. ‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection 
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Table 1b continued. Samples of a known FIV sero-status (Sero-positive) 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
179850 13.0 FN DSH  10K 10.288   NG 
179582 2.0 M DSH 10K 14.828   NG 
179638 8.0 MN DSH 10K 12.455 FeLV Ag neg Healthy 
179550 1.4 FN DSH 10K 12.970   Healthy 
179466 5.0 M NG 10K 12.091   NG 
179481 14.0 MN DSH 10K 12.197 FeLV Ag neg Confirmatory screen 
181091 2.0 F  DSH 10K 8.733 FeLV Ag neg Healthy 
378291 2.1 M DSH 10K 9.505 FeLV Ag neg/ FCoV 0 Lethargy. Abscess on neck 
378385 11.0 F DSH 10K 14.338   Confirmatory screen 
378477 2.9 M DSH 10K 20.562   Castrated 
378479 4.0 FN DSH 10K 18.938 FeLV Ag neg/FCV positive Gingivostomatitis 
378264 0.7 FN DSH 10K 8.185   Confirmatory screen 
378282 NG MN DSH 10K 4.586   Confirmatory screen 
378253 2.9 M DSH 10K 3.846   Confirmatory screen 
378262 8.2 FN PLH 10K 5.764   Confirmatory screen 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection. 
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Table 1b continued. Samples of a known FIV sero-status (Sero-positive) 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
183039 5.6 MN DSH 10K 7.519 FeLV Ag neg Keratitis. Anterior uveitis 
182421 5.0 M  DSH 10K 5.705 FeLV Ag neg 
Severe back trauma (very pruritic). Mild 
gingivitis 
182337 4.0 MN DSH 10K 5.256 FeLV Ag neg Stray. Uncontrollable bleeding upon castration 
182313 NG M DSH 10K 8.027   Inappetence, lethargy, ocular discharge 
182387 2.9 M DSH 10K 6.519   Healthy 
180724 10.0 M DSH 10K 18.203 FeLV Ag neg/FCV positive 9-month history of gingivitis/dental problems 
180652 4.0 M DSH 10K 18.330 Previous FIV IFA inconclusive. NG 
180795 Adult MN DSH 10K 17.844 FeLV Ag neg/FCV positive Tongue ulcerations- purulent discharge 
180801 2.5 M PL 10K 18.964   Healthy 
180800 NG M DSH 10K 16.996   NG 
180659 13.6 FN Siames 10K 16.866   NG 
180647 NG M DSH 10K 17.906   NG 
180644 9.4 MN DSH 10K 18.286   NG 
180638 2.0 M DSH 10K 17.243 FeLV Ag neg. FCV positive. 
Severe periodontitis, all teeth lost. Swollen and 
lysed jaw bones. Thickened bowel loop. 
180389 8.0 MN DSH 1K 15.214   Diabetes. Influenza like symptoms 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection. 
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Table 1b continued. Samples of a known FIV sero-status (Sero-positive) 
Cat I.D. Age  Sex* Breed# IFA 
Negative 
fold. 
Other† Clinical signs‡ 
180536 10.8 M BSH 10K 16.866 FeLV Ag neg. FCV positive Unceraltive glossitis 
CPG41 N/A N/A N/A 10k 18.460     
180498 8.0 F DSH 10K 18.181 FCoV 1280 Chronic gingivitis 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection 
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Signalment table 2a. IFA inconclusive samples – individual samples. 
Cat I.D. Age  Sex* Breed# 
 
IFAΘ 
Negative 
FoldФ 
Other† Clinical symptoms/history‡ 
347731 4.0 M DSH 
 
100 NS 1.619 
Giardia positive. Nematode/protozoan 
free 
Pyrexic for 2 weeks with occasional 
incontinence. 
346577 2.0 M DSH  0 0.636 FeLV Ag neg Confirmatory screen 
378475 4.0 M DSH  0 0.710 FeLV Ag neg Confirmatory screen 
364988 NG M DSH  0 0.756   Confirmatory screen 
364869 2.0 M NG  0 1.517 FeLV Ag neg Stray. Routine screen 
364888 NG M NG  0 1.660   None given 
364376 NG M DSH  0 0.648   Confirmatory screen 
346495 0.3 M NG  0 0.374   Confirmatory screen 
346515 10.3 M DSH  0 1.134 FeLV Ag neg Severe infected Stomatitis 
346538 4.0 M DSH  0 0.720   Confirmatory screen 
346639 2.3 M DSH  0 0.735   Confirmatory screen 
346816 NG M DSH  0 1.061   Confirmatory screen. 
364790 8.1 MN DSH  0 0.462   Confirmatory screen 
378601 5.0 MN DSH  10/100 0.448   Confirmatory screen 
367547 14.0 MN DSH  0 0.525   Confirmatory screen. No History 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
Θ NS= None specific fluorescence, Toxic= Sample adversely reacts with fixed culture. 
Ф Green = TM ELISA negative, Yellow= TM ELISA inconclusive, Pink= TM ELISA positive 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. ‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection, Confirmatory screen = Has tested positive in house 
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Table 2a continued. IFA inconclusive samples – individual samples. 
Cat I.D. Age  Sex* Breed# IFAΘ 
Negative 
Fold Ф 
Other† Clinical symptoms/history‡ 
347644 8.0 MN DSH 0 0.692   Confirmatory screen 
346405 12.5 MN DSH 0 0.819   Weight loss, Jaundice, constipation, anaemic. 
346594 2.0 MN DSH 0 0.712 From multi-cat house (57 total) Confirmatory screen 
347621 0.1 MN DSH 0 (toxic) 0.717   Confirmatory screen 
347721 4.1 MN DSH 0 0.821   Confirmatory screen 
347140 0.6 MN DSH 
0 NS 
(toxic) 
0.415 FeLV Ag neg Unwell, off food, vomiting blood. 
347309 8.0 MN DSH 0 0.396   Confirmatory screen. Weight loss 
363127 7.0 MN DSH 0 (toxic) 0.629 FeLV/FCV/FHV neg  Chronic facial dermatitis and ocular discharge.  
364094 2.1 MN DSH 0 0.752   Confirmatory screen 
363764 NG F DSH 0 0.538   Confirmatory screen 
346532 11.0 F Siamese 0 0.616 FeLV Ag neg/ FCoV 0 No history 
365011 0.4 F DSH 0 0.408 FeLV Ag neg Confirmatory screen 
365080 1.0 F DSH 0 NS 0.455 FCoV 1280. FeLV Ag neg 
Confirmatory screen, from same house hold 365081 1.0 F DSH 0 NS 0.539 FCoV 1280. FeLV Ag neg 
365083 4.0 M DSH 0 0.714 FCoV 320. FeLV Ag neg 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
Θ NS= None specific fluorescence, Toxic= Sample adversely reacts with fixed culture. 
Ф Green = TM ELISA negative, Yellow= TM ELISA inconclusive, Pink= TM ELISA positive 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein.‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection, Confirmatory screen = Has tested positive in house. 
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Table 2a continued. IFA inconclusive samples – individual samples. 
Cat I.D. Age  Sex* Breed# IFAΘ 
Negative 
Fold Ф 
Other† Clinical symptoms/history‡ 
346700 Adult F NG 0 0.420   Confirmatory screen 
345182 NG F DSH 0 0.527   Thin, renal disease, anaemic 
346533 3.1 F DR 0 0.667 FeLV Ag neg/toxoplasma 50 Head and Neck puritis 
347177 NG F DSH 0 1.079   Confirmatory screen 
378474 3.0 F DLH 0 0.714   Confirmatory screen 
346444 0.3 F DLH 0.1/1K 0.478 FeLV Ag neg Routine screen. Littermate FIV positive 
346595 NG FN DSH 0 1.008   Confirmatory screen 
346596 NG FN NG 0 0.955   Chronic gingivitis. Confirmatory screen 
346793 1.5 FN DSH 100? NS? 0.575 FeLV Ag neg/FCoV 0  
Peripheral Lymphadenopathy, persistent 
PUO 3mths 
346823 0.2 FN DSH 0 0.349 Different results from different test Confirmatory screen 
346909 0.2 FN DSH 0 0.459 FeLV neg. No History 
346933 12.0 FN DSH 0 (toxic) 0.909 FeLV Ag neg/FCoV 0  Uveitis. Intra ocular haemorrhage  
347467 2.0 FN DSH 0 0.437   Confirmatory screen 
347398 2.3 FN NG 0 (toxic) 1.239 FeLV/FCoV neg Weight loss 
364945 5.0 FN MC 0 (toxic) 0.548 FeLV Ag neg. FCV positive Gingivo-stomatitis 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
Θ NS= None specific fluorescence, Toxic= Sample adversely reacts with fixed culture. 
Ф Green = TM ELISA negative, Yellow= TM ELISA inconclusive, Pink= TM ELISA positive 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein.‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection, Confirmatory screen = Has tested positive in house 
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Table 2a continued. IFA inconclusive samples – individual samples. 
Cat I.D. Age  Sex* Breed# IFAΘ 
Negative 
Fold Ф 
Other† Clinical symptoms/history‡ 
346639 2.0 NG DSH 0/10 0.577   Confirmatory screen. Sick cat 
346262 11.0 NG NG 0 0.574   None given 
347447 5.2 NG DSH 0 0.545   Gingivitis and stomatitis 
347464 Adult NG PLH 0 0.613   Confirmatory screen 
378531 NG M DSH 10/100NS 0.525 FCoV 1280. FeLV Ag neg Prev:366983 Pyrexic. 
367445 13.5 NG DSH 0 0.611 366983 re-test None healing ulcerated wound to rear flank.  
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
Θ NS= None specific fluorescence, Toxic= Sample adversely reacts with fixed culture. 
Ф Green = TM ELISA negative, Yellow= TM ELISA inconclusive, Pink= TM ELISA positive 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection, Confirmatory screen = Has tested positive in house 
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Table 2a continued. IFA inconclusive samples – individual samples. 
Cat I.D. Age  Sex* Breed# IFAΘ 
Negative 
Fold Ф 
Other† Clinical symptoms/history‡ 
345387 NG M DSH 1k 17.826   Gingivitis 
364982 NG M DSH 100 6.423   
Stray trapped for neutering. Many fight 
abscesses 
345592 2.0 MN DSH 10k 22.337 FeLV Ag neg Sanctuary cat. No clinical signs 
346406 8.0 MN DSH 10K 11.782 FeLV neg/FCV positive No history 
346657 2.0 MN DSH 1K? 4.306   Stray fighter. Abscess. Confirmatory screen 
346430 7.5 F DSH 10K 20.799 
Blood Glucose 8.8mmol/l. Taking 
Noroclair 
Acute weight loss, history of gingivitis, mass in 
mouth. 
347930 4.0 F DSH 0 6.544   Confirmatory screen 
364989 8.5 FN DSH 10K 15.923 FeLV Ag neg. FCV/FHV neg Chronic suppurative Cheilitis 
363353 NG M DSH 0 2.997   Confirmatory screen 
 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
Θ NS= None specific fluorescence, Toxic= Sample adversely reacts with fixed culture. 
Ф Green = TM ELISA negative, Yellow= TM ELISA inconclusive, Pink= TM ELISA positive 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection, Confirmatory screen = Has tested positive in house 
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Signalment table 2b. IFA inconclusive samples – sequential samples. 
Cat I.D. 
Re-sample 
date 
Age  Sex* Breed# IFAΘ 
Negative 
Fold Ф 
Other† Clinical symptoms/history‡ 
3470731 04/09/2014 
2.0 F DSH 
0 1.115 
  Confirmatory screen 
3475732 30/09/2014 0 1.195 
345089 1 08/05/2014 
3.0 M DSH 
0 1.067 
  Confirmatory screen/healthy  
345547 2 09/06/2014 0 NS 1.033 
346097 1 11/07/2014 
5.0 M DSH 
0 NS 0.619 
  Confirmatory screen 
346440 2 01/08/2014 0 0.634 
3461321 14/07/2014 
5.0 M PLH 
0 (toxic) 0.736 
FeLV Ag neg/ FCoV 1280/ Toxoplasma 
40 Seizures 
3467362 19/08/2014 0 0.560 FCoV 320/ α1-AGP = 1300 
346228 1 18/07/2014 
3.0 M DSH 
0 0.712 
  Confirmatory screen 
346368 2 28/07/2014 0 0.636 
3637791 01/12/2014 
12.0 M DSH 
0 1.022 
  
Stray. Non-healing wound, 
broken teeth, plaque, oral 
infected stomatitis. 364144
2 22/12/2014 0 0.796 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
Θ NS= None specific fluorescence, Toxic= Sample adversely reacts with fixed culture. 
Ф Green = TM ELISA negative, Yellow= TM ELISA inconclusive, Pink= TM ELISA positive 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection, Confirmatory screen = Has tested positive in house 
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Table 2b. IFA inconclusive samples – sequential samples. 
Cat I.D. 
Re-sample 
date 
Age  Sex* Breed# IFAΘ 
Negative 
Fold Ф 
Other† Clinical symptoms/history‡ 
3637031 26/11/2014 
Adult M DSH 
0 NS 0.981 
  
Confirmatory screen. Semi-
feral - neglect case 3648672 30/01/2015 0 1.569 
346170 1 16/07/2014 
3.4 MN DSH 
0 0.907 
FeLV Ag neg Fighter.  
347929 2 20/10/2014 0 0.384 
347132 1 10/09/2014 
4.0 MN DSH 
0 0.585 
  Confirmatory screen 347317 2 17/09/2014 0 0.616 
363027 3 22/10/2014   0.565 
3477611 13/10/2014 
10.0 MN DSH 
100 NS 0.771 
  
Persistent pyrex. Weight loss, 
confirmatory screen. Rescue 
case. 363782
2 01/12/2014 0 0.941 
3472571 16/09/2014 
3.0 FN DLH 
0(toxic) 0.469 
FCoV 160/FeLV neg 
Dehydrated and anorexic. 
Pyrexic 3630382 22/10/2014 
0 
(toxic) 
0.485 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
Θ NS= None specific fluorescence, Toxic= Sample adversely reacts with fixed culture. 
Ф Green = TM ELISA negative, Yellow= TM ELISA inconclusive, Pink= TM ELISA positive 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= Feline herpes 
virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection, Confirmatory screen = Has tested positive in house 
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Table 2b continued. IFA inconclusive samples – sequential samples. 
Cat I.D. 
Re-sample 
date 
Age  Sex* Breed# IFAΘ 
Negative 
Fold Ф 
Other† Clinical symptoms/history‡ 
347226 1 15/09/2014 
13.0 FN DSH 
0 0.568 
  Poor coat, lethargic 
347445 2 25/09/2014 0 0.527 
3473071 17/09/2014 
9.0 FN DSH 
0 0.634 
FeLV Ag neg Precaution screen. 
3477602 13/10/2014 100 NS 0.733 
345855 1 27/06/2014 
Adult NG NG 
0 NS 0.715 
  Confirmatory screen 
346573 2 12/08/2014 0NS 0.456 
345879 1 27/06/2014 
Adult NG NG 
0 NS 0.722 
  Confirmatory screen 
346572 2 08/08/2014 0NS 0.583 
3645031 14/01/2015 
8.0 MN DSH 
0 1.022 
  Confirmatory screen 
3646372 20/01/2015 0 3.625 
 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
Θ NS= None specific fluorescence, Toxic= Sample adversely reacts with fixed culture. 
Ф Green = TM ELISA negative, Yellow= TM ELISA inconclusive, Pink= TM ELISA positive 
† FCV= Feline Calcivirus, FCoV= Feline Coronavirus (Feline intraperitoneal virus), FeLV= Feline leukaemia virus, FIV= Feline immunodeficiency virus, FHV= 
Feline herpes virus, α1-AGP= Alpha-1 acid glycoprotein. 
‡ URT= Upper respiratory tract disease, UTI= Urinary tract infection, Confirmatory screen = Has tested positive in house 
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Signalment table 3a. Australian vaccinate samples. 
Cat I.D. Age Sex* Breed#  Cat I.D. Age Sex* Breed
#  Cat I.D. Age Sex* Breed
# 
FIV-2 2.4 MN Bengal  FIV-24 4 FN DSH  FIV-116 5.3 FN DSH 
FIV-3 16.3 FN DSH  FIV-25 7.5 MN DSH  FIV-117 10.8 FN DSH 
FIV-4 11.5 FN DSH  FIV-28 5.4 MN DSH  FIV-118 10 MN DSH 
FIV-5 11 FN DSH  FIV-59 5.3 FN DMH  FIV-120 7.7 FN DSH 
FIV-6 5 FN DSH  FIV-84 6.8 FN DSH  FIV-121 7.7 FN DSH 
FIV-7 13 MN DSH  FIV-93 7 FN Russian Blue X  FIV-122 4.8 MN Russian Blue X 
FIV-8 13 MN DSH  FIV-95 8.8 FN DMH  FIV-123 10.8 MN DMH 
FIV-9 3 FN DSH  FIV-96 7.8 FN DSH  FIV-131 4.3 FN DSH 
FIV-10 8.8 MN DSH  FIV-97 8.4 FN DSH  FIV-132 4.5 FN DSH 
FIV-11 5.3 FN Himalayan  FIV-98 9.6 MN DMH  FIV-133 4.8 FN DSH 
FIV-12 4.3 MN DSH  FIV-99 5.3 MN DSH  FIV-134 5.8 MN DSH 
FIV-13 5.3 FN DSH  FIV-100 9.7 MN DSH  FIV-135 4.7 FN DSH 
FIV-14 5.3 MN DSH  FIV-101 6.9 FN DSH  FIV-136 4.7 MN DSH 
FIV-15 6 FN DSH  FIV-102 13.7 MN DSH  FIV-138 8.7 MN DSH 
FIV-16 7.3 FN DSH  FIV-103 5.5 MN DSH  FIV-139 7 MN DLH 
FIV-17 9.2 FN DSH  FIV-104 6.3 MN DSH  FIV-140 4.6 FN DSH 
FIV-18 5 MN DSH  FIV-105 7.3 FN DMH  FIV-141 15.8 MN Tonkinese 
FIV-20 8.3 FN DSH  FIV-107 5 FN DSH  FIV-142 9.7 MN DSH 
FIV-21 4 MN DSH  FIV-108 8.8 FN DSH  FIV-143 10 MN DLH 
FIV-22 13.2 MN DSH  FIV-109 12 FN Himalayan  FIV-144 10 FN DSH 
FIV-23 13.2 FN DSH  FIV-110 5.3 MN DSH  FIV-145 11.1 MN DSH 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given, #DSH= Domestic short hair, DMH= Domestic medium hair, DLH=Domestic long hair, 
PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, AB=Abbysian, BI=Birman, NF=Norwegian forest. 
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Table 3a continued. Australian vaccinate samples. 
Cat I.D. Age Sex* Breed#  Cat I.D. Age Sex* Breed
#  Cat I.D. Age Sex* Breed
# 
FIV-146 12.3 FN DSH  FIV-213 7.2 FN Burmese  FIV-350 6.9 FN DSH 
FIV-147 10.7 MN DSH  FIV-214 7.2 MN Burmese  FIV-351 8.4 MN DSH 
FIV-148 10.7 MN DSH  FIV-215 6.4 MN DMH  FIV-352 8.4 MN DSH 
FIV-149 4.8 MN DMH  FIV-216 6.2 FN DSH  FIV-357 6.6 FN DSH 
FIV-150 4 FN DSH  FIV-236 3.9 MN DMH  FIV-359 5.8 FN DSH 
FIV-151 7.2 FN Ragdoll X  FIV-296 13.3 MN DSH  FIV-362 9.2 MN DMH 
FIV-153 4.8 FN DSH  FIV-297 6.8 MN DSH  FIV-388 3.3 MN DSH 
FIV-168 6.3 MN DSH  FIV-298 6.8 MN Burmese X  FIV-390 4.5 MN DSH 
FIV-170 13.8 MN DSH  FIV-299 6.3 MN DSH      
FIV-171 6.3 FN DSH  FIV-300 4.7 FN DMH      
FIV-172 5.4 FN Abyssinian  FIV-301 4.7 MN Burmese      
FIV-173 3.5 MN Abyssinian  FIV-302 3.7 FN DSH      
FIV-174 5.1 MN DSH  FIV-339 4.2 MN DSH      
FIV-175 10.3 MN DSH  FIV-340 11.8 MN Siamese        
FIV-179 4 FN DSH  FIV-341 4.9 MN DLH      
FIV-183 7.8 FN Tonkinese  FIV-342 18.1 MN Burmese      
FIV-184 7.8 MN Tonkinese  FIV-343 4.9 MN DSH      
FIV-185 6.7 MN DLH  FIV-344 10.3 FN DSH      
FIV-186 6.5 MN Burmese  FIV-345 9.2 FN DSH      
FIV-189 6.8 MN DSH  FIV-346 9.2 MN DSH      
FIV-212 13.5 FN DSH  FIV-349 10.2 MN DSH      
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given 
#DSH= Domestic short hair, DMH= Domestic medium hair, DLH=Domestic long hair, PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, 
AB=Abbysian, BI=Birman, NF=Norwegian forest. 
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Signalment table 3b. American vaccinate samples 
Cat I.D. Age Sex* Breed# 
US-1 5.3 MN DLH 
US-2 5.1 MN DLH 
US-3 6.3 FN DSH 
US-4 13.4 MN Manx/Siamese 
US-5 12.6 MN DSH 
US-6 2.5 FN DSH 
US-7 4.6 FN DSH 
US-8 4.6 MN DSH 
US-9 4.1 MN DSH 
US-10 17.7 MN DSH 
US-11 4.9 FN DLH 
US-12 11.3 MN DLH 
US-13 3.0 FN DSH 
US-14 13.7 FN DSH 
US-15 6.3 MN DSH 
US-16 9.2 FN DSH 
US-17 4.7 FN DSH 
US-18 3.1 FN DMH 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given, #DSH= Domestic short hair, DMH= Domestic medium hair, DLH=Domestic long hair, 
PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, AB=Abbysian, BI=Birman, NF=Norwegian forest. 
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Signalment table 3c. Australian uninfected samples. 
Cat I.D. Age Sex* Breed#  Cat I.D. Age Sex* Breed
#  Cat I.D. Age Sex* Breed
# 
FIV-26 6.5 FN DSH  FIV-53 5 MN DSH  FIV-188 4 MN DSH 
FIV-27 20.2 FN DSH  FIV-54 7 MN DSH  FIV-191 11.3 MN DSH 
FIV-29 12 FN Siamese  FIV-56 14.2 MN DSH  FIV-193 7.1 FN Spotted Mist 
FIV-30 12 MN Siamese  FIV-57 2.5 FN DSH  FIV-196 12.2 MN DLH 
FIV-31 13 MN DLH  FIV-61 4.4 FN Abyssinian X  FIV-198 7.5 FN DSH 
FIV-32 4 FN DSH  FIV-65 5.6 FN DMH  FIV-199 6.3 FN DSH 
FIV-34 8.3 MN DSH  FIV-71 6 FN DSH  FIV-200 7.9 FN DMH 
FIV-35 7 FN DSH  FIV-154 8.2 MN DSH  FIV-201 7 FN DSH 
FIV-36 7 MN DSH  FIV-155 12.4 MN DSH  FIV-204 8.3 MN DSH 
FIV-37 7 MN DSH  FIV-156 5.2 MN DSH  FIV-205 12.5 FN DSH 
FIV-38 8 FN DSH  FIV-159 7 MN DSH  FIV-206 12.5 MN DSH 
FIV-39 7 MN DSH  FIV-160 6.8 MN DSH  FIV-217 5.3 MN Ragdoll 
FIV-40 6.9 MN DSH  FIV-165 5.6 MN DSH  FIV-219 7.4 MN DSH 
FIV-41 15 MN DSH  FIV-166 7.2 MN DSH  FIV-220 7.1 FN DSH 
FIV-42 12.5 FN DMH  FIV-167 4.1 FN DSH  FIV-225 5.1 FN DSH 
FIV-43 6.5 FN DMH  FIV-169 5.1 MN DSH  FIV-230 6.7 FN DSH 
FIV-44 2.3 MN DSH  FIV-177 3.4 FN Persian    FIV-231 7.6 FN DSH 
FIV-45 16 FN DLH  FIV-178 3.6 FN DSH  FIV-232 7.5 MN DMH 
FIV-46 8.5 FN DSH  FIV-180 5.1 MN DSH  FIV-233 7.6 MN DSH 
FIV-47 3 FN DSH  FIV-181 6.8 MN Burmese  FIV-235 5.3 MN DSH 
FIV-48 12 MN DSH  FIV-182 5.2 MN Burmese  FIV-242 6.3 FN DSH 
 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given, #DSH= Domestic short hair, DMH= Domestic medium hair, DLH=Domestic long hair, 
PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, AB=Abbysian, BI=Birman, NF=Norwegian forest. 
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Signalment table 3c. Australian uninfected samples. 
Cat I.D. Age Sex* Breed#  Cat I.D. Age Sex* Breed
#  Cat I.D. Age Sex* Breed
# 
FIV-243 12 MN DSH  FIV-316 5.3 FN DSH  FIV-372 6.3 MN DSH 
FIV-244 13 MN DSH  FIV-320 6.5 MN DLH  FIV-375 7.7 MN DMH 
FIV-245 10.9 FN DSH  FIV-321 13 FN DSH  FIV-377 6.3 MN DMH 
FIV-259 10.7 FN Birman  FIV-322 9.7 FN DLH  FIV-378 4.8 MN Burmese 
FIV-260 6.4 FN DSH  FIV-323 9 MN DLH  FIV-380 6.5 MN DSH 
FIV-261 6.1 MN DSH  FIV-324 12.1 MN Ragdoll  FIV-381 7.6 MN DSH 
FIV-262 11.6 FN DSH  FIV-325 8.7 MN Ragdoll  FIV-386 11.4 MN DLH 
FIV-263 6 FN DSH  FIV-326 7.8 FN DSH  FIV-389 3.5 FN DLH 
FIV-265 7 FN DSH  FIV-327 6.7 FN Siamese X    
 
 
FIV-271 6.3 MN DSH  FIV-333 13.2 MN DSH    
 
 
FIV-273 8.3 FN DSH  FIV-337 4.8 MN DSH    
 
 
FIV-277 7.4 FN DSH  FIV-347 14.3 FN DSH    
 
 
FIV-280 6.5 MN DSH  FIV-348 11.8 MN Ragdoll    
 
 
FIV-283 5.6 MN DLH  FIV-353 6.2 FN DSH    
 
 
FIV-284 5.8 FN DSH  FIV-354 8.2 FN DMH    
 
 
FIV-285 6 MN DSH  FIV-355 6.1 MN DMH    
 
 
FIV-291 9.2 MN DSH  FIV-358 4.2 FN DSH    
 
 
FIV-295 4 FN DSH  FIV-360 5.8 MN DSH    
 
 
FIV-304 6y FN DSH  FIV-361 5.8 FN DSH    
 
 
FIV-309 10.5 MN DMH  FIV-369 4.1 MN DSH    
 
 
FIV-314 12 MN Burmese  FIV-370 9.5 FN DLH    
 
 
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given, #DSH= Domestic short hair, DMH= Domestic medium hair, DLH=Domestic long hair, 
PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, AB=Abbysian, BI=Birman, NF=Norwegian forest. 
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Signalment table 3d. Australian infected samples. 
Cat I.D. Age Sex* Breed#  Cat I.D. Age Sex* Breed
# 
FIV-1 7.3 MN DSH  FIV-279 10.1 MN DSH 
FIV-19 8.8 FN DSH  FIV-281 9.3 MN DSH 
FIV-106 5.5 MN DLH  FIV-303 16.1 MN DSH 
FIV-152 8.1 FN DSH  FIV-319 6.4 FN DSH 
FIV-33 13.4 MN DSH  FIV-371 10.9 MN Bengal 
FIV-62 3.4 MN DSH  FIV-374 4.9 MN DSH 
FIV-80 4 FN DSH      
FIV-85 9.5 FN Persian X      
FIV-92 5 MN DSH      
FIV-127 7.1 FN DLH      
FIV-157 4.1 FN DLH      
FIV-163 13.6 MN DSH      
FIV-190 9.4 MN DSH      
FIV-192 9.3 MN DSH      
FIV-203 11.3 MN DSH      
FIV-208 4.6 MN DSH      
FIV-209 6.1 MN DSH      
FIV-218 5.7 FN Himalayan      
FIV-250 5.5 MN DSH      
FIV-272 4.3 M DSH      
FIV-274 6.4 MN DSH      
*F = Female, FN= Female neutered, M=Male, MN=Male neutered, NG=Not given, #DSH= Domestic short hair, DMH= Domestic medium hair, DLH=Domestic long hair, 
PLH=Persian long hair, BSH=British short hair, DR=Devon rex, MC=Main coon, AB=Abbysian, BI=Birman, NF=Norwegian forest. 
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Appendix 5. Immunostain analysis; vaccinates. 
 
Seroconversion of vaccinated animals following immunisation with the DIVA virus and challenge with FIVGL8-414.  Small arrows indicate the timings of 
FIV vaccine immunisations, whilst the large arrow denotes the week of challenge.   
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 Appendix 5. Immunostain analysis; controls. 
 
 
Seroconversion of control cats following immunisation with the control vaccine and challenge with FIVGL8-414.  Small arrows indicate the timings of 
control vaccine immunisations; large arrows indicate the week of challenge.
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